Mutational landscape of metastatic cancer revealed fro of 10,000 patients

Nature Medicine

23, 703-713

DOI: 10.1038/nm.4333

Citation Report

#	Article	IF	Citations
1	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. Clinical Cancer Research, 2017, 23, 7225-7231.	3.2	17
2	Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes. Nature Communications, 2017, 8, 857.	5.8	182
3	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Annals of Oncology, 2017, 28, 3015-3021.	0.6	79
4	Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nature Reviews Clinical Oncology, 2017, 14, 735-748.	12.5	234
5	Fishing for answers in precision cancer medicine. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10306-10308.	3.3	17
6	KRAS Alleles: The Devil Is in the Detail. Trends in Cancer, 2017, 3, 686-697.	3.8	257
7	Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation?. Journal of Hepatology, 2017, 67, 893-895.	1.8	4
8	Precision Oncology: The Road Ahead. Trends in Molecular Medicine, 2017, 23, 874-898.	3.5	131
9	The Potential and Challenges of Expanded Germline Testing in Clinical Oncology. JAMA - Journal of the American Medical Association, 2017, 318, 801.	3.8	6
10	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	3.8	366
11	The Evolving Genomic Landscape of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2017, 153, 657-673.e1.	0.6	69
12	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	5.2	578
13	Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood, 2017, 130, 1644-1648.	0.6	82
14	Development of <scp>RET</scp> mutant cutaneous angiosarcoma during <scp>BRAF</scp> inhibitor therapy. Journal of Cutaneous Pathology, 2017, 44, 1053-1056.	0.7	4
15	Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell, 2017, 32, 169-184.e7.	7.7	534
16	New Views into the Genetic Landscape of Metastatic Breast Cancer. Cancer Cell, 2017, 32, 131-133.	7.7	2
18	Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. Nature Communications, 2017, 8, 2053.	5.8	78
19	Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. Clinical Cancer Research, 2017, 23, 7521-7530.	3.2	144

#	Article	IF	Citations
20	DNAJB1â€“PRKACA fusion kinase interacts with Î²-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13076-13084.	3.3	125
21	A prescription for cancer diagnostics. Nature Medicine, 2017, 23, 789-789.	15.2	1
22	Preclinical and clinical development of neoantigen vaccines. Annals of Oncology, 2017, 28, xii11-xii17.	0.6	160
23	Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. BMC Cancer, 2017, 17, 602.	1.1	17
25	Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion. JCO Precision Oncology, 2017, 1, 1-5.	1.5	11
26	Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 131-138.	1.8	45
27	Molecular determinants of prostate cancer metastasis. Oncotarget, 2017, 8, 88211-88231.	0.8	19
28	A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer. Cancer Convergence, 2017, 1, 5.	8.0	50
29	Somatic mutations in CDH1 and CTNNB1 in primary carcinomas at 13 anatomic sites. Oncotarget, 2017, 8, 85680-85691.	0.8	16
30	Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precision Oncology, 2017, 2017, 1-17.	1.5	209
31	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	1,266
32	Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas. JCO Precision Oncology, 2017, 2017, 1-11.	1.5	36
33	Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma. JCO Precision Oncology, 2017, 2017, 1-8.	1.5	31
34	Clinical Use of Precision Oncology Decision Support. JCO Precision Oncology, 2017, 2017, 1-12.	1.5	22
35	Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion. JCO Precision Oncology, 2017, 2017, 1-6.	1.5	103
36	Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget, 2017, 8, 114371-114392.	0.8	96
37	Novel biomarkers in bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 115-119.	0.8	5
38	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	6.0	1,199

#	Article	IF	Citations
39	Systematic Protein Prioritization for Targeted Proteomics Studies through Literature Mining. Journal of Proteome Research, 2018, 17, 1383-1396.	1.8	16
40	Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacological Reviews, 2018, 70, 348-383.	7.1	441
41	ESR1 and endocrine therapy resistance: more than just mutations. Annals of Oncology, 2018, 29, 787-789.	0.6	10
42	Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, e34-e36.	0.5	28
43	Personalized cancer therapyâ€”leveraging a knowledge base for clinical decision-making. Journal of Physical Education and Sports Management, 2018, 4, a001578.	0.5	50
44	Implementation of â€œclinical sequencingâ€•in cancer genome medicine in Japan. Cancer Science, 2018, 109, 507-512.	1.7	31
45	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	3.0	170
46	EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?. Journal of Thoracic Oncology, 2018, 13, e33-e34.	0.5	17
47	Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Nonâ€“Small Cell Lung Cancer Patients. Clinical Cancer Research, 2018, 24, 3097-3107.	3.2	357
48	Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining. Cellular Oncology (Dordrecht), 2018, 41, 395-408.	2.1	7
49	Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. Clinical Cancer Research, 2018, 24, 3539-3549.	3.2	307
50	Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nature Reviews Cancer, 2018, 18, 377-388.	12.8	148
51	PD-L1 expression testing in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876349.	1.4	120
52	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clinical Cancer Research, 2018, 24, 3059-3068.	3.2	366
53	Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer Discovery, 2018, 8, 686-695.	7.7	149
54	Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell, 2018, 173, 515-528.e17.	13.5	540
55	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	13.5	2,111
56	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002279.	0.5	21

#	Article	IF	Citations
57	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene, 2018, 37, 3740-3752.	2.6	89
58	Evaluating tumor-suppressor gene combinations. Nature Genetics, 2018, 50, 480-482.	9.4	2
59	Antitumor activity of panâ€•HER inhibitors in HER 2â€positive gastric cancer. Cancer Science, 2018, 109, 1166-1176.	1.7	29
60	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4.	7.7	827
61	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, 2018, 173, 581-594.e12.	13.5	609
62	Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Oncology Reports, 2018, 39, 1081-1089.	1.2	20
63	Development of new preclinical models to advance adrenocortical carcinoma research. Endocrine-Related Cancer, 2018, 25, 437-451.	1.6	45
64	The value of cellâ€free DNA for molecular pathology. Journal of Pathology, 2018, 244, 616-627.	2.1	91
65	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	13.7	572
66	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clinical Cancer Research, 2018, 24, 2719-2731.	3.2	54
67	Making Use of Cancer Genomic Databases. Current Protocols in Molecular Biology, 2018, 121, 19.14.1-19.14.13.	2.9	13
68	2016 New Horizons Lecture: Beyond Imagingâ€”Radiology of Tomorrow. Radiology, 2018, 286, 764-775.	3.6	33
69	Established, emerging and elusive molecular targets in the treatment of lung cancer. Journal of Pathology, 2018, 244, 565-577.	2.1	15
70	Leveraging Genomics for Head and Neck Cancer Treatment. Journal of Dental Research, 2018, 97, 603-613.	2.5	8
71	Microsatellite instability status determined by nextâ€generation sequencing and compared with <scp>PD</scp>â€L1 and tumor mutational burden in 11,348 patients. Cancer Medicine, 2018, 7, 746-756.	1.3	348
72	Functional Analysis of Cancer-Associated DNA Polymerase Îµ Variants inSaccharomyces cerevisiae. G3: Genes, Genomes, Genetics, 2018, 8, 1019-1029.	0.8	49
73	PD-1/PD-L1 Axis in Lung Cancer. Cancer Journal (Sudbury, Mass), 2018, 24, 15-19.	1.0	61
74	Polymerase epsilon mutations and concomitant Î²2-microglobulin mutations in cancer. Gene, 2018, 647, 31-38.	1.0	14

#	Article	IF	Citations
75	Gene Fusions in Thyroid Cancer. Thyroid, 2018, 28, 158-167.	2.4	84
76	EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report. Lung Cancer, 2018, 115, 131-134.	0.9	22
77	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	7.7	275
78	Dual drive coexistence of EML4â€ALK and TPM3â€ROS1 fusion in advanced lung adenocarcinoma. Thoracic Cancer, 2018, 9, 324-327.	0.8	12
79	Interactive or static reports to guide clinical interpretation of cancer genomics. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 458-464.	2.2	14
80	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	7.7	589
81	From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards. Genome Medicine, 2018, 10, 18.	3.6	36
82	The impact of phosphatases on proliferative and survival signaling in cancer. Cellular and Molecular Life Sciences, 2018, 75, 2695-2718.	2.4	27
83	Targeted therapy according to next generation sequencing-based panel sequencing. Fukushima Journal of Medical Sciences, 2018, 64, 9-14.	0.1	17
84	Technical Note: Scintillation well counters and particle counting digital autoradiography devices can be used to detect activities associated with genomic profiling adequacy of biopsy specimens obtained after a low activity ¹⁸Fâ€<scp>FDG</scp> injection. Medical Physics, 2018, 45, 2179-2185.	1.6	8
85	Low clinical adoption of tumor genomic profiling: cause for concern?. Journal of Medical Economics, 2018, 21, 721-723.	1.0	0
86	Nonâ€“small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations. Human Pathology, 2018, 78, 138-143.	1.1	21
87	Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology. Journal of Visualized Experiments, 2018, , .	0.2	3
88	The emerging clinical relevance of genomics in cancer medicine. Nature Reviews Clinical Oncology, 2018, 15, 353-365.	12.5	351
89	Sample-Index Misassignment Impacts Tumour Exome Sequencing. Scientific Reports, 2018, 8, 5307.	1.6	17
90	The long tail of oncogenic drivers in prostate cancer. Nature Genetics, 2018, 50, 645-651.	9.4	601
91	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical Cancer Research, 2018, 24, 3108-3118.	3.2	200
92	Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene, 2018, 37, 3183-3199.	2.6	317

#	Article	IF	Citations
93	Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. Clinical Cancer Research, 2018, 24, 2732-2739.	3.2	30
94	<scp>CEP72â€ROS1</scp>: <scp>A</scp> novel <scp>ROS1</scp> oncogenic fusion variant in lung adenocarcinoma identified by nextâ€generation sequencing. Thoracic Cancer, 2018, 9, 652-655.	0.8	17
95	TissGDB: tissue-specific gene database in cancer. Nucleic Acids Research, 2018, 46, D1031-D1038.	6.5	63
96	Tumor origin detection with tissue-specific miRNA and DNA methylation markers. Bioinformatics, 2018, 34, 398-406.	1.8	308
97	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European Urology Focus, 2018, 4, 986-994.	1.6	29
98	Immunotherapy for metastatic urothelial carcinoma. Current Opinion in Urology, 2018, 28, 1-7.	0.9	6
99	Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study. International Journal of Cancer, 2018, 142, 1890-1900.	2.3	15
100	New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Advances in Anatomic Pathology, 2018, 25, 131-142.	2.4	37
101	Prostate cancer immunotherapy. Current Opinion in Urology, 2018, 28, 15-24.	0.9	40
102	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutationsâ€"The Lung Cancer Mutation Consortium (LCMC2). Clinical Cancer Research, 2018, 24, 1038-1047.	3.2	154
103	Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers. Nature Structural and Molecular Biology, 2018, 25, 61-72.	3.6	140
104	Targeting mutant p53 for efficient cancer therapy. Nature Reviews Cancer, 2018, 18, 89-102.	12.8	655
105	Telomerase reverse transcriptase promoter alterations across cancer types as detected by nextâ€generation sequencing: A clinical and molecular analysis of 423 patients. Cancer, 2018, 124, 1288-1296.	2.0	21
106	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018, 359, 582-587.	6.0	834
107	Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. Annual Review of Medicine, 2018, 69, 319-331.	5.0	61
108	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	7.7	275
109	RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Nonâ€"Small Cell Lung Carcinomas Sensitive to MEK Inhibition. Clinical Cancer Research, 2018, 24, 1436-1447.	3.2	56
110	Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precision Oncology, 2018, 2018, 1-7.	1.5	7

#	Article	IF	Citations
111	Frameshift events predict antiâ€“PD-1/L1 response in head and neck cancer. JCI Insight, 2018, 3, .	2.3	190
112	Clinicopathologic Features of Nonâ€“Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precision Oncology, 2018, 2018, 1-12.	1.5	112
113	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	14
114	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precision Oncology, 2018, 2, 1-12.	1.5	13
115	BRAF Inhibition in BRAF^{V600}-Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36, 3477-3484.	0.8	247
116	Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary. JCO Precision Oncology, 2018, 2, 1-25.	1.5	10
117	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	0.8	399
118	Artificial Intelligence Approach for Variant Reporting. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	1.0	13
119	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology, 2018, 36, 2532-2537.	0.8	381
120	Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 56-64.	1.8	5
121	Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 139-146.	1.8	10
122	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	0.8	1,109
123	Tumor Mutation Burden as a Biomarker in Resected Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2995-3006.	0.8	223
124	Reply to S. Zhang et al. Journal of Clinical Oncology, 2018, 36, 3057-3058.	0.8	1
125	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. Translational Lung Cancer Research, 2018, 7, 647-660.	1.3	66
126	Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?. Translational Lung Cancer Research, 2018, 7, 631-638.	1.3	68
127	Implementing tumor mutational burden (TMB) analysis in routine diagnosticsâ€”a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	1.3	152
128	The ins and outs of telomere crisis in cancer. Genome Medicine, 2018, 10, 89.	3.6	10

#	Article	IF	Citations
129	The mutational landscape of recurrent versus nonrecurrent human papillomavirusâ€“related oropharyngeal cancer. JCI Insight, 2018, 3, .	2.3	30
130	High-throughput binding affinity calculations at extreme scales. BMC Bioinformatics, 2018, 19, 482.	1.2	14
131	TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumorâ€™s Genetic Defects to Therapeutic Options. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	1.0	1
132	Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer. JCO Precision Oncology, 2018, 2, 1-7.	1.5	32
133	Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions. JCO Precision Oncology, 2018, 2, 1-6.	1.5	11
134	ALK Fusions in Renal Cell Carcinoma: Response to Entrectinib. JCO Precision Oncology, 2018, 2, 1-8.	1.5	16
135	Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. ELife, 2018, 7, .	2.8	126
136	Roche splashes $2.4 billion on Foundation Medicine's cancer platform. Nature Biotechnology, 2018, 36, 779-780.	9.4	3
137	Aggressive-Variant Microsatellite-Stable POLE Mutant Prostate Cancer With High Mutation Burden and Durable Response to Immune Checkpoint Inhibitor Therapy. JCO Precision Oncology, 2018, 2, 1-8.	1.5	9
138	Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology. JCO Precision Oncology, 2018, 2, 1-16.	1.5	2
139	Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program. JCO Precision Oncology, 2018, 2, 1-15.	1.5	14
140	NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12034-12039.	3.3	41
141	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine, 2018, 10, 85.	3.6	94
142	Precision oncology: separating the wheat from the chaff. ESMO Open, 2018, 3, e000446.	2.0	37
143	Criticality in tumor evolution and clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11101-E11110.	3.3	23
144	A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay. Translational Lung Cancer Research, 2018, 7, 616-630.	1.3	41
145	Advances in Next-Generation Sequencing Bioinformatics for Clinical Diagnostics. Advances in Molecular Pathology, 2018, 1, 149-166.	0.2	4
146	How theBRAFV600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications. Gastroenterology Research and Practice, 2018, 2018, 1-14.	0.7	34

#	Article	IF	Citations
147	Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas. Cancers, 2018, 10, 489.	1.7	18
149	Prime time for immunotherapy in advanced urothelial cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 24-32.	0.7	2
150	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	7.7	307
151	Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3925-3930.	1.8	106
152	Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nature Communications, 2018, 9, 3962.	5.8	142
153	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genetics, 2018, 50, 1399-1411.	9.4	145
154	Exome scale map of genetic alterations promoting metastasis in colorectal cancer. BMC Genetics, 2018, 19, 85.	2.7	22
155	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. , 2018, 6, 97.		19
156	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	1.6	53
157	Loss of Notch1 predisposes oro-esophageal epithelium to tumorigenesis. Experimental Cell Research, 2018, 372, 129-140.	1.2	20
158	Typing tumors using pathways selected by somatic evolution. Nature Communications, 2018, 9, 4159.	5.8	19
159	Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine. Journal of Thoracic Disease, 2018, 10, 1294-1299.	0.6	4
160	Structural snapshots of RAF kinase interactions. Biochemical Society Transactions, 2018, 46, 1393-1406.	1.6	28
161	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery, 2018, 8, 1540-1547.	7.7	138
162	Tumor Type-Agnostic Treatment and the Future of Cancer Therapy. Targeted Oncology, 2018, 13, 541-544.	1.7	7
163	RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. Oncotarget, 2018, 9, 29654-29664.	0.8	20
164	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell, 2018, 34, 852-862.e4.	7.7	73
165	Radioactive Iodineâ€"Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4216-4223.	1.8	33

#	Article	IF	Citations
166	Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer. New England Journal of Medicine, 2018, 379, 1087-1089.	13.9	55
167	Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases â€“ potentially novel therapeutic targets. Expert Opinion on Therapeutic Targets, 2018, 22, 869-877.	1.5	12
168	Molecular Diagnostics in Clinical Oncology. Frontiers in Molecular Biosciences, 2018, 5, 76.	1.6	93
169	Genetic Alterations of TRAF Proteins in Human Cancers. Frontiers in Immunology, 2018, 9, 2111.	2.2	67
170	Disruption of the Î²1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. Cancer Cell, 2018, 34, 513-528.e8.	7.7	103
171	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	7.7	633
172	Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cellular and Molecular Life Sciences, 2018, 75, 4151-4162.	2.4	150
173	Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discovery, 2018, 8, 1422-1437.	7.7	126
174	Ras proteins as therapeutic targets. Biochemical Society Transactions, 2018, 46, 1303-1311.	1.6	4
175	Multidomain architecture of estrogen receptor reveals interfacial cross-talk between its DNA-binding and ligand-binding domains. Nature Communications, 2018, 9, 3520.	5.8	38
176	PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Annals of Oncology, 2018, 29, 2085-2091.	0.6	221
177	Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clinical Cancer Research, 2018, 24, 6471-6482.	3.2	42
178	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. Clinical Cancer Research, 2018, 24, 4887-4899.	3.2	74
179	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	7.7	1,108
180	Multiâ€layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/Î²â€catenin signaling activation (Review). International Journal of Molecular Medicine, 2018, 42, 713-725.	1.8	125
181	Next-generation sequencing in drug development: target identification and genetically stratified clinical trials. Drug Discovery Today, 2018, 23, 1776-1783.	3.2	46
182	Bronchiolar Adenoma. American Journal of Surgical Pathology, 2018, 42, 1010-1026.	2.1	91
183	Type A thymoma presenting with bone metastasis. Histopathology, 2018, 73, 701-703.	1.6	1

#	Article	IF	Citations
184	Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell, 2018, 33, 791-793.	7.7	20
185	High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2. Clinical Cancer Research, 2018, 24, 5112-5122.	3.2	60
186	Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2018, 6, 257-276.	2.3	50
187	The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer, 2018, 123, 70-75.	0.9	125
188	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2018, 4, 1228.	3.4	132
189	Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature, 2018, 559, 125-129.	13.7	223
190	Analytical Validation of a Hybrid Captureâ€“Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. Journal of Molecular Diagnostics, 2018, 20, 686-702.	1.2	149
191	Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. Bladder Cancer, 2018, 4, 9-18.	0.2	18
192	Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nature Cell Biology, 2018, 20, 811-822.	4.6	124
193	Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations. Communications Biology, 2018, 1, 70.	2.0	66
194	Early stage NSCLC â€” challenges to implementing ctDNA-based screening and MRD detection. Nature Reviews Clinical Oncology, 2018, 15, 577-586.	12.5	281
195	Challenges in next generation sequencing analysis of somatic mutations in transplant patients. Cancer Genetics, 2018, 226-227, 17-22.	0.2	1
196	Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation. International Journal of Radiation Oncology Biology Physics, 2018, 101, 833-844.	0.4	1
197	Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology, 2018, 18, 647-654.	0.5	35
198	Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood, 2018, 132, 1265-1278.	0.6	39
199	Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care. Annals of Internal Medicine, 2018, 168, 221.	2.0	6
200	Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Nonâ€“Small Cell Lung Cancer in the Community Oncology Setting. JAMA - Journal of the American Medical Association, 2018, 320, 469.	3.8	110
201	Downregulation of TRIM58 expression is associated with a poor patient outcome and enhances colorectal cancer cell invasion. Oncology Reports, 2018, 40, 1251-1260.	1.2	28

#	Article	IF	Citations
202	Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice. Journal of Clinical Pathology, 2018, 71, 1001-1006.	1.0	14
203	BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi. , 2018, 59, 117.		27
204	MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis. Journal of Hematology and Oncology, 2018, 11, 76.	6.9	42
205	Overview of precision oncology trials: challenges and opportunities. Expert Review of Clinical Pharmacology, 2018, 11, 797-804.	1.3	31
206	SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discovery, 2018, 8, 1237-1249.	7.7	216
207	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. Scientific Reports, 2018, 8, 11570.	1.6	64
208	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	3.2	100
209	Exploring the OncoGenomic Landscape of cancer. Genome Medicine, 2018, 10, 61.	3.6	7
210	Precision Medicine in Hormone Receptor-Positive Breast Cancer. Frontiers in Oncology, 2018, 8, 144.	1.3	32
211	Machine Learning and Radiogenomics: Lessons Learned and Future Directions. Frontiers in Oncology, 2018, 8, 228.	1.3	54
212	Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas. PLoS ONE, 2018, 13, e0199688.	1.1	25
213	What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies. International Journal of Molecular Sciences, 2018, 19, 1251.	1.8	11
214	Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics, 2018, 50, 1189-1195.	9.4	411
215	An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression. Biochemistry, 2018, 57, 4675-4689.	1.2	37
216	FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. Oncogene, 2018, 37, 6096-6104.	2.6	10
217	Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. Cell Systems, 2018, 7, 161-179.e14.	2.9	53
218	Isocitrate dehydrogenase 1 mutations in melanoma frequently coâ€occur with NRAS mutations. Histopathology, 2018, 73, 963-968.	1.6	15
219	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459

#	Article	IF	Citations
220	Clinical tumour sequencing for precision oncology: time for a universal strategy. Nature Reviews Cancer, 2018, 18, 527-528.	12.8	34
221	Applications of RNA Indexes for Precision Oncology in Breast Cancer. Genomics, Proteomics and Bioinformatics, 2018, 16, 108-119.	3.0	16
222	Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer. Breast Cancer Research, 2018, 20, 22.	2.2	15
224	The contributions of cancer cell metabolism to metastasis. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	58
225	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Nonâ€“Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2018, 6, 758-765.	1.6	89
226	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. Annual Review of Biomedical Data Science, 2018, 1, 1-27.	2.8	27
227	A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib. Cancer Biology and Therapy, 2018, 19, 1097-1101.	1.5	6
228	Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma. Clinical Cancer Research, 2018, 24, 5815-5819.	3.2	25
229	RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nature Cell Biology, 2018, 20, 1064-1073.	4.6	276
230	Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening. Journal of Molecular Diagnostics, 2018, 20, 836-848.	1.2	15
231	Metastatic tumor cells â€“ genotypes and phenotypes. Frontiers in Biology, 2018, 13, 277-286.	0.7	10
232	Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer. Journal of Molecular Diagnostics, 2018, 20, 822-835.	1.2	23
233	Genomic Sequencing Assays Characterize the Mutational Landscape of Advanced Thyroid Cancers. Clinical Thyroidology, 2018, 30, 371-373.	0.0	0
234	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines, 2018, 6, 87.	1.4	8
235	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, 2018, 29, 1895-1902.	0.6	424
236	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. Cancer Journal (Sudbury, Mass), 2018, 24, 153-162.	1.0	17
237	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncology, 2018, 4, 1589.	3.4	139
238	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 1312-1323.	0.5	103

#	Article	IF	Citations
239	RHO GTPases in cancer: known facts, open questions, and therapeutic challenges. Biochemical Society Transactions, 2018, 46, 741-760.	1.6	58
240	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer Journal, 2018, 8, 60.	2.8	25
241	Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. Expert Review of Precision Medicine and Drug Development, 2018, 3, 205-213.	0.4	7
242	Extending experimentation: oncologyâ€™s fading boundary between research and care. New Genetics and Society, 2018, 37, 207-226.	0.7	38
243	A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor. Cancer Discovery, 2018, 8, 1130-1141.	7.7	56
244	Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions. Health Affairs, 2018, 37, 751-756.	2.5	24
245	Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. British Journal of Cancer, 2018, 118, 1571-1579.	2.9	2
246	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clinical Cancer Research, 2019, 25, 1063-1069.	3.2	257
247	Whole-Genome Sequencing in Cancer. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a034579.	2.9	38
248	Implementing precision cancer medicine in the genomic era. Seminars in Cancer Biology, 2019, 55, 16-27.	4.3	24
249	Hormone-Responsive Cancers. , 2019, , 717-741.e8.		2
250	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. Journal of the National Cancer Institute, 2019, 111, 388-398.	3.0	81
251	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer, 2019, 22, 355-362.	2.7	11
252	Impact of tumour profiling on clinical trials in salivary gland cancer. Clinical Otolaryngology, 2019, 44, 1-6.	0.6	1
253	ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 977-988.	3.2	104
254	Clinical actionability of molecular targets in endometrial cancer. Nature Reviews Cancer, 2019, 19, 510-521.	12.8	261
255	ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib. BMC Cancer, 2019, 19, 769.	1.1	23
256	Designing gene panels for tumor mutational burden estimation: the need to shift from â€˜correlationâ€™ to â€˜accuracyâ€™. , 2019, 7, 206.		37

#	Article	IF	Citations
257	Utilization of tumor genomics in clinical practice: an international survey among ASCO members. Future Oncology, 2019, 15, 2463-2470.	1.1	12
258	G3viz: an R package to interactively visualize genetic mutation data using a lollipop-diagram. Bioinformatics, 2020, 36, 928-929.	1.8	16
259	The role of TP53 in acute myeloid leukemia: Challenges and opportunities. Genes Chromosomes and Cancer, 2019, 58, 875-888.	1.5	79
260	Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants. BMC Cancer, 2019, 19, 783.	1.1	17
261	Genomic and clinical characterization of pulmonaryâ€only metastatic prostate cancer: A unique molecular subtype. Prostate, 2019, 79, 1572-1579.	1.2	23
262	Predicting Kinase Inhibitor Resistance: Physics-Based and Data-Driven Approaches. ACS Central Science, 2019, 5, 1468-1474.	5.3	40
263	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine, 2019, 25, 1422-1427.	15.2	144
264	Comprehensive assessment of HER2 alteration in a colorectal cancer cohort: from next-generation sequencing to clinical significance . Cancer Management and Research, 2019, Volume 11, 7867-7875.	0.9	7
265	Iron and lung cancer. Cancer Letters, 2019, 464, 56-61.	3.2	48
266	ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma. Oncotarget, 2019, 10, 245-251.	0.8	19
267	Cancer-associated mutations in DICER1 RNase IIIa and IIIb domains exert similar effects on miRNA biogenesis. Nature Communications, 2019, 10, 3682.	5.8	48
268	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer Cell, 2019, 36, 194-209.e9.	7.7	184
269	Co-occurring genomic alterations inÂnon-small-cell lung cancer biology and therapy. Nature Reviews Cancer, 2019, 19, 495-509.	12.8	573
270	Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing. Cancer Science, 2019, 110, 2652-2657.	1.7	37
271	STAG Mutations in Cancer. Trends in Cancer, 2019, 5, 506-520.	3.8	38
272	Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma byÂNext-Generation Sequencing. Journal of Thoracic Oncology, 2019, 14, e181-e183.	0.5	12
273	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 6160-6169.	3.2	73
274	Leveraging Clinical Tumor-Profiling Programs to Achieve Comprehensive Germline-Inclusive Precision Cancer Medicine. JCO Precision Oncology, 2019, 3, 1-3.	1.5	6

#	Article	IF	Citations
275	Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. Cancer Immunology, Immunotherapy, 2019, 68, 1689-1700.	2.0	68
276	Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. Acta OncolÃ³gica, 2019, 58, 1634-1639.	0.8	10
277	Tumor mutational burden. Cancer Cytopathology, 2019, 127, 735-736.	1.4	43
278	Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. , 2019, 7, 183.		231
279	Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers. Oncologist, 2019, 24, e1303-e1314.	1.9	64
280	Overcoming Resistance to PARP Inhibition. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 161-189.	0.1	0
281	MOLI: multi-omics late integration with deep neural networks for drug response prediction. Bioinformatics, 2019, 35, i501-i509.	1.8	206
282	Estimating the predictability of cancer evolution. Bioinformatics, 2019, 35, i389-i397.	1.8	28
283	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations. Clinical Cancer Research, 2019, 25, 5832-5842.	3.2	64
284	Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma â€“ results of a prospective biomarker study. , 2019, 7, 180.		137
285	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	13.7	295
286	Advances in epigenetics link genetics to the environment and disease. Nature, 2019, 571, 489-499.	13.7	863
287	Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. JCI Insight, 2019, 4, .	2.3	30
288	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecologic Oncology, 2019, 154, 516-523.	0.6	62
289	Distinct Colorectal Cancerâ€“Associated APC Mutations Dictate Response to Tankyrase Inhibition. Cancer Discovery, 2019, 9, 1358-1371.	7.7	54
290	Ten years of DICER1 mutations: Provenance, distribution, and associated phenotypes. Human Mutation, 2019, 40, 1939-1953.	1.1	76
291	Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer. Clinical Cancer Research, 2019, 25, 6546-6553.	3.2	45
292	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head and Neck, 2019, 41, 3670-3676.	0.9	29

#	Article	IF	Citations
293	Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer. Molecular Diagnosis and Therapy, 2019, 23, 507-520.	1.6	39
294	Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. Journal of Molecular Diagnostics, 2019, 21, 756-767.	1.2	37
295	The protein secretion modulator TMED9 drives CNIH4/TGFÎ±/GLI signaling opposing TMED3-WNT-TCF to promote colon cancer metastases. Oncogene, 2019, 38, 5817-5837.	2.6	36
296	ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation. Journal of Neuropathology and Experimental Neurology, 2019, 78, 703-708.	0.9	7
297	FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist, 2019, 24, 1462-1468.	1.9	16
298	FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. Npj Breast Cancer, 2019, 5, 19.	2.3	46
299	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	3.2	107
300	ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Annals of Oncology, 2019, 30, 1417-1427.	0.6	263
301	PAX8â€“GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. Modern Pathology, 2019, 32, 1734-1743.	2.9	38
302	Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Science Translational Medicine, 2019, 11, .	5.8	451
303	Dynamic Histone H3 Incorporation Fuels Metastatic Progression. Trends in Molecular Medicine, 2019, 25, 933-935.	3.5	2
304	Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers. Expert Review of Anticancer Therapy, 2019, 19, 929-938.	1.1	3
305	Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacological Reviews, 2019, 71, 671-697.	7.1	13
306	Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. Cell Reports, 2019, 29, 573-588.e7.	2.9	62
307	Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report. BMC Medical Genomics, 2019, 12, 136.	0.7	22
308	A Complex Interplay of Anionic Phospholipid Binding Regulates 3â€²-Phosphoinositide-Dependent-Kinase-1 Homodimer Activation. Scientific Reports, 2019, 9, 14527.	1.6	12
309	Investigating the feasibility and reliability of the Pictorial Fit-Frail Scale. Age and Ageing, 2019, 48, 832-837.	0.7	11
310	The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA. Frontiers in Oncology, 2019, 9, 952.	1.3	6

#	Article	IF	Citations
311	Huge whole-genome study of human metastatic cancers. Nature, 2019, 575, 60-61.	13.7	3
312	Pathogenic Loss-of-Function Germline TERT Mutations in Patients With Solid Tumors. JCO Precision Oncology, 2019, 3, 1-5.	1.5	2
313	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers, 2019, 11, 1689.	1.7	44
314	Progress on the proton-radius puzzle. Nature, 2019, 575, 61-62.	13.7	24
315	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. Journal of Thoracic Oncology, 2019, 14, 2009-2018.	0.5	22
316	TCDD-Inducible Poly-ADP-Ribose Polymerase (TIPARP), A Novel Therapeutic Target Of Breast Cancer . Cancer Management and Research, 2019, Volume 11, 8991-9004.	0.9	13
317	A concise review on cancer treatment methods and delivery systems. Journal of Drug Delivery Science and Technology, 2019, 54, 101350.	1.4	60
318	OCTANE (Ontario-Wide Cancer Targeted Nucleic Acid Evaluation): A Platform for Intraprovincial, National, and International Clinical Data-Sharing. Current Oncology, 2019, 26, 618-623.	0.9	9
319	Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. Advances in Experimental Medicine and Biology, 2019, , .	0.8	0
320	Intron 1â€“Mediated Regulation of EGFR Expression in EGFR-Dependent Malignancies Is Mediated by AP-1 and BET Proteins. Molecular Cancer Research, 2019, 17, 2208-2220.	1.5	10
321	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. Clinical Cancer Research, 2019, 25, 7113-7125.	3.2	69
322	Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3KÎ± inhibitors. Science, 2019, 366, 714-723.	6.0	185
323	ACVR1 Function in Health and Disease. Cells, 2019, 8, 1366.	1.8	47
324	Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, 1924-1934.	0.5	60
325	Genomic stratification beyond Ras/Bâ€Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. Cancer Medicine, 2019, 8, 6538-6548.	1.3	8
326	The histone demethylase UTX/KDM6A in cancer: Progress and puzzles. International Journal of Cancer, 2019, 145, 614-620.	2.3	60
327	Emerging agents and regimens for hepatocellular carcinoma. Journal of Hematology and Oncology, 2019, 12, 110.	6.9	71
328	Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Annals of Oncology, 2019, 30, viii36-viii40.	0.6	73

#	Article	IF	Citations
329	Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Molecular Cancer, 2019, 18, 7.	7.9	48
330	Predicting Resistance Is (Not) Futile. ACS Central Science, 2019, 5, 1312-1314.	5.3	5
331	GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-ÎºB-Dependent Mechanism. Cancer Cell, 2019, 36, 268-287.e10.	7.7	34
332	Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study. Translational Oncology, 2019, 12, 1488-1495.	1.7	6
333	Immune Microenvironment of Brain Metastasesâ€"Are Microglia and Other Brain Macrophages Little Helpers?. Frontiers in Immunology, 2019, 10, 1941.	2.2	41
334	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. European Journal of Cancer, 2019, 120, 54-64.	1.3	18
335	Impact of NCI-MATCH: a Nationwide Oncology Precision Medicine Trial. Expert Review of Precision Medicine and Drug Development, 2019, 4, 251-258.	0.4	8
336	Stress-triggered YAP1/SOX2 activation transcriptionally reprograms head and neck squamous cell carcinoma for the acquisition of stemness. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2433-2444.	1.2	12
337	Symptom-based patient stratification in mental illness using clinical notes. Journal of Biomedical Informatics, 2019, 98, 103274.	2.5	20
338	Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Annals of Oncology, 2019, 30, 1821-1830.	0.6	99
339	Intraductal Papillary Mucinous Neoplasms Arise From Multiple Independent Clones, Each With Distinct Mutations. Gastroenterology, 2019, 157, 1123-1137.e22.	0.6	82
340	Prospects and Problems of Cancer Genome Analysis for Establishing Cancer Precision Medicine. Cancer Investigation, 2019, 37, 427-431.	0.6	3
341	Personalized Medicine, Genomic Profiling and Germline Mutations: Toward More Precise Decisions. Journal of Oncology Practice, 2019, 15, e755-e757.	2.5	2
342	HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Scientific Reports, 2019, 9, 13404.	1.6	103
344	A video-based, flipped classroom, simulation curriculum for dermatologic surgery: A prospective, multi-institution study. Journal of the American Academy of Dermatology, 2019, 81, 1271-1276.	0.6	35
345	Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer. Clinical Cancer Research, 2019, 25, 7413-7423.	3.2	211
346	Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	0.8	83
347	Molecular Profiles and Metastasis Markers in Chinese Patients with Gastric Carcinoma. Scientific Reports, 2019, 9, 13995.	1.6	44

#	Article	IF	Citations
348	A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine, 2019, 25, 1607-1614.	15.2	320
349	Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. International Journal of Molecular Sciences, 2019, 20, 4267.	1.8	10
350	Cancer-Specific Thresholds Adjust for Whole Exome Sequencingâ€“Based Tumor Mutational Burden Distribution. JCO Precision Oncology, 2019, 3, 1-12.	1.5	21
351	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	1.5	24
352	Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes and Cancer, 2019, 58, 578-588.	1.5	173
353	Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21. IScience, 2019, 12, 27-40.	1.9	8
354	GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas. Ophthalmology, 2019, 126, 759-763.	2.5	26
355	Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia, 2019, 33, 1635-1649.	3.3	74
356	Salt-Inducible Kinase 2: An Oncogenic Signal Transmitter and Potential Target for Cancer Therapy. Frontiers in Oncology, 2019, 9, 18.	1.3	43
357	A germline HLTF mutation in familial MDS induces DNA damage accumulation through impaired PCNA polyubiquitination. Leukemia, 2019, 33, 1773-1782.	3.3	11
358	Heterozygous mutations cause genetic instability in a yeast model of cancer evolution. Nature, 2019, 566, 275-278.	13.7	27
359	Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open, 2019, 4, e000442.	2.0	257
361	Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Cancer Cell, 2019, 35, 267-282.e7.	7.7	151
362	Spontaneous Transdifferentiation from Small Cell Lung Carcinoma to Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2019, 14, e31-e34.	0.5	3
363	The genomic imprint of cancer therapies helps timing the formation of metastases. International Journal of Cancer, 2019, 145, 694-704.	2.3	4
364	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature, 2019, 565, 654-658.	13.7	361
365	Attitudes toward genomic tumor profiling tests in Japan: patients, family members, and the public. Journal of Human Genetics, 2019, 64, 481-485.	1.1	6
366	Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. Cancer Immunology Research, 2019, 7, 534-543.	1.6	100

#	Article	IF	Citations
367	Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer. Cancers, 2019, 11, 805.	1.7	44
368	Precision Medicine in Cancer Therapy. Cancer Treatment and Research, 2019, , .	0.2	4
369	CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers. Cell Systems, 2019, 9, 9-23.e8.	2.9	83
370	Genomics-Enabled Precision Medicine for Cancer. Cancer Treatment and Research, 2019, 178, 137-169.	0.2	9
371	A CRISPR Way to Identify Cancer Targets. New England Journal of Medicine, 2019, 380, 2475-2477.	13.9	5
372	A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology, 2019, 30, 1437-1447.	0.6	437
373	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Molecular Cancer Therapeutics, 2019, 18, 1506-1519.	1.9	16
374	Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations. Clinical Cancer Research, 2019, 25, 5513-5524.	3.2	46
375	Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. Diagnostic Pathology, 2019, 14, 62.	0.9	4
376	Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine. ESMO Open, 2019, 4, e000516.	2.0	29
377	Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature, 2019, 571, 413-418.	13.7	192
378	Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication. Journal of Clinical Medicine, 2019, 8, 903.	1.0	13
379	Functional characterisation of a novel class of in-frame insertion variants of KRAS and HRAS. Scientific Reports, 2019, 9, 8239.	1.6	12
380	Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing. Journal of Translational Medicine, 2019, 17, 189.	1.8	80
381	Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations. Clinical Cancer Research, 2019, 25, 6346-6356.	3.2	75
382	Precision Oncology: Three Small Steps Forward. Cancer Cell, 2019, 35, 825-826.	7.7	11
383	Adrenocortical carcinoma â€" towards genomics guided clinical care. Nature Reviews Endocrinology, 2019, 15, 548-560.	4.3	92
384	The evolving landscape of precision medicine in primary liver cancer. Hepatic Oncology, 2019, 6, HEP12.	4.2	7

#	Article	IF	Citations
385	DNA methylation-based classification of sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 1447-1459.	2.9	82
386	Current Status of Patient-Derived Ovarian Cancer Models. Cells, 2019, 8, 505.	1.8	69
387	Association between histone lysine methyltransferase KMT2C mutation and clinicopathological factors in breast cancer. Biomedicine and Pharmacotherapy, 2019, 116, 108997.	2.5	21
388	Effectiveness of a genetic test panel designed for gynecological cancer: an exploratory study. Medical Oncology, 2019, 36, 62.	1.2	2
389	Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma. Cell, 2019, 177, 1842-1857.e21.	13.5	153
390	Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date . Cancer Management and Research, 2019, Volume 11, 4893-4904.	0.9	10
391	Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. PLoS ONE, 2019, 14, e0217399.	1.1	12
392	Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay. Oncologist, 2019, 24, e1401-e1408.	1.9	9
393	Detection ofNTRKFusions: Merits and Limitations of Current Diagnostic Platforms. Cancer Research, 2019, 79, 3163-3168.	0.4	138
394	A driving test for oncogenic mutations. Journal of Biological Chemistry, 2019, 294, 9390-9391.	1.6	0
395	Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e126-e140.	1.8	28
396	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Gynecologic Oncology, 2019, 154, 144-149.	0.6	24
397	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusionâ€“Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	7.7	254
398	In perspective: An update on telomere targeting in cancer. Molecular Carcinogenesis, 2019, 58, 1581-1588.	1.3	41
399	Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Annals of Oncology, 2019, 30, 1221-1231.	0.6	143
401	Assessment of tumor mutation burden calculation from gene panel sequencing data . OncoTargets and Therapy, 2019, Volume 12, 3401-3409.	1.0	38
402	Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. Journal of Molecular Diagnostics, 2019, 21, 553-571.	1.2	161
403	Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. Journal of Thoracic Oncology, 2019, 14, 802-815.	0.5	71

#	Article	IF	Citations
404	Portrait of a cancer: mutational signature analyses for cancer diagnostics. BMC Cancer, 2019, 19, 457.	1.1	84
405	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	2.3	76
406	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular Cancer Therapeutics, 2019, 18, 1149-1157.	1.9	26
407	The Status and Impact of Clinical Tumor Genome Sequencing. Annual Review of Genomics and Human Genetics, 2019, 20, 413-432.	2.5	20
408	Metastasis Organotropism: Redefining the Congenial Soil. Developmental Cell, 2019, 49, 375-391.	3.1	202
409	A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients. Scientific Reports, 2019, 9, 6577.	1.6	21
410	Genetic diversity of tumors with mismatch repair deficiency influences antiâ€“PD-1 immunotherapy response. Science, 2019, 364, 485-491.	6.0	395
411	Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors. Pathology Research and Practice, 2019, 215, 152395.	1.0	21
412	RAC1 Takes the Lead in Solid Tumors. Cells, 2019, 8, 382.	1.8	80
413	Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. JCO Precision Oncology, 2019, 3, 1-14.	1.5	61
414	Basket Trials for Intractable Cancer. Frontiers in Oncology, 2019, 9, 229.	1.3	22
415	RB constrains lineage fidelity and multiple stages of tumour progression and metastasis. Nature, 2019, 569, 423-427.	13.7	62
416	Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers. Clinical Science, 2019, 133, 953-970.	1.8	79
417	Towards individualized therapy for metastatic renal cell carcinoma. Nature Reviews Clinical Oncology, 2019, 16, 621-633.	12.5	148
418	Feasibility and utility of a panel testing for 114 cancerâ€associated genes in a clinical setting: A hospitalâ€based study. Cancer Science, 2019, 110, 1480-1490.	1.7	238
419	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Modern Pathology, 2019, 32, 1344-1358.	2.9	49
420	Differentially mutated subnetworks discovery. Algorithms for Molecular Biology, 2019, 14, 10.	0.3	7
421	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical Cancer Research, 2019, 25, 4712-4722.	3.2	292

#	Article	IF	Citations
422	Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC Medical Genomics, 2019, 12, 56.	0.7	7
423	The expanding landscape of â€˜oncohistoneâ€™ mutations in human cancers. Nature, 2019, 567, 473-478.	13.7	271
424	Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Annals of Oncology, 2019, 30, 597-603.	0.6	114
425	Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Annals of Oncology, 2019, 30, 721-732.	0.6	53
426	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. Breast Cancer Research, 2019, 21, 39.	2.2	17
427	Predicting mutations deleterious to function in beta-lactamase TEM1 using MM-GBSA. PLoS ONE, 2019, 14, e0214015.	1.1	11
428	A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib. Clinical Lung Cancer, 2019, 20, e224-e228.	1.1	11
429	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. Journal of Pathology, 2019, 248, 260-265.	2.1	37
430	Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?. Digestive Diseases and Sciences, 2019, 64, 918-927.	1.1	26
431	Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets. Human Pathology, 2019, 87, 83-94.	1.1	24
432	Diverse and cancer typeâ€‘specific roles of the p53 R248Q gainâ€‘ofâ€‘function mutation in cancer migration and invasiveness. International Journal of Oncology, 2019, 54, 1168-1182.	1.4	12
433	Exploiting rare driver mutations for precision cancer medicine. Current Opinion in Genetics and Development, 2019, 54, 1-6.	1.5	13
434	Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity. Frontiers in Genetics, 2019, 10, 194.	1.1	11
435	Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Current Oncology Reports, 2019, 21, 42.	1.8	15
436	Comprehensive assay for the molecular profiling of cancer by target enrichment from formalinâ€fixed paraffinâ€embedded specimens. Cancer Science, 2019, 110, 1464-1479.	1.7	48
437	Genomic analysis of recurrences and highâ€grade forms of polymorphous adenocarcinoma. Histopathology, 2019, 75, 193-201.	1.6	10
438	Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer. Scientific Reports, 2019, 9, 3931.	1.6	15
439	STAT3 mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells. International Journal of Hematology, 2019, 109, 563-571.	0.7	21

#	Article	IF	Citations
440	Next generation sequencing and anti-cancer therapy. Journal of the Korean Medical Association, 2019, 62, 119.	0.1	4
441	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusionâ€“Driven Cancer. Cancer Discovery, 2019, 9, 605-616.	7.7	11
442	Using clinical genomic sequencing to guide personalized cancer therapy in China. Personalized Medicine, 2019, 16, 287-299.	0.8	2
443	First-Line Nivolumab Plus Ipilimumab in Advanced Nonâ€“Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Journal of Clinical Oncology, 2019, 37, 992-1000.	0.8	457
444	Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Nonâ€“Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA - Journal of the American Medical Association, 2019, 321, 1391.	3.8	370
445	Prioritization of cancer therapeutic targets using CRISPRâ€“Cas9 screens. Nature, 2019, 568, 511-516.	13.7	886
446	Hepatocellular Carcinoma. New England Journal of Medicine, 2019, 380, 1450-1462.	13.9	2,966
447	An unbiased in vitro screen for activating epidermal growth factor receptor mutations. Journal of Biological Chemistry, 2019, 294, 9377-9389.	1.6	17
448	Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open, 2019, 4, e000444.	2.0	8
449	Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nature Genetics, 2019, 51, 912-919.	9.4	209
450	Prospective Clinical Sequencing of Adult Glioma. Molecular Cancer Therapeutics, 2019, 18, 991-1000.	1.9	15
451	Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. , 2019, 7, 87.		60
452	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocrine-Related Cancer, 2019, 26, R31-R52.	1.6	49
453	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology, 2019, 70, 1262-1277.	1.8	150
454	Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. International Journal of Gynecological Cancer, 2019, 29, 430-433.	1.2	33
455	Road map for fibrolamellar carcinoma: progress and goals of a diversified approach . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 41-48.	1.8	5
456	Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. Haematologica, 2019, 104, e163-e166.	1.7	17
457	Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecologic Oncology, 2019, 153, 471-478.	0.6	18

#	Article	IF	Citations
458	PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. Journal of Clinical Medicine, 2019, 8, 435.	1.0	106
459	Polycomb/Trithorax Antagonism: Cellular Memory in Stem Cell Fate and Function. Cell Stem Cell, 2019, 24, 518-533.	5.2	48
460	Efficacy of Combined VEGFR1-3, PDGFÎ±/Î², and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	3.2	10
461	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	0.8	397
462	Prognostic implications of a molecular classifier derived from wholeâ€exome sequencing in nasopharyngeal carcinoma. Cancer Medicine, 2019, 8, 2705-2716.	1.3	13
463	Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients. Gynecologic Oncology, 2019, 153, 304-311.	0.6	7
464	Nonâ€invasive analysis of tumor mutation profiles and druggable mutations by sequencing of cell free DNA of Chinese metastatic breast cancer patients. Thoracic Cancer, 2019, 10, 807-814.	0.8	7
465	High prevalence of cancerâ€associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering. Human Mutation, 2019, 40, 516-524.	1.1	17
466	Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects. Blood, 2019, 133, 1977-1988.	0.6	61
467	Targeting Alterations in the RAFâ€“MEK Pathway. Cancer Discovery, 2019, 9, 329-341.	7.7	282
468	Application of Fluorescence in Life Sciences for Basic Research and Medical Diagnostics. Springer Series on Fluorescence, 2019, , 341-363.	0.8	0
469	Targeted mutation detection in breast cancer using MammaSeqâ„¢. Breast Cancer Research, 2019, 21, 22.	2.2	28
470	Decoding genetic and epigenetic information embedded in cell free DNA with adapted SALPâ€seq. International Journal of Cancer, 2019, 145, 2395-2406.	2.3	8
472	ESR1 mutations in metastatic lobular breast cancer patients. Npj Breast Cancer, 2019, 5, 9.	2.3	26
473	Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer Cell, 2019, 35, 369-384.e7.	7.7	238
474	Phase III trials in ovarian cancer: The evolving landscape of front line therapy. Gynecologic Oncology, 2019, 153, 436-444.	0.6	17
475	Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors. Modern Pathology, 2019, 32, 957-966.	2.9	19
476	Prospective analysis of 895 patients on a UK Genomics Review Board. ESMO Open, 2019, 4, e000469.	2.0	22

#	Article	IF	Citations
477	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. Oncologist, 2019, 24, e518-e525.	1.9	1
478	PAS-MUT with Somatic Mutations in Cancer and Classified Diseases for Clinical-Genomics Research: PAS-MUT & Somatic Mutations. , 2019, , .		0
479	Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. JCO Precision Oncology, 2019, 3, 1-13.	1.5	6
480	Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. JCO Precision Oncology, 2019, 3, 1-9.	1.5	23
481	TFEB Expression Profiling in Renal Cell Carcinomas. American Journal of Surgical Pathology, 2019, 43, 1445-1461.	2.1	38
482	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	1.5	7
483	Precision Oncology and the Universal Health Coverage System in Japan. JCO Precision Oncology, 2019, 3, 1-12.	1.5	39
484	Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion. Oncologist, 2019, 24, 1027-1030.	1.9	12
485	Duality of Purpose: Participant and Parent Understanding of the Purpose of Genomic Tumor Profiling Research Among Children and Young Adults With Solid Tumors. JCO Precision Oncology, 2019, 3, 1-17.	1.5	11
486	Predicting Tumor Mutational Burden from Liver Cancer Pathological Images Using Convolutional Neural Network. , 2019, , .		12
487	Genomic Analysis of Metastatic Solid Tumors in Veterans: Findings From the VHA National Precision Oncology Program. JCO Precision Oncology, 2019, 3, 1-13.	1.5	7
488	Structural and Functional Analysis of human lung cancer risk associated hOGG1 variant Ser326Cys in DNA repair gene by molecular dynamics simulation. Non-coding RNA Research, 2019, 4, 109-119.	2.4	5
489	TRK inhibitors in TRK fusion-positive cancers. Annals of Oncology, 2019, 30, viii23-viii30.	0.6	192
490	Identifying patients with NTRK fusion cancer. Annals of Oncology, 2019, 30, viii16-viii22.	0.6	169
491	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2019, 3, 1-12.	1.5	58
492	Tumour mutational burden: primary versus metastatic tissue creates systematic bias. Immuno-Oncology Technology, 2019, 4, 8-14.	0.2	26
493	Thyroid Cancer Brain Metastasis. Clinical Nuclear Medicine, 2019, 44, 544-549.	0.7	13
494	Tankyrase inhibition sensitizes cells to CDK4 blockade. PLoS ONE, 2019, 14, e0226645.	1.1	6

#	Article	IF	Citations
495	New and Emerging Biomarkers in Endocrine Pathology. Advances in Anatomic Pathology, 2019, 26, 198-209.	2.4	11
496	The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. Journal of Thoracic Disease, 2019, 11, 4507-4515.	0.6	27
497	A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. BioMed Research International, 2019, 2019, 1-10.	0.9	16
498	RAS as Supporting Actor in Breast Cancer. Frontiers in Oncology, 2019, 9, 1199.	1.3	46
499	Biomarkers in renal cell carcinoma. Memo - Magazine of European Medical Oncology, 2019, 12, 342-346.	0.3	1
500	Old Soldiers Never Die: Is There Still a Role for Immunohistochemistry in the Era of Next-Generation Sequencing Panel Testing?. Journal of Thoracic Oncology, 2019, 14, 2035-2038.	0.5	10
501	The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2019, 9, 1161.	1.3	96
502	Applications and analysis of targeted genomic sequencing in cancer studies. Computational and Structural Biotechnology Journal, 2019, 17, 1348-1359.	1.9	88
503	Using somatic variant richness to mine signals from rare variants in the cancer genome. Nature Communications, 2019, 10, 5506.	5.8	10
504	A view on drug resistance in cancer. Nature, 2019, 575, 299-309.	13.7	1,391
505	Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. Cancers, 2019, 11, 1904.	1.7	11
506	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2019, 25, 5961-5971.	3.2	118
507	Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. Nature Communications, 2019, 10, 5712.	5.8	27
508	Metastatic Mixed Adenoneuroendocrine Carcinoma of the Colon with Response to Immunotherapy with Pembrolizumab: A Case Report. Journal of Immunotherapy, 2019, 42, 274-277.	1.2	9
509	Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. Frontiers in Oncology, 2019, 9, 1287.	1.3	22
510	Pan-cancer whole-genome analyses of metastatic solid tumours. Nature, 2019, 575, 210-216.	13.7	722
511	Integrated genomic profiling expands clinical options for patients with cancer. Nature Biotechnology, 2019, 37, 1351-1360.	9.4	103
512	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer Journal, 2019, 9, 101.	2.8	40

#	Article	IF	Citations
513	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nature Medicine, 2019, 25, 1715-1720.	15.2	194
514	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	15.2	485
515	GliomaDB: A Web Server for Integrating Glioma Omics Data and Interactive Analysis. Genomics, Proteomics and Bioinformatics, 2019, 17, 465-471.	3.0	19
516	Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. American Journal of Dermatopathology, 2019, 41, 264-272.	0.3	29
517	Detection of Early Human Papillomavirusâ€“Associated Cancers by Liquid Biopsy. JCO Precision Oncology, 2019, 3, 1-17.	1.5	64
518	Tumor Mutational Burden Is Site Specific in Nonâ€“Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases. JCO Precision Oncology, 2019, 3, 1-13.	1.5	13
519	Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. JCO Precision Oncology, 2019, 3, 1-9.	1.5	26
520	Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. JCO Precision Oncology, 2019, 3, 1-11.	1.5	19
521	An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. Oncologist, 2019, 24, e1294-e1302.	1.9	67
522	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern Pathology, 2019, 32, 81-87.	2.9	10
523	JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy. Human Pathology, 2019, 88, 87-91.	1.1	20
524	The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 205-215.	2.9	22
525	Mutational Landscape of Ovarian Adult Granulosa Cell Tumors from Whole Exome and Targeted TERT Promoter Sequencing. Molecular Cancer Research, 2019, 17, 177-185.	1.5	36
526	DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression. EBioMedicine, 2019, 39, 280-291.	2.7	21
527	Phosphatidylinositol 3â€kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. Cancer, 2019, 125, 1185-1199.	2.0	36
528	Next-Generation Sequencingâ€“Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. Journal of Molecular Diagnostics, 2019, 21, 307-317.	1.2	19
529	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	3.4	426
530	Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing. Journal of Molecular Diagnostics, 2019, 21, 198-213.	1.2	2

#	Article	IF	Citations
531	Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. Japanese Journal of Clinical Oncology, 2019, 49, 174-182.	0.6	4
532	What Makes a Kinase Promiscuous for Inhibitors?. Cell Chemical Biology, 2019, 26, 390-399.e5.	2.5	59
533	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Annals of Oncology, 2019, 30, 44-56.	0.6	1,742
534	High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer. Molecular Cancer Research, 2019, 17, 469-475.	1.5	18
535	Current and future perspectives ofÂliquid biopsies in genomics-driven oncology. Nature Reviews Genetics, 2019, 20, 71-88.	7.7	912
536	Prevalence of ROS1 fusion in Chinese patients with nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 47-53.	0.8	29
537	PreMedKB: an integrated precision medicine knowledgebase for interpreting relationships between diseases, genes, variants and drugs. Nucleic Acids Research, 2019, 47, D1090-D1101.	6.5	45
538	Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing. Annals of Hematology, 2019, 98, 657-668.	0.8	7
539	The Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to Clinic. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a036269.	2.9	43
540	Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Annals of Oncology, 2019, 30, 115-123.	0.6	63
541	Estrogen Receptor and Breast Cancer. Cancer Drug Discovery and Development, 2019, , .	0.2	4
542	Novel rearrangements involving the RET gene in papillary thyroid carcinoma. Cancer Genetics, 2019, 230, 13-20.	0.2	20
543	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	7.7	115
544	Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Modern Pathology, 2019, 32, 609-620.	2.9	112
545	The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target. Medical Oncology, 2019, 36, 5.	1.2	19
546	Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy. Clinical Cancer Research, 2019, 25, 2064-2071.	3.2	59
547	Innovation in oncology clinical trial design. Cancer Treatment Reviews, 2019, 74, 15-20.	3.4	41
548	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer, 2019, 125, 1441-1448.	2.0	28

#	Article	IF	Citations
549	Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer, 2019, 130, 50-58.	0.9	127
550	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
551	Should next-generation sequencing tests be performed on all cancer patients?. Expert Review of Molecular Diagnostics, 2019, 19, 89-93.	1.5	21
552	Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14â€“mutant Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 1248-1260.	3.2	92
553	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical Cancer Research, 2019, 25, 967-976.	3.2	164
554	Molecular Mechanisms of Endocrine Resistance. Cancer Drug Discovery and Development, 2019, , 265-307.	0.2	5
555	Fibroblast growth factor receptors as treatment targets in clinical oncology. Nature Reviews Clinical Oncology, 2019, 16, 105-122.	12.5	227
556	Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Molecular Cancer Research, 2019, 17, 457-468.	1.5	29
557	Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 407-420.	1.4	39
558	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research, 2019, 25, 2116-2126.	3.2	390
559	Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptorâ€“directed therapies. Nature Genetics, 2019, 51, 207-216.	9.4	170
560	Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nature Reviews Clinical Oncology, 2019, 16, 227-240.	12.5	132
561	Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Pharmacogenomics, 2019, 20, 113-127.	0.6	9
562	Next generation sequencingâ€based gene panel tests for the management of solid tumors. Cancer Science, 2019, 110, 6-15.	1.7	107
563	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute, 2019, 111, 575-583.	3.0	96
564	Relationship between formalin reagent and success rate of targeted sequencing analysis using formalin fixed paraffin embedded tissues. Clinica Chimica Acta, 2019, 488, 129-134.	0.5	30
565	Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development. Molecular and Cellular Proteomics, 2019, 18, 437-447.	2.5	22
566	Size matters: Dissecting key parameters for panelâ€based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	2.3	131

#	Article	IF	Citations
567	Genomic Differences Between â€œPrimaryâ€•and â€œSecondaryâ€•Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European Urology, 2019, 75, 231-239.	0.9	104
568	DNA repair defects in prostate cancer: impact for screening, prognostication and treatment. BJU International, 2019, 123, 769-776.	1.3	35
569	A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. Nature Reviews Clinical Oncology, 2019, 16, 9-10.	12.5	4
570	Intracellular Signaling. , 2020, , 24-46.e12.		0
571	HER2-targeted therapies â€” a role beyond breast cancer. Nature Reviews Clinical Oncology, 2020, 17, 33-48.	12.5	569
572	ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene, 2020, 39, 487-502.	2.6	72
573	Microsatellite instability detection using a large next-generation sequencing cancer panel across diverse tumour types. Journal of Clinical Pathology, 2020, 73, 83-89.	1.0	18
574	Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. Seminars in Cancer Biology, 2020, 61, 180-198.	4.3	28
575	Tumor-Based Genetic Testing and Familial Cancer Risk. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036590.	2.9	27
576	ID1 Mediates Escape from TGFÎ² Tumor Suppression in Pancreatic Cancer. Cancer Discovery, 2020, 10, 142-157.	7.7	59
577	Genetic alterations in cell cycle regulation-associated genes may promote primary progression of gastrointestinal stromal tumors. Laboratory Investigation, 2020, 100, 426-437.	1.7	6
578	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2020, 22, 823-834.	1.2	29
579	Rapid fully-automated assay for routine molecular diagnosis of BRAF mutations for personalized therapy of low grade gliomas. Pediatric Hematology and Oncology, 2020, 37, 29-40.	0.3	4
580	Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing. Journal of Human Genetics, 2020, 65, 125-132.	1.1	6
581	Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clinical Cancer Research, 2020, 26, 419-427.	3.2	60
582	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist, 2020, 25, e147-e159.	1.9	220
583	NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Modern Pathology, 2020, 33, 38-46.	2.9	373
584	Sclerosing epithelioid mesenchymal neoplasm of the pancreasÂâ€“Âa proposed new entity. Modern Pathology, 2020, 33, 456-467.	2.9	10

#	Article	IF	Citations
585	CLAmpâ€seq: A Novel Ampliconâ€Based NGS Assay with Concatemer Error Correction for Improved Detection of Actionable Mutations in Plasma cfDNA from Patients with NSCLC. Small Methods, 2020, 4, 1900357.	4.6	9
586	New Insights into Tumor Heterogeneity: A Case of Solid-Oncocytic Epithelial-Myoepithelial Carcinoma of the Parotid Gland Harboring a HRAS and Heterogeneous Terminating ARID1A Mutation. Head and Neck Pathology, 2020, 14, 554-558.	1.3	12
587	New insights on human essential genes based on integrated analysis and the construction of the HEGIAP web-based platform. Briefings in Bioinformatics, 2020, 21, 1397-1410.	3.2	51
588	Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers. Seminars in Cancer Biology, 2020, 60, 334-343.	4.3	32
589	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology, 2020, 6, 84.	3.4	66
590	Clinical and molecular characterization of primary sclerosing epithelioid fibrosarcoma of bone and review of the literature. Genes Chromosomes and Cancer, 2020, 59, 217-224.	1.5	26
591	The genetic script of metastasis. Biological Reviews, 2020, 95, 244-266.	4.7	9
592	The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discovery, 2020, 10, 54-71.	7.7	820
593	DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Modern Pathology, 2020, 33, 648-656.	2.9	90
594	Engaging chromatin: PRC2 structure meets function. British Journal of Cancer, 2020, 122, 315-328.	2.9	81
595	The anaphaseâ€promoting complex: A key mitotic regulator associated with somatic mutations occurring in cancer. Genes Chromosomes and Cancer, 2020, 59, 189-202.	1.5	12
596	The mutational landscape of mucosal melanoma. Seminars in Cancer Biology, 2020, 61, 139-148.	4.3	112
597	Precision Treatment and Prevention of Colorectal Cancerâ€"Hope or Hype?. Gastroenterology, 2020, 158, 441-446.	0.6	12
598	Cancerâ€associated missense mutations enhance the pluripotency reprogramming activity of OCT4 and SOX17. FEBS Journal, 2020, 287, 122-144.	2.2	11
599	A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nature Cancer, 2020, 1, 59-74.	5.7	124
600	Diffuse capillary malformation with overgrowth contains somatic PIK3CA variants. Clinical Genetics, 2020, 97, 736-740.	1.0	22
601	In Search of the Long-Desired â€˜Copernican Therapeutic Revolutionâ€™ in Small-Cell Lung Cancer. Drugs, 2020, 80, 241-262.	4.9	12
602	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. Journal of the National Cancer Institute, 2020, 112, 1021-1029.	3.0	138

#	Article	IF	Citations
603	Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer, 2020, 126, 1274-1282.	2.0	37
604	Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. Modern Pathology, 2020, 33, 1092-1103.	2.9	18
605	Relevance and actionable mutational spectrum in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2020, 49, 427-434.	1.4	10
606	Molecular profiling of CNS tumors for the treatment and management of disease. Journal of Clinical Neuroscience, 2020, 71, 311-315.	0.8	6
607	ATRX affects the repair of telomeric DSBs by promoting cohesion and a DAXX-dependent activity. PLoS Biology, 2020, 18, e3000594.	2.6	46
608	An Activating Mutation in ERK Causes Hyperplastic Tumors in a scribble Mutant Tissue in Drosophila. Genetics, 2020, 214, 109-120.	1.2	9
609	Molecular Characterization of a Rare Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation in a 24 Year Old. International Journal of Surgical Pathology, 2020, 28, 454-463.	0.4	1
610	Tumor Mutation Burden and Checkpoint Immunotherapy Markers in NUT Midline Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 495-500.	0.6	16
611	Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursorâ€"a case report and review of literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 609-614.	1.4	19
612	Simultaneous Detection of Gene Fusions and Base Mutations in Cancer Tissue Biopsies by Sequencing Dual Nucleic Acid Templates in Unified Reaction. Clinical Chemistry, 2020, 66, 178-187.	1.5	20
613	Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clinical Cancer Research, 2020, 26, 2047-2064.	3.2	77
614	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Journal of Clinical Oncology, 2020, 38, 406-414.	0.8	60
615	Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeqâ„¢ Assay. Molecular Diagnosis and Therapy, 2020, 24, 103-111.	1.6	1
616	Methods and resources to access mutation-dependent effects on cancer drug treatment. Briefings in Bioinformatics, 2020, 21, 1886-1903.	3.2	5
617	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of Thoracic Oncology, 2020, 15, 231-247.	0.5	172
618	Ewing sarcoma with FEV gene rearrangements is a rare subset with predilection for extraskeletal locations and aggressive behavior. Genes Chromosomes and Cancer, 2020, 59, 286-294.	1.5	18
619	Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 1114-1125.	3.2	57
620	Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecologic Oncology, 2020, 156, 194-202.	0.6	35

#	Article	IF	Citations
621	Exceptional Responses After Cessation of Therapy With Alkylating Agents for Pancreatic Neuroendocrine Tumors. Pancreas, 2020, 49, e14-e16.	0.5	2
622	Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFRâ€ANXA2, EGFRâ€RAD51, ATR and BRCA2 mutations: A case report. Thoracic Cancer, 2020, 11, 456-460.	0.8	8
623	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical Cancer Research, 2020, 26, 1624-1632.	3.2	103
624	Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes. Journal of Cancer, 2020, 11, 776-780.	1.2	77
625	Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma. Modern Pathology, 2020, 33, 1207-1219.	2.9	43
626	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
627	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. Frontiers in Oncology, 2020, 10, 1634.	1.3	2
628	Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutationsâ€"A Perspective from a Real-World Precision Medicine Cohort. Molecular Cancer Therapeutics, 2020, 19, 2612-2620.	1.9	10
629	KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Annals of Oncology, 2020, 31, 1746-1754.	0.6	140
630	Genetic Alterations of Metastatic Colorectal Cancer. Biomedicines, 2020, 8, 414.	1.4	27
631	Systems Biology and Experimental Model Systems of Cancer. Journal of Personalized Medicine, 2020, 10, 180.	1.1	15
632	Genetic basis of SMARCB1 protein loss in 22 sinonasal carcinomas. Human Pathology, 2020, 104, 105-116.	1.1	14
633	KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma. Lung Cancer, 2020, 149, 41-45.	0.9	46
634	Transcriptomics and solid tumors: The next frontier in precision cancer medicine. Seminars in Cancer Biology, 2022, 84, 50-59.	4.3	36
635	Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies. Trends in Genetics, 2020, 36, 936-950.	2.9	172
636	Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer. Frontiers in Oncology, 2020, 10, 1643.	1.3	4
637	The Role of Stereotactic Biopsy in Brain Metastases. Neurosurgery Clinics of North America, 2020, 31, 515-526.	0.8	6
638	The role of the SWI/SNF chromatin remodelling complex in the response to DNA double strand breaks. DNA Repair, 2020, 93, 102919.	1.3	26

#	Article	IF	Citations
639	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199.		7
640	Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey. BMC Cancer, 2020, 20, 994.	1.1	10
641	Clonal Evolution and Timing of Metastatic Colorectal Cancer. Cancers, 2020, 12, 2938.	1.7	9
642	Chromosome 3p loss of heterozygosity and reduced expression of H3K36me3 correlate with longer relapse-free survival in sacral conventional chordoma. Human Pathology, 2020, 104, 73-83.	1.1	5
643	SMARCB1-deficient carcinomas of the head and neck region: a cytopathologic characterization. Journal of the American Society of Cytopathology, 2020, 9, 494-501.	0.2	3
644	Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers. Scientific Reports, 2020, 10, 17769.	1.6	35
645	Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions. BMC Cancer, 2020, 20, 944.	1.1	9
646	Lung adenocarcinoma in a patient with a cis EGFR L858Râ€K860I doublet mutation identified using NGS â€based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib. Thoracic Cancer, 2020, 11, 3599-3604.	0.8	2
647	Impact of DNA integrity on the success rate of tissueâ€based nextâ€generation sequencing: Lessons from nationwide cancer genome screening project SCRUMâ€Japan GIâ€SCREEN. Pathology International, 2020, 70, 932-942.	0.6	19
648	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology, 2020, 38, 3883-3894.	0.8	168
649	Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma. Journal of Cancer, 2020, 11, 6516-6529.	1.2	9
650	The Immunotherapy Landscape in Renal Cell Carcinoma. BioDrugs, 2020, 34, 733-748.	2.2	27
651	Direct plasmonic detection of circulating RAS mutated DNA in colorectal cancer patients. Biosensors and Bioelectronics, 2020, 170, 112648.	5.3	24
652	Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants. Human Pathology, 2020, 106, 45-53.	1.1	13
653	Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel. Acta OncolÃ³gica, 2020, 59, 1438-1446.	0.8	4
654	BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency. Cancer Research, 2020, 80, 3841-3854.	0.4	32
655	Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts. Journal of Neuropathology and Experimental Neurology, 2020, 79, 843-854.	0.9	32
656	Catalog of 5â€² fusion partners in RET+ NSCLC Circa 2020. JTO Clinical and Research Reports, 2020, 1, 100037.	0.6	17

#	Article	IF	Citations
657	Progresses Toward Precision Medicine in RET-altered Solid Tumors. Clinical Cancer Research, 2020, 26, 6102-6111.	3.2	39
658	Basket trials: From tumour gnostic to tumour agnostic drug development. Cancer Treatment Reviews, 2020, 90, 102082.	3.4	15
659	Advances in epigenetic techniques to study development and diseases. , 2020, , 673-691.		0
660	Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes. Nature Communications, 2020, 11, 3563.	5.8	26
661	Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC). American Journal of Surgical Pathology, 2020, 44, 901-916.	2.1	34
662	Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma. Acta Neuropathologica Communications, 2020, 8, 111.	2.4	19
663	Response to Crizotinib in ROS1 Fusionâ€“Positive Intrahepatic Cholangiocarcinoma. JCO Precision Oncology, 2020, 4, 825-828.	1.5	7
664	Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. Cancer, 2020, 126, 4126-4135.	2.0	5
665	Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer. Cancers, 2020, 12, 3355.	1.7	29
666	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nature Cancer, 2020, 1, 1188-1203.	5.7	114
667	A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients. Annals of Translational Medicine, 2020, 8, 1290-1290.	0.7	11
668	Construction of a diseaseâ€specific lncRNAâ€miRNAâ€mRNA regulatory network reveals potential regulatory axes and prognostic biomarkers for hepatocellular carcinoma. Cancer Medicine, 2020, 9, 9219-9235.	1.3	16
669	Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic. Genes, 2020, 11, 1367.	1.0	5
670	Role of the KEAP1-NRF2 Axis in Renal Cell Carcinoma. Cancers, 2020, 12, 3458.	1.7	17
671	Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Seminars in Cancer Biology, 2022, 79, 180-196.	4.3	64
672	Mastermind: A Comprehensive Genomic Association Search Engine for Empirical Evidence Curation and Genetic Variant Interpretation. Frontiers in Genetics, 2020, 11, 577152.	1.1	46
673	A complex DICER1 syndrome phenotype associated with a germline pathogenic variant affecting the RNase IIIa domain of DICER1. Journal of Medical Genetics, 2022, 59, 141-146.	1.5	9
674	Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Reports, 2020, 33, 108444.	2.9	118

#	Article	IF	Citations
675	Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer, 2020, 20, 1185.	1.1	75
676	Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering. Genome Medicine, 2020, 12, 110.	3.6	22
677	Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nature Communications, 2020, 11, 5679.	5.8	41
679	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. Molecular Cell, 2020, 80, 562-577.	4.5	54
680	Molecular Markers Guiding Thyroid Cancer Management. Cancers, 2020, 12, 2164.	1.7	34
681	Discovery through clinical sequencing in oncology. Nature Cancer, 2020, 1, 774-783.	5.7	29
682	The emerging role of PARP inhibitors in prostate cancer. Expert Review of Anticancer Therapy, 2020, 20, 715-726.	1.1	12
683	A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial). Medicine (United States), 2020, 99, e21457.	0.4	9
684	Dabrafenib and Trametinib in Patients With Tumors With BRAF^{V600E} Mutations: Results of the NCI-MATCH Trial Subprotocol H. Journal of Clinical Oncology, 2020, 38, 3895-3904.	0.8	145
685	Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers. Future Oncology, 2020, 16, 2295-2306.	1.1	5
686	CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors. Frontiers in Immunology, 2020, 11, 1620.	2.2	44
687	Lung cancer biomarker tests: the history and perspective in Japan. Translational Lung Cancer Research, 2020, 9, 879-886.	1.3	3
688	Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3285-3294.	1.8	19
689	Precision medicine in non-small cell lung cancer: Current applications and future directions. Seminars in Cancer Biology, 2022, 84, 184-198.	4.3	106
690	Rare Germline DICER1 Variants in Pediatric Patients With Cushing's Disease: What Is Their Role?. Frontiers in Endocrinology, 2020, 11, 433.	1.5	7
691	Prognostic Value of Immune Environment Analysis in Small Bowel Adenocarcinomas with Verified Mutational Landscape and Predisposing Conditions. Cancers, 2020, 12, 2018.	1.7	5
692	Targeting p53 for the treatment of cancer. Seminars in Cancer Biology, 2022, 79, 58-67.	4.3	177
693	Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic Oncology, 2020, 159, 150-156.	0.6	43

#	Article	IF	Citations
694	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. British Journal of Cancer, 2020, 123, 1262-1270.	2.9	18
695	Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. Journal of Molecular Diagnostics, 2020, 22, 1238-1245.	1.2	9
696	Clinical utility of target captureâ€based panel sequencing in hematological malignancies: A multicenter feasibility study. Cancer Science, 2020, 111, 3367-3378.	1.7	11
697	Genome-Wide Screen for Context-Dependent Tumor Suppressors Identified Using in Vivo Models for Neoplasia in Drosophila. G3: Genes, Genomes, Genetics, 2020, 10, 2999-3008.	0.8	3
698	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European Urology, 2020, 78, 907-915.	0.9	21
699	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
700	Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. Cancers, 2020, 12, 1965.	1.7	31
701	A pan-cancer analysis reveals nonstop extension mutations causing SMAD4 tumour suppressor degradation. Nature Cell Biology, 2020, 22, 999-1010.	4.6	12
702	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. Experimental Hematology and Oncology, 2020, 9, 17.	2.0	21
703	An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants. Cancer Discovery, 2020, 10, 1654-1671.	7.7	71
704	TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma. Cancers, 2020, 12, 2224.	1.7	8
705	Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma. Cell Systems, 2020, 11, 196-207.e7.	2.9	24
706	The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2020, 15, 1844-1856.	0.5	83
707	Immune Oncology Biomarkers in Lung Cancer: an Overview. Current Oncology Reports, 2020, 22, 107.	1.8	8
708	Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas. Clinical Orthopaedics and Related Research, 2020, 478, 2461-2476.	0.7	9
710	Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma. Clinical Colorectal Cancer, 2021, 20, 177-185.e13.	1.0	23
711	Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 541479.	1.3	26
712	Targeting KRAS-Mutant Nonâ€“Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. Journal of Clinical Oncology, 2020, 38, 4208-4218.	0.8	30

#	Article	IF	Citations
713	CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC). Cancer Cell International, 2020, 20, 519.	1.8	21
714	PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come. ESMO Open, 2020, 5, e000890.	2.0	8
715	Retrospective Cohort: Genomic Differences Between Pigmented Spindle Cell Nevi of Reed and Reed-Like Melanomas. American Journal of Dermatopathology, 2020, 42, 641-647.	0.3	0
716	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. Clinical Cancer Research, 2020, 26, 5448-5455.	3.2	12
717	Metastatic colon cancer of the small intestine diagnosed using genetic analysis: a case report. Diagnostic Pathology, 2020, 15, 106.	0.9	1
718	The Prognostic Significance ofÂRB and PI3K Pathway Alterations in IDH-Mutant Grade II/III Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1019-1023.	0.9	3
719	Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188420.	3.3	34
720	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell, 2020, 38, 534-550.e9.	7.7	67
721	Epigenomic Reprogramming as a Driver of Malignant Glioma. Cancer Cell, 2020, 38, 647-660.	7.7	66
722	Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell, 2020, 182, 1232-1251.e22.	13.5	371
723	From Patient Engagement to Precision Oncology: Leveraging Informatics to Advance Cancer Care. Yearbook of Medical Informatics, 2020, 29, 235-242.	0.8	8
724	Pten and Dicer1 loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma. Oncogene, 2020, 39, 6286-6299.	2.6	9
725	RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?. Critical Reviews in Biochemistry and Molecular Biology, 2020, 55, 386-407.	2.3	27
726	BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine, 2020, 60, 102988.	2.7	27
727	Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 5952-5961.	3.2	5
728	Analysis of NTRK mutation and clinicopathologic factors in lung cancer patients in northeast China. International Journal of Biological Markers, 2020, 35, 36-40.	0.7	5
729	Metabolic Constrains Rule Metastasis Progression. Cells, 2020, 9, 2081.	1.8	13
730	Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer. Cancers, 2020, 12, 2616.	1.7	16

#	Article	IF	Citations
731	Clinical implications of nextâ€generation sequencingâ€based panel tests for malignant ovarian tumors. Cancer Medicine, 2020, 9, 7407-7417.	1.3	23
732	Inhibitors of BRAF dimers using an allosteric site. Nature Communications, 2020, 11, 4370.	5.8	48
733	KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma . OncoTargets and Therapy, 2020, Volume 13, 8317-8321.	1.0	13
734	RNA Sequencing of Hepatobiliary Cancer Cell Lines: Data and Applications to Mutational and Transcriptomic Profiling. Cancers, 2020, 12, 2510.	1.7	6
735	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine, 2020, 12, 78.	3.6	10
736	Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients. Cancers, 2020, 12, 2245.	1.7	2
738	TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for antiâ€CTLA4 treatment. Cancer Medicine, 2020, 9, 7151-7160.	1.3	33
739	Sharing the initial experience of pan-cancer panel analysis in high-risk renal cell carcinoma in the Korean population. BMC Urology, 2020, 20, 125.	0.6	6
740	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Research, 2020, 22, 91.	2.2	32
741	Isabl Platform, a digital biobank for processing multimodal patient data. BMC Bioinformatics, 2020, 21, 549.	1.2	26
742	Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. Hepatology, 2021, 74, 233-247.	3.6	18
743	Mutation Spectra of the MRN (MRE11, RAD50, NBS1/NBN) Break Sensor in Cancer Cells. Cancers, 2020, 12, 3794.	1.7	10
744	Molecular Features and Clinical Management of Hereditary Gynecological Cancers. International Journal of Molecular Sciences, 2020, 21, 9504.	1.8	13
745	A Catalog of 5â€™ Fusion Partners in ROS1-Positive NSCLC Circa 2020. JTO Clinical and Research Reports, 2020, 1, 100048.	0.6	9
746	Clinical impact of a cancer genomic profiling test using an inâ€house comprehensive targeted sequencing system. Cancer Science, 2020, 111, 3926-3937.	1.7	20
747	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	1.5	18
748	Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes. Cancers, 2020, 12, 2935.	1.7	4
749	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers, 2020, 12, 3236.	1.7	23

#	Article	IF	Citations
750	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO Precision Oncology, 2020, 4, 1307-1320.	1.5	9
751	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. JCO Precision Oncology, 2020, 4, 1280-1284.	1.5	1
752	Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. Npj Breast Cancer, 2020, 6, 59.	2.3	32
753	Biology- and Location-Oriented Precision Treatment of Rectal Cancer: Present and Future. Visceral Medicine, 2020, 36, 381-387.	0.5	1
754	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discovery, 2020, 10, 1808-1825.	7.7	388
755	Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. Acta Neuropathologica Communications, 2020, 8, 186.	2.4	26
756	Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. JAMA Network Open, 2020, 3, e2019452.	2.8	76
757	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nature Communications, 2020, 11, 5549.	5.8	76
758	Molecular Profilingâ€“Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges. Frontiers in Oncology, 2020, 10, 532403.	1.3	20
759	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in nonâ€“small cell lung cancer: Analysis of over 8000 cases. Cancer, 2020, 126, 3219-3228.	2.0	106
760	The clinical heterogeneity of round cell sarcomas with <scp>EWSR1</scp>/<scp>FUS</scp> gene fusions: Impact of gene fusion type on clinical features and outcome. Genes Chromosomes and Cancer, 2020, 59, 525-534.	1.5	35
761	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 4135-4142.	3.2	95
762	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nature Communications, 2020, 11, 2408.	5.8	86
763	Biomarkers in melanoma and nonâ€melanoma skin cancer prevention and risk stratification. Experimental Dermatology, 2022, 31, 4-12.	1.4	30
764	Increased activation of PI3 kinase-Î´ predisposes to B-cell lymphoma. Blood, 2020, 135, 638-643.	0.6	29
765	Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice. Cancers, 2020, 12, 1156.	1.7	21
766	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 821-831.	5.1	243
767	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discovery, 2020, 10, 1129-1139.	7.7	245

#	Article	IF	Citations
768	Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions. Frontiers in Immunology, 2020, 11, 777.	2.2	2
769	Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. Cancer Communications, 2020, 40, 260-269.	3.7	18
770	Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. Clinical Cancer Research, 2020, 26, 3662-3670.	3.2	107
771	Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis. Cancer Discovery, 2020, 10, 1038-1057.	7.7	37
772	Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nature Communications, 2020, 11, 2350.	5.8	45
773	Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer. Cancer Immunology Research, 2020, 8, 844-850.	1.6	12
774	Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e197-e206.	1.8	10
775	Genomic landscape of platinum resistant and sensitive testicular cancers. Nature Communications, 2020, 11, 2189.	5.8	43
776	The tumour microenvironment in pancreatic cancer â€" clinical challenges and opportunities. Nature Reviews Clinical Oncology, 2020, 17, 527-540.	12.5	590
777	High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. Diagnostic Pathology, 2020, 15, 50.	0.9	34
778	The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptorâ€"Positive Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 1174-1193.	7.7	176
779	Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort. Annals of Translational Medicine, 2020, 8, 446-446.	0.7	16
780	FGFR4: A promising therapeutic target for breast cancer and other solid tumors. , 2020, 214, 107590.		42
781	Molecular Profiling in Drug Development: Paving a Way Forward. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e309-e318.	1.8	5
782	Whole Genome Analysis of Ovarian Granulosa Cell Tumors Reveals Tumor Heterogeneity and a High-Grade TP53-Specific Subgroup. Cancers, 2020, 12, 1308.	1.7	41
783	Clinical patterns and genomic profiling of recurrent â€˜ultra-low riskâ€™ endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 717-723.	1.2	20
784	Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib. Frontiers in Oncology, 2020, 10, 729.	1.3	9
785	The dormant cancer cell life cycle. Nature Reviews Cancer, 2020, 20, 398-411.	12.8	286

#	Article	IF	Citations
786	Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. Breast Cancer Research and Treatment, 2020, 182, 491-502.	1.1	2
787	The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. PLoS ONE, 2020, 15, e0231999.	1.1	36
788	Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation. Modern Pathology, 2020, 33, 1989-2000.	2.9	14
789	Effects of estrogen receptor signaling on prostate cancer carcinogenesis. Translational Research, 2020, 222, 56-66.	2.2	7
790	Phase and context shape the function of composite oncogenic mutations. Nature, 2020, 582, 100-103.	13.7	31
791	Predictive markers of immune response in glioblastoma: hopes and facts. Future Oncology, 2020, 16, 1053-1063.	1.1	13
792	Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. Journal of the American Society of Cytopathology, 2020, 9, 332-345.	0.2	21
793	CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. Modern Pathology, 2020, 33, 2614-2625.	2.9	9
794	The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients. Frontiers in Oncology, 2020, 10, 726.	1.3	21
795	Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS ONE, 2020, 15, e0234302.	1.1	13
796	BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice. Nature Communications, 2020, 11, 3018.	5.8	16
797	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	0.5	182
798	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. Journal of Thoracic Oncology, 2020, 15, 1611-1623.	0.5	43
799	Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer. Pharmacological Research, 2020, 159, 105028.	3.1	45
800	Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Seminars in Cancer Biology, 2022, 79, 203-216.	4.3	12
801	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer, 2020, 126, 3939-3949.	2.0	44
802	Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. Modern Pathology, 2020, 33, 2397-2406.	2.9	16
803	Molecular characterization of diffuse malignant peritoneal mesothelioma. Modern Pathology, 2020, 33, 2269-2279.	2.9	34

#	Article	IF	Citations
804	The Hippo Pathway as a Driver of Select Human Cancers. Trends in Cancer, 2020, 6, 781-796.	3.8	39
805	FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091530.	1.4	12
806	BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. JCO Precision Oncology, 2020, 4, 665-679.	1.5	29
807	A Driver Never Works Aloneâ€"Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer. Cancers, 2020, 12, 1532.	1.7	12
808	The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Review of Anticancer Therapy, 2020, 20, 551-561.	1.1	23
809	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer, 2020, 146, 174-181.	0.9	8
810	Clonal Origin Evaluated by Trunk and Branching Drivers and Prevalence of Mutations in Multiple Lung Tumor Nodules. Molecular Diagnosis and Therapy, 2020, 24, 461-472.	1.6	3
811	Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma. Blood Advances, 2020, 4, 2392-2403.	2.5	11
812	Beyond the Variants: Mutational Patterns in Next-Generation Sequencing Data for Cancer Precision Medicine. Frontiers in Cell and Developmental Biology, 2020, 8, 370.	1.8	6
813	Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen. Nature Communications, 2020, 11, 2908.	5.8	40
814	Panâ€cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment. Clinical and Translational Medicine, 2020, 10, e109.	1.7	6
815	Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. Future Oncology, 2020, 16, 1751-1766.	1.1	20
816	The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. Cell and Bioscience, 2020, 10, 35.	2.1	57
817	Hormone Receptorâ€"Positive/Human Epidermal Growth Receptor 2â€"Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents. Oncologist, 2020, 25, e900-e908.	1.9	15
818	Targeting Kras^{g12c}â€mutant cancer with a mutationâ€specific inhibitor. Journal of Internal Medicine, 2020, 288, 183-191.	2.7	56
819	Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes. Annals of Translational Medicine, 2020, 8, 141-141.	0.7	44
820	The first case of gastric carcinoma with NTRK rearrangement: identification of a novel ATP1Bâ€"NTRK1 fusion. Gastric Cancer, 2020, 23, 944-947.	2.7	19
821	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature Communications, 2020, 11, 1459.	5.8	176

#	Article	IF	Citations
822	ecTMB: a robust method to estimate and classify tumor mutational burden. Scientific Reports, 2020, 10, 4983.	1.6	17
823	Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. Frontiers in Cell and Developmental Biology, 2020, 8, 155.	1.8	32
824	Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. Modern Pathology, 2020, 33, 1606-1617.	2.9	38
825	Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma. OncoImmunology, 2020, 9, 1734156.	2.1	21
826	Interplay between DNA damage repair and apoptosis shapes cancer evolution through aneuploidy and microsatellite instability. Nature Communications, 2020, 11, 1234.	5.8	23
827	Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-p53 Combined with Chemotherapy Treatment. Human Gene Therapy, 2020, 31, 881-890.	1.4	3
828	PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer. Npj Precision Oncology, 2020, 4, 6.	2.3	32
829	Acquisition of chromosome instability is a mechanism to evade oncogene addiction. EMBO Molecular Medicine, 2020, 12, e10941.	3.3	45
830	Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions. Theranostics, 2020, 10, 2949-2964.	4.6	25
831	Library preparation for next generation sequencing: A review of automation strategies. Biotechnology Advances, 2020, 41, 107537.	6.0	88
832	Artificial intelligence in oncology. Cancer Science, 2020, 111, 1452-1460.	1.7	166
833	Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet, The, 2020, 395, 1078-1088.	6.3	302
834	Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma. PLoS ONE, 2020, 15, e0229728.	1.1	31
835	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Drugs in R and D, 2020, 20, 55-73.	1.1	84
836	A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nature Genetics, 2020, 52, 448-457.	9.4	104
837	Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in LungÂAdenocarcinoma Patients . Lung Cancer: Targets and Therapy, 2020, Volume 11, 19-25.	1.3	7
838	Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncology, 2020, 104, 104631.	0.8	42
839	Clonal Hematopoiesis From Next Generation Sequencing of Plasma From a Patient With Lung Adenocarcinoma: A Case Report. Frontiers in Oncology, 2020, 10, 113.	1.3	3

#	Article	IF	Citations
840	Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors. Frontiers in Oncology, 2020, 10, 142.	1.3	37
841	The Functional Consequences of Eukaryotic Topoisomerase 1 Interaction with G-Quadruplex DNA. Genes, 2020, 11, 193.	1.0	13
842	Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. Modern Pathology, 2020, 33, 1466-1474.	2.9	28
843	Fibromatosis-like metaplastic carcinoma: a case report and review of the literature. Diagnostic Pathology, 2020, 15, 20.	0.9	15
844	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations ofÂtheÂQuality in Pathology Study. Journal of Thoracic Oncology, 2020, 15, 1177-1189.	0.5	81
845	Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, , .	0.8	5
846	The mutREAD method detects mutational signatures from low quantities of cancer DNA. Nature Communications, 2020, 11, 3166.	5.8	9
848	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. Modern Pathology, 2020, 33, 2221-2232.	2.9	23
849	Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud. , 2020, 8, e000381.		35
850	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clinical Cancer Research, 2020, 26, 4767-4776.	3.2	68
851	Metabolic Adaptations in Cancer Stem Cells. Frontiers in Oncology, 2020, 10, 1010.	1.3	100
852	Nextâ€generation sequencing of residual cytologic fixative preserved DNA from pancreatic lesions: A pilot study. Cancer Cytopathology, 2020, 128, 840-851.	1.4	6
853	Cellâ€free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience. Cancer Medicine, 2020, 9, 6093-6101.	1.3	32
854	Finding new cancer epigenetic and genetic biomarkers from cell-free DNA by combining SALP-seq and machine learning. Computational and Structural Biotechnology Journal, 2020, 18, 1891-1903.	1.9	13
855	The molecular basis for immune dysregulation by the hyperactivated E62K mutant of the GTPase RAC2. Journal of Biological Chemistry, 2020, 295, 12130-12142.	1.6	9
856	Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer Research, 2020, 80, 4233-4243.	0.4	18
857	Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood, 2020, 136, 1477-1486.	0.6	43
858	Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location. Oncology and Therapy, 2020, 8, 59-66.	1.0	4

#	Article	IF	Citations
859	An immune competent orthotopic model of endometrial cancer with metastasis. Heliyon, 2020, 6, e04075.	1.4	9
860	DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden. Cell Reports Medicine, 2020, 1, 100034.	3.3	46
861	The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. Oncogene, 2020, 39, 5455-5467.	2.6	12
862	The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. International Journal of Molecular Sciences, 2020, 21, 4507.	1.8	289
863	The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials, 2020, 21, 579.	0.7	16
864	Expanding molecular roles of UV-DDB: Shining light on genome stability and cancer. DNA Repair, 2020, 94, 102860.	1.3	22
865	Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma. Modern Pathology, 2020, 33, 2244-2255.	2.9	23
866	E-cadherin immunohistochemical expression in invasive lobular carcinoma of the breast: correlation with morphology and CDH1 somatic alterations. Human Pathology, 2020, 102, 44-53.	1.1	20
867	From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor. Genes, 2020, 11, 691.	1.0	30
868	Identification of the Mutational Landscape of Gynecological Malignancies. Journal of Cancer, 2020, 11, 4870-4883.	1.2	11
869	Mutation Status and Epithelial Differentiation Stratify Recurrence Risk in Chordoid Meningiomaâ€”A Multicenter Study with High Prognostic Relevance. Cancers, 2020, 12, 225.	1.7	14
870	A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability. Cell Reports, 2020, 30, 1385-1399.e7.	2.9	29
871	Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery, 2020, 10, 657-663.	7.7	93
872	The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 990-1002.	1.8	101
873	The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nature Medicine, 2020, 26, 181-187.	15.2	158
874	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. Cancer, 2020, 126, 1995-2002.	2.0	26
875	Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. Journal of Translational Medicine, 2020, 18, 99.	1.8	12
876	A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants. Frontiers in Cell and Developmental Biology, 2020, 8, 48.	1.8	30

#	Article	IF	Citations
877	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 507-516.	2.0	10
878	Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Annals of Oncology, 2020, 31, 599-608.	0.6	183
879	Establishment and Characterization of a Novel Primitive Yolk Sac Tumour Cell Line, TC587. Anticancer Research, 2020, 40, 759-766.	0.5	2
880	Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. Scientific Reports, 2020, 10, 2707.	1.6	29
881	Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. Expert Review of Molecular Diagnostics, 2020, 20, 601-610.	1.5	2
882	Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection. Cell Reports, 2020, 30, 2402-2415.e5.	2.9	51
883	Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. Science Immunology, 2020, 5, .	5.6	39
884	Chromosome arm aneuploidies shape tumour evolution and drug response. Nature Communications, 2020, 11, 449.	5.8	65
885	A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib. Lung Cancer, 2020, 142, 59-62.	0.9	18
886	Regorafenib in Combination with Firstâ€Line Chemotherapy for Metastatic Esophagogastric Cancer. Oncologist, 2020, 25, e68-e74.	1.9	10
887	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 2546-2555.	3.2	33
888	Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. Journal of Clinical Oncology, 2020, 38, 1655-1663.	0.8	138
889	Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. International Journal of Clinical Oncology, 2020, 25, 403-417.	1.0	19
890	Cancer Genome Evolutionary Trajectories in Metastasis. Cancer Cell, 2020, 37, 8-19.	7.7	140
891	Implementation and use of whole exome sequencing for metastatic solid cancer. EBioMedicine, 2020, 51, 102624.	2.7	29
892	Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes. Communications Biology, 2020, 3, 6.	2.0	9
893	Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. Lung Cancer, 2020, 141, 82-88.	0.9	23
894	Assessment of PDGFRÎ² promoter methylation in canine osteosarcoma using methylationâ€sensitive highâ€resolution melting analysis. Veterinary and Comparative Oncology, 2020, 18, 484-493.	0.8	2

#	Article	IF	Citations
895	Precision Medicine in Soft Tissue Sarcoma Treatment. Cancers, 2020, 12, 221.	1.7	20
896	â€œMetastatic Cancer of Unknown Primaryâ€•or â€œPrimary Metastatic Cancerâ€?. Frontiers in Oncology, 2019, 9, 1546.	1.3	35
897	KRAS: Structure, function, and development of anticancer drugs. , 2020, , 359-389.		0
898	Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients. Cancer Science, 2020, 111, 687-699.	1.7	58
899	Novel patient-derived preclinical models of liver cancer. Journal of Hepatology, 2020, 72, 239-249.	1.8	41
900	Molecular profiling for precision cancer therapies. Genome Medicine, 2020, 12, 8.	3.6	447
901	A proteinâ€•centric approach for exome variant aggregation enables sensitive association analysis with clinical outcomes. Human Mutation, 2020, 41, 934-945.	1.1	3
902	A Rare EGFRâ€“SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib. Oncologist, 2020, 25, 203-207.	1.9	16
903	Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Cells, 2020, 9, 198.	1.8	314
904	Genomic profiling in oncology clinical practice. Clinical and Translational Oncology, 2020, 22, 1430-1439.	1.2	4
905	Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2 â€wildtype astrocytomas. Brain Pathology, 2020, 30, 653-660.	2.1	3
906	Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?. Cancers, 2020, 12, 230.	1.7	9
907	In-silico Analysis of NF1 Missense Variants in ClinVar: Translating Variant Predictions into Variant Interpretation and Classification. International Journal of Molecular Sciences, 2020, 21, 721.	1.8	9
908	Modeling rectal cancer to advance neoadjuvant precision therapy. International Journal of Cancer, 2020, 147, 1405-1418.	2.3	25
909	Negative reactions ofBRAFmutationâ€specific immunohistochemistry tononâ€V600Emutations ofBRAF. Pathology International, 2020, 70, 253-261.	0.6	13
910	Molecular profiling of gynecologic cancers for treatment and management of disease â€“ demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants. Cancer Genetics, 2020, 242, 25-34.	0.2	2
911	Genomic profiling of multiple myeloma: New insights and modern technologies. Best Practice and Research in Clinical Haematology, 2020, 33, 101153.	0.7	7
912	Support of a molecular tumour board by an evidence-based decision management system for precision oncology. European Journal of Cancer, 2020, 127, 41-51.	1.3	25

#	Article	IF	Citations
913	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 198-213.	7.7	83
914	The current status and future prospects of precision medicine. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1423-1425.	1.4	1
915	An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. Journal of Cancer, 2020, 11, 883-892.	1.2	5
916	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. Journal of Clinical Oncology, 2020, 38, 1398-1408.	0.8	60
917	Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma. Acta Neuropathologica Communications, 2020, 8, 10.	2.4	26
918	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Therapy, 2020, 27, 841-853.	2.2	94
919	Clinical outcomes, localâ€“regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiotherapy and Oncology, 2020, 149, 205-211.	0.3	39
920	NRF2 as a regulator of cell metabolism and inflammation in cancer. Carcinogenesis, 2020, 41, 405-416.	1.3	160
921	Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity. Modern Pathology, 2020, 33, 1764-1772.	2.9	14
922	Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors. Clinical and Translational Gastroenterology, 2020, 11, e00149.	1.3	8
923	The Clinical Relevance of Frequent Germline Genetic Variants Detected by Targeted Sequencing in Patients With Rectal Adenocarcinoma (READ). Cancer Genomics and Proteomics, 2020, 17, 291-299.	1.0	2
924	Prevalence of Cytoplasmic Actin Mutations in Diffuse Large B-Cell Lymphoma and Multiple Myeloma: A Functional Assessment Based on Actin Three-Dimensional Structures. International Journal of Molecular Sciences, 2020, 21, 3093.	1.8	10
925	Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. JCO Precision Oncology, 2020, 4, 258-271.	1.5	16
926	CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. Molecular Cancer Therapeutics, 2020, 19, 661-672.	1.9	26
927	Implementation of a molecular tumor board at a regional level to improve access to targeted therapy. International Journal of Clinical Oncology, 2020, 25, 1234-1241.	1.0	9
928	JSCOâ€"ESMOâ€"ASCOâ€"JSMOâ€"TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Annals of Oncology, 2020, 31, 861-872.	0.6	94
929	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. Clinical Lung Cancer, 2020, 21, e488-e492.	1.1	5
930	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	5.7	96

#	Article	IF	Citations
931	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nature Cancer, 2020, 1, 452-468.	5.7	103
932	CDK12: cellular functions and therapeutic potential of versatile player in cancer. NAR Cancer, 2020, 2, zcaa003.	1.6	18
933	Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma. Liver International, 2020, 40, 1997-2007.	1.9	16
934	Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open, 2020, 5, e000634.	2.0	20
935	Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. , 2020, 8, e000147.		329
936	Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e47-e57.	1.8	30
937	Targeted deep sequencing helps distinguish independent primary tumors from intrapulmonary metastasis for lung cancer diagnosis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2359-2367.	1.2	9
938	ScaRâ€”a tool for sensitive detection of known fusion transcripts: establishing prevalence of fusions in testicular germ cell tumors. NAR Genomics and Bioinformatics, 2020, 2, lqz025.	1.5	1
939	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	1.6	47
940	RET Gene Fusions in Malignancies of the Thyroid and Other Tissues. Genes, 2020, 11, 424.	1.0	78
941	IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution. Cancer Medicine, 2020, 9, 4386-4394.	1.3	18
942	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications, 2020, 11, 1975.	5.8	37
943	The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis. International Journal of Molecular Sciences, 2020, 21, 2824.	1.8	18
944	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. European Urology, 2020, 78, 671-679.	0.9	72
945	Toward a More Precise Future for Oncology. Cancer Cell, 2020, 37, 431-442.	7.7	21
946	Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Leukemia, 2020, 34, 3206-3214.	3.3	8
947	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	13.7	374
948	Tumor Mutation Burden Computation in Two Pan-Cancer Precision Medicine Next-Generation Sequencing Panels. Journal of Computational Biology, 2020, 27, 1553-1560.	0.8	2

#	Article	IF	Citations
949	Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival. Cancer Research, 2020, 80, 2461-2471.	0.4	22
950	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical Cancer Research, 2020, 26, 3881-3888.	3.2	59
951	Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor. Biological Research, 2020, 53, 13.	1.5	5
952	Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data. JCO Clinical Cancer Informatics, 2020, 4, 321-335.	1.0	20
953	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precision Oncology, 2020, 4, 355-366.	1.5	93
954	Hypoxia Inducible Factor-1Î± Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells. Anticancer Research, 2020, 40, 1867-1874.	0.5	4
955	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood, 2020, 135, 773-777.	0.6	115
956	NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy. Oncologist, 2020, 25, e955-e963.	1.9	39
957	Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. Cancers, 2020, 12, 848.	1.7	14
958	The genomic landscape of advanced cancer. Nature Cancer, 2020, 1, 372-373.	5.7	8
959	Testing tumors from different anatomic sites for clonal relatedness using somatic mutation data. Biometrics, 2021, 77, 283-292.	0.8	2
960	Deciphering the impact of missense mutations on structure and dynamics of SMAD4 protein involved in pathogenesis of gall bladder cancer. Journal of Biomolecular Structure and Dynamics, 2021, 39, 1940-1954.	2.0	6
961	Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review. Clinical Lung Cancer, 2021, 22, e466-e469.	1.1	2
962	Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Seminars in Cancer Biology, 2021, 68, 209-229.	4.3	39
963	Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Seminars in Cancer Biology, 2021, 72, 123-135.	4.3	162
964	PDâ€L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced nonâ€small cell lung cancer?. Journal of Gene Medicine, 2021, 23, e3294.	1.4	14
965	Wholeâ€slide laser microdissection for tumour enrichment. Journal of Pathology, 2021, 253, 225-233.	2.1	4
966	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients withPIK3CA-Mutant Cancers. Clinical Cancer Research, 2021, 27, 447-459.	3.2	22

#	Article	IF	Citations
967	Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	3.0	38
968	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Research, 2021, 31, 178-186.	5.7	146
969	Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2021, 28, 817-825.	0.7	8
970	Whole-Exome and Transcriptome Analysis of UV-Exposed Epidermis and Carcinoma In Situ Reveals Early Drivers of Carcinogenesis. Journal of Investigative Dermatology, 2021, 141, 295-307.e13.	0.3	25
971	The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. British Journal of Cancer, 2021, 124, 156-160.	2.9	21
972	Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. Journal of Hepatology, 2021, 74, 613-626.	1.8	34
973	A novel GPCR target in correlation with androgen deprivation therapy for prostate cancer drug discovery. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 195-203.	1.2	4
974	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discovery, 2021, 11, 126-141.	7.7	34
975	Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. Modern Pathology, 2021, 34, 983-993.	2.9	11
976	Genomic mutational profiling of circulating tumour DNA in metastatic angiosarcoma. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e293-e295.	1.3	2
977	Combined Inhibition of GÎ±q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. Clinical Cancer Research, 2021, 27, 1476-1490.	3.2	29
978	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	49
979	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. Clinical Cancer Research, 2021, 27, 1997-2010.	3.2	15
980	Stimuliâ€Responsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy. Advanced Healthcare Materials, 2021, 10, e2001044.	3.9	27
981	Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. Cell Death and Differentiation, 2021, 28, 1477-1492.	5.0	26
982	A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing. Journal of Molecular Diagnostics, 2021, 23, 253-263.	1.2	20
983	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood, 2021, 137, 2103-2113.	0.6	57
984	Comprehensive molecular profiling broadens treatment options for breast cancer patients. Cancer Medicine, 2021, 10, 529-539.	1.3	23

#	Article	IF	Citations
985	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. Clinical Cancer Research, 2021, 27, 1316-1328.	3.2	39
986	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. Oncologist, 2021, 26, e394-e402.	1.9	39
987	Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA). Breast Cancer Research and Treatment, 2021, 185, 639-646.	1.1	2
988	Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus. Clinical and Translational Oncology, 2021, 23, 1304-1313.	1.2	4
989	Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Annals of Oncology, 2021, 32, 197-207.	0.6	94
991	Brain metastasis models: What should we aim to achieve better treatments?. Advanced Drug Delivery Reviews, 2021, 169, 79-99.	6.6	13
992	A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. Journal of Thoracic Oncology, 2021, 16, 419-427.	0.5	33
993	Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC. Molecular Therapy - Nucleic Acids, 2021, 23, 89-100.	2.3	25
994	Rapid and ultrasensitive detection of circulating human papillomavirus E7 cell-free DNA as a cervical cancer biomarker. Experimental Biology and Medicine, 2021, 246, 654-666.	1.1	16
995	RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	9
996	Clinicopathologic, genomic and protein expression characterization of 356 <scp>ROS1</scp> fusion driven solid tumors cases. International Journal of Cancer, 2021, 148, 1778-1788.	2.3	14
997	Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases. Molecular Cancer Therapeutics, 2021, 20, 564-576.	1.9	4
998	Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer. Advances in Radiation Oncology, 2021, 6, 100615.	0.6	6
999	Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 836-843.e1.	0.4	62
1000	Comprehensive genomic profiling for patients with chemotherapyâ€naÃ¯ve advanced cancer. Cancer Science, 2021, 112, 296-304.	1.7	21
1001	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell, 2021, 39, 154-173.	7.7	491
1002	Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. Cancer Discovery, 2021, 11, 282-292.	7.7	132
1003	IDH clonal heterogeneity segregates a subgroup of nonâ€1p/19q codeleted gliomas with unfavourable clinical outcome. Neuropathology and Applied Neurobiology, 2021, 47, 394-405.	1.8	4

#	Article	IF	Citations
1004	SMARCA4 mutations in KRASâ€mutant lung adenocarcinoma: a multiâ€cohort analysis. Molecular Oncology, 2021, 15, 462-472.	2.1	29
1005	Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation. Modern Pathology, 2021, 34, 438-444.	2.9	19
1006	Adverse histology, homozygous loss of CDKN2A/B, and complex genomic alterations in locally advanced/metastatic renal mucinous tubular and spindle cell carcinoma. Modern Pathology, 2021, 34, 445-456.	2.9	15
1007	Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut, 2021, 70, 743-760.	6.1	49
1008	Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. Oncologist, 2021, 26, e78-e89.	1.9	18
1009	Driver mutations occur frequently in metastases of wellâ€differentiated small intestine neuroendocrine tumours. Histopathology, 2021, 78, 556-566.	1.6	11
1010	CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features. Modern Pathology, 2021, 34, 358-370.	2.9	12
1011	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nature Reviews Clinical Oncology, 2021, 18, 56-62.	12.5	99
1012	Clinical use of a machine learning histopathological image signature in diagnosis and survival prediction of clear cell renal cell carcinoma. International Journal of Cancer, 2021, 148, 780-790.	2.3	27
1013	Molecular and clinicopathological features of appendiceal mucinous neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 413-426.	1.4	12
1014	Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer. Cancer Biology and Medicine, 2021, 18, 105-119.	1.4	4
1015	Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer. JCO Precision Oncology, 2021, 5, 27-32.	1.5	2
1016	Tumor Profiling at the Service of Cancer Therapy. Frontiers in Oncology, 2020, 10, 595613.	1.3	9
1017	The management of metastatic GIST: current standard and investigational therapeutics. Journal of Hematology and Oncology, 2021, 14, 2.	6.9	107
1018	Cancer research needs a better map. Nature, 2021, 589, 514-516.	13.7	57
1019	Benchmarking HLA genotyping and clarifying HLA impact on survival in tumor immunotherapy. Molecular Oncology, 2021, 15, 1764-1782.	2.1	17
1020	Liquid biopsy enters the clinic â€" implementation issues and future challenges. Nature Reviews Clinical Oncology, 2021, 18, 297-312.	12.5	609
1021	The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics, 2021, 53, 11-15.	9.4	139

#	Article	IF	Citations
1022	Genomic pan-cancer classification using image-based deep learning. Computational and Structural Biotechnology Journal, 2021, 19, 835-846.	1.9	5
1023	Recent Advancements in the Treatment of Brain Metastasis. Japanese Journal of Neurosurgery, 2021, 30, 365-373.	0.0	0
1024	Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis. Cell Death and Disease, 2021, 12, 106.	2.7	16
1025	A Novel m6A Gene Signature Associated With Regulatory Immune Function for Prognosis Prediction in Clear-Cell Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology, 2020, 8, 616972.	1.8	5
1026	Cancer type-specific alterations in actin genes: Worth a closer look?. International Review of Cell and Molecular Biology, 2021, 360, 133-184.	1.6	5
1027	Cancer of Unknown Primary: Challenges and Progress in Clinical Management. Cancers, 2021, 13, 451.	1.7	24
1028	Update on biology and management of mesothelioma. European Respiratory Review, 2021, 30, 200226.	3.0	37
1029	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. Translational Lung Cancer Research, 2021, 10, 202-220.	1.3	29
1030	Application of Next Generation Sequencing in Laboratory Medicine. Annals of Laboratory Medicine, 2021, 41, 25-43.	1.2	99
1031	Advances in anti-BRAF therapies for lung cancer. Investigational New Drugs, 2021, 39, 879-890.	1.2	22
1032	Genomic Profiling of Prostate Cancer: An Updated Review. World Journal of Men?s Health, 2022, 40, 368.	1.7	19
1033	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nature Communications, 2021, 12, 338.	5.8	64
1034	Cancer Genomic Profiling of Gynecological Malignancies by Todai OncoPanel, a Twin DNA and RNA Panel. Current Human Cell Research and Applications, 2021, , 27-39.	0.1	0
1035	Pediatric Mesothelioma With ALK Fusions. American Journal of Surgical Pathology, 2021, 45, 653-661.	2.1	22
1036	Clinical trials in drug delivery for the treatment of cancer. , 2021, , 509-519.		1
1037	Next-generation sequencing analysis suggests varied multistep mutational pathogenesis for endocrine mucin-producing sweat gland carcinoma with comments on INSM1 and MUC2 suggesting a conjunctival origin. Journal of the American Academy of Dermatology, 2022, 86, 1072-1079.	0.6	8
1038	Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). JCO Precision Oncology, 2021, 5, 215-226.	1.5	22
1039	Drug Sensitivity and Drug Repurposing Platform for Cancer Precision Medicine. Advances in Experimental Medicine and Biology, 2021, 1326, 47-53.	0.8	6

#	Article	IF	Citations
1040	Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors. British Journal of Cancer, 2021, 124, 1249-1259.	2.9	34
1041	Exploration of Coding and Non-coding Variants in Cancer Using GenomePaint. Cancer Cell, 2021, 39, 83-95.e4.	7.7	18
1043	Prognostic and immunological role of CD36: A pan-cancer analysis. Journal of Cancer, 2021, 12, 4762-4773.	1.2	23
1044	Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nature Communications, 2021, 12, 11.	5.8	121
1045	Results of a nationwide survey of Japanese pharmacists regarding the application of pharmacogenomic testing in precision medicine. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 649-657.	0.7	10
1046	Clinicopathological and molecular characteristics of patients with hypermutant lung cancer: A retrospective cohort study. Oncology Letters, 2021, 21, 329.	0.8	8
1047	The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma. Annals of the New York Academy of Sciences, 2021, 1490, 90-104.	1.8	12
1048	Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma. Oncologist, 2021, 26, e756-e768.	1.9	12
1049	Network-Based Target Prioritization and Drug Candidate Identification for Multiple Sclerosis: From Analyzing â€œOmics Dataâ€•to Druggability Simulations. ACS Chemical Neuroscience, 2021, 12, 917-929.	1.7	5
1050	Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance. Journal of Physical Education and Sports Management, 2021, 7, a005801.	0.5	9
1052	Mutations in the RAS/MAPK Pathway Drive Replication Repairâ€“Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. Cancer Discovery, 2021, 11, 1454-1467.	7.7	19
1053	ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. Journal of Clinical Investigation, 2021, 131, .	3.9	107
1054	Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing. American Journal of Clinical Pathology, 2021, 155, 781-792.	0.4	11
1055	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncology, 2021, 7, 525-533.	3.4	65
1056	Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Diagnostics, 2021, 11, 252.	1.3	2
1057	Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1365-1378.	1.2	2
1058	Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma. BMC Cancer, 2021, 21, 152.	1.1	7
1059	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. Modern Pathology, 2021, 34, 1425-1433.	2.9	19

#	Article	IF	Citations
1060	KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 2604-2612.	3.2	20
1061	Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. Cell Reports, 2021, 34, 108707.	2.9	16
1062	Association of clinico-genomic characteristics with tumor mutational burden in small cell lung cancer patients. Future Oncology, 2021, 17, 423-433.	1.1	2
1063	Performance Characteristics of Mutational Signature Analysis in Targeted Panel Sequencing. Archives of Pathology and Laboratory Medicine, 2021, 145, 1424-1431.	1.2	7
1064	Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. Cancer Cell, 2021, 39, 225-239.e8.	7.7	125
1065	Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Cancers, 2021, 13, 799.	1.7	28
1066	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	5.7	74
1067	Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan. Japanese Journal of Clinical Oncology, 2021, 51, 753-761.	0.6	10
1068	Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. Expert Review of Molecular Diagnostics, 2021, 21, 161-173.	1.5	2
1069	Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	1.5	10
1070	Molecular mechanics and dynamic simulations of well-known Kabuki syndrome-associated KDM6A variants reveal putative mechanisms of dysfunction. Orphanet Journal of Rare Diseases, 2021, 16, 66.	1.2	11
1071	Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2021, 70, 2367-2378.	2.0	7
1072	Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas. Clinical Cancer Research, 2021, 27, 2613-2623.	3.2	49
1073	Immune checkpoint blockade in renal cell carcinoma. Journal of Surgical Oncology, 2021, 123, 739-750.	0.8	13
1074	Clinical benefit for clinical sequencing using cancer panel testing. PLoS ONE, 2021, 16, e0247090.	1.1	3
1075	Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. Cancers, 2021, 13, 673.	1.7	9
1076	A Functional Taxonomy of Tumor Suppression in Oncogenic KRASâ€“Driven Lung Cancer. Cancer Discovery, 2021, 11, 1754-1773.	7.7	35
1077	Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?. Frontiers in Endocrinology, 2021, 12, 623182.	1.5	10

#	Article	IF	Citations
1078	Proteogenomics drives therapeutic hypothesis generation for precision oncology. British Journal of Cancer, 2021, 125, 1-3.	2.9	8
1079	Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates. Annals of Translational Medicine, 2021, 9, 465-465.	0.7	14
1081	Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers, 2021, 13, 1304.	1.7	2
1082	Noncanonical Gene Fusions Detected at the DNA Level Necessitate Orthogonal Diagnosis Methods Before Targeted Therapy. Journal of Thoracic Oncology, 2021, 16, 344-348.	0.5	6
1083	Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	28
1084	Multiâ€modal metaâ€analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor. Molecular Systems Biology, 2021, 17, e9526.	3.2	8
1085	Growth Hormone/Insulin Growth Factor Axis in Sex Steroid Associated Disorders and Related Cancers. Frontiers in Cell and Developmental Biology, 2021, 9, 630503.	1.8	16
1086	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. Molecular Cancer Research, 2021, 19, 1146-1155.	1.5	14
1087	Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy. Expert Review of Anticancer Therapy, 2021, 21, 887-900.	1.1	4
1088	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	3.9	32
1089	Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors. Journal of Pathology, 2021, 254, 20-30.	2.1	9
1091	Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development. OncoTargets and Therapy, 2021, Volume 14, 2121-2130.	1.0	8
1093	Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opinion on Investigational Drugs, 2021, 30, 401-409.	1.9	10
1094	Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3KÎ± Inhibitors. Cancer Research, 2021, 81, 2470-2480.	0.4	20
1095	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Medicine, 2021, 10, 2627-2635.	1.3	5
1096	Predictive biomarkers and clinical evidence. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 642-648.	1.2	9
1097	Telomerase Regulation: A Role for Epigenetics. Cancers, 2021, 13, 1213.	1.7	39
1098	Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer. Cancers, 2021, 13, 1397.	1.7	9

#	Article	IF	Citations
1099	Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. Oncologist, 2021, 26, 375-382.	1.9	8
1100	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical Cancer Research, 2021, 27, 3845-3853.	3.2	25
1101	Structural based screening of potential inhibitors of SMAD4: a step towards personalized medicine for gall bladder and other associated cancers. Molecular Diversity, 2021, 25, 1945-1961.	2.1	1
1102	Systematic characterization of mutations altering protein degradation in human cancers. Molecular Cell, 2021, 81, 1292-1308.e11.	4.5	36
1103	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	1.0	51
1104	Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma. International Journal of Gynecological Pathology, 2022, 41, 168-179.	0.9	9
1105	Histologyâ€based molecular profiling improves mutation detection for advanced thyroid cancer. Genes Chromosomes and Cancer, 2021, 60, 531-545.	1.5	5
1106	Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma. Molecular Cancer Research, 2021, 19, 991-1004.	1.5	19
1107	Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2021, 80, 354-365.	0.9	12
1108	Primary cutaneous SMARCB1 â€deficient carcinoma. Journal of Cutaneous Pathology, 2021, 48, 1051-1060.	0.7	3
1109	IDH-mutant gliomas with additional class-defining molecular events. Modern Pathology, 2021, 34, 1236-1244.	2.9	13
1110	Difference in tumor mutation burden between squamous cell carcinoma in the oral cavity and larynx. Oral Oncology, 2021, 114, 105142.	0.8	4
1111	Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. Cancers, 2021, 13, 1091.	1.7	21
1112	Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Diagnostics, 2021, 11, 469.	1.3	2
1113	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2021, 11, 622648.	1.3	11
1115	Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Frontiers in Oncology, 2021, 11, 638360.	1.3	42
1116	Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. Frontiers in Immunology, 2021, 12, 653358.	2.2	19
1117	When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncology and Therapy, 2021, 9, 89-110.	1.0	36

#	Article	IF	Citations
1118	Prognosis and Genomic Landscape of Liver Metastasis in Patients With Breast Cancer. Frontiers in Oncology, 2021, 11, 588136.	1.3	10
1119	The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients. Lung Cancer, 2021, 153, 66-72.	0.9	24
1120	Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	13
1121	Structureâ€"function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. Nature Communications, 2021, 12, 1382.	5.8	34
1122	Rapid EGFR Mutation Detection Using the Idylla Platform. Journal of Molecular Diagnostics, 2021, 23, 310-322.	1.2	19
1123	Roles of the nervous system in pancreatic cancer. Annals of Gastroenterological Surgery, 2021, 5, 623-633.	1.2	11
1124	Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo. Cancer Discovery, 2021, 11, 1736-1753.	7.7	59
1125	A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study). Annals of Surgical Oncology, 2021, 28, 8497-8505.	0.7	8
1126	Adult pilocytic astrocytoma in the molecular era: a comprehensive review. CNS Oncology, 2021, 10, CNS68.	1.2	13
1127	Clinical cancer genomic profiling. Nature Reviews Genetics, 2021, 22, 483-501.	7.7	79
1128	Mechanisms of Resistance to KRASG12C-Targeted Therapy. Cancer Discovery, 2021, 11, 1345-1352.	7.7	60
1131	A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer. Annals of Surgery, 2021, 274, 248-254.	2.1	4
1132	Mechanistic Differences of Activation of Rac1^{P29S} and Rac1^{A159V}. Journal of Physical Chemistry B, 2021, 125, 3790-3802.	1.2	9
1133	The RIT1 C-terminus associates with lipid bilayers via charge complementarity. Computational Biology and Chemistry, 2021, 91, 107437.	1.1	6
1134	Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy. Thyroid, 2021, 31, 1451-1462.	2.4	10
1135	Novel KRAS mutation in an unusual tectal low-grade glioma. BMJ Case Reports, 2021, 14, e242306.	0.2	1
1136	Predicting clinical outcomes using cancer progression associated signatures. Oncotarget, 2021, 12, 845-858.	0.8	1
1137	An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector Machine. Frontiers in Oncology, 2021, 11, 651809.	1.3	3

#	Article	IF	Citations
1138	Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine. Advanced Science, 2021, 8, 2100166.	5.6	18
1139	Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 3834-3844.	3.2	36
1140	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5586-5594.	3.2	178
1141	Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome. Leukemia Research, 2021, 103, 106540.	0.4	1
1142	Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab. Lung Cancer, 2021, 154, 105-112.	0.9	15
1143	Implications of the germline variants of DNA damage response genes detected by cancer precision medicine for radiological risk communication and cancer therapy decisions. Journal of Radiation Research, 2021, 62, i44-i52.	0.8	5
1144	MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer. Frontiers in Pharmacology, 2021, 12, 625593.	1.6	7
1145	Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. Clinical and Molecular Hepatology, 2021, 27, 236-245.	4.5	38
1146	Genomic profile of advanced breast cancer in circulating tumour DNA. Nature Communications, 2021, 12, 2423.	5.8	54
1147	Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma. Cancers, 2021, 13, 1769.	1.7	21
1148	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. Npj Breast Cancer, 2021, 7, 43.	2.3	16
1149	Argonaute integrated single-tube PCR system enables supersensitive detection of rare mutations. Nucleic Acids Research, 2021, 49, e75-e75.	6.5	66
1151	Enhancing the landscape of colorectal cancer using targeted deep sequencing. Scientific Reports, 2021, 11, 8154.	1.6	26
1152	TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 160, 103288.	2.0	20
1153	Molecular Characterization of â€œTrueâ€•Low-Grade IDH-Wildtype Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2021, 80, 431-435.	0.9	12
1154	Optimizing the diagnosis and management of ductal prostate cancer. Nature Reviews Urology, 2021, 18, 337-358.	1.9	21
1155	Identification of combinations of somatic mutations that predict cancer survival and immunotherapy benefit. NAR Cancer, 2021, 3, zcab017.	1.6	2
1156	A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing. International Cancer Conference Journal, 2021, 10, 174-180.	0.2	2

#	Article	IF	Citations
1157	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. Clinical Cancer Research, 2021, 27, 3491-3498.	3.2	8
1158	Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA. Nature Metabolism, 2021, 3, 558-570.	5.1	58
1159	Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nature Genetics, 2021, 53, 707-718.	9.4	61
1160	Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds. Oncogenesis, 2021, 10, 33.	2.1	13
1161	Predictive Value of KDM5C Alterations for Immune Checkpoint Inhibitors Treatment Outcomes in Patients With Cancer. Frontiers in Immunology, 2021, 12, 664847.	2.2	5
1162	Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations. Cancers, 2021, 13, 2172.	1.7	25
1163	PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2021, 153, 153-160.	1.4	20
1164	IDH1 and IDH2 Mutations in Colorectal Cancers. American Journal of Clinical Pathology, 2021, 156, 777-786.	0.4	12
1165	Genetics and Mutational Landscape of Ovarian Sex Cord-Stromal Tumors. , 0, , .		1
1166	The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy. Cells, 2021, 10, 1082.	1.8	20
1167	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, 2021, 13, 87.	3.6	24
1168	Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2021, 188, 661-673.	1.1	6
1169	Efficacy and Safety of Trametinib in <scp>Non-V600 BRAF </scp> Mutant Melanoma: A Phase II Study. Oncologist, 2021, 26, 731-e1498.	1.9	20
1170	Comparative genomic characterization of melanoma of known and unknown primary. Clinical and Translational Oncology, 2021, 23, 2302-2308.	1.2	6
1171	High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Annals of Oncology, 2021, 32, 661-672.	0.6	586
1172	Mining mutation contexts across the cancer genome to map tumor site of origin. Nature Communications, 2021, 12, 3051.	5.8	8
1174	A common classification framework for histone sequence alterations in tumours: an expert consensus proposal. Journal of Pathology, 2021, 254, 109-120.	2.1	5
1176	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecologic Oncology, 2021, 161, 535-544.	0.6	16

#	Article	IF	Citations
1177	Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. Cancer Cell International, 2021, 21, 270.	1.8	117
1178	Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. Oncologist, 2021, 26, e1263-e1272.	1.9	24
1179	Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary. European Journal of Clinical Investigation, 2021, 51, e13583.	1.7	15
1180	Selective multiplexed enrichment for the detection and quantitation of low-fraction DNA variants via low-depth sequencing. Nature Biomedical Engineering, 2021, 5, 690-701.	11.6	27
1181	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	3.6	26
1182	ARID1 proteins: from transcriptional and post-translational regulation to carcinogenesis and potential therapeutics. Epigenomics, 2021, 13, 809-823.	1.0	12
1184	Nextâ€‘generation genome sequencing of a matched normalâ€‘tumor pair from a patient with intractable gestational choriocarcinoma: A case report. Molecular and Clinical Oncology, 2021, 15, 143.	0.4	1
1185	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Studyâ€”An Asian Tertiary Cancer Center Experience. JCO Precision Oncology, 2021, 5, 859-875.	1.5	4
1186	Limited effect of afatinib in a nonâ€‰small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report. Thoracic Cancer, 2021, 12, 1770-1774.	0.8	1
1187	Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody. Expert Review of Molecular Diagnostics, 2021, 21, 437-444.	1.5	10
1188	High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 5561.	1.8	4
1189	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. Clinical Cancer Research, 2021, 27, 4066-4076.	3.2	45
1190	FGFR3, TERT, Đ¢Đ53 mutations and the FGFR3 gene expression in bladder cancer as prognostic markers. Onkourologiya, 2021, 17, 89-100.	0.1	0
1191	Influence of low tumor content on tumor mutational burden estimation by wholeâ€‰exome sequencing and targeted panel sequencing. Clinical and Translational Medicine, 2021, 11, e415.	1.7	7
1192	Metastatic NSCLCs With Limited Tissues: How to Effectively Identify Driver Alterations to Guide Targeted Therapy in Chinese Patients. JTO Clinical and Research Reports, 2021, 2, 100167.	0.6	0
1193	Merging Genomics Public Datasets with Clinical Cancer Registry Data â€“ Lessons Learned. Studies in Health Technology and Informatics, 2021, 278, 150-155.	0.2	0
1194	Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Seminars in Cancer Biology, 2022, 84, 242-254.	4.3	22
1195	RAF-MEK-ERK pathway in cancer evolution and treatment. Seminars in Cancer Biology, 2022, 85, 123-154.	4.3	113

#	Article	IF	Citations
1196	Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8+ tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma. Surgery Today, 2021, 51, 1985-1995.	0.7	9
1198	Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. , 2021, 9, e002345.		7
1199	Histone H2B Mutations in Cancer. Biomedicines, 2021, 9, 694.	1.4	5
1201	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. Cancer Treatment Reviews, 2021, 97, 102204.	3.4	24
1202	Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms. Journal of Human Genetics, 2021, 66, 853-868.	1.1	5
1203	Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population. Annals of Gastroenterological Surgery, 2021, 5, 853-864.	1.2	5
1204	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers, 2021, 13, 2776.	1.7	9
1205	Comprehensive molecular profiling of pulmonary pleomorphic carcinoma. Npj Precision Oncology, 2021, 5, 57.	2.3	6
1206	Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular Tumors. Dermato, 2021, 1, 18-25.	0.6	0
1207	Genetic profile of primary mucinous cystadenocarcinoma of the breastâ€”A case report. Breast Journal, 2021, 27, 731-734.	0.4	7
1208	E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. Biomarker Research, 2021, 9, 44.	2.8	30
1210	TIRR inhibits the 53BP1-p53 complex to alter cell-fate programs. Molecular Cell, 2021, 81, 2583-2595.e6.	4.5	16
1211	Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy. Cancers, 2021, 13, 3276.	1.7	6
1212	Longitudinal Genomic Evolution of Conventional Papillary Thyroid Cancer With Brain Metastasis. Frontiers in Oncology, 2021, 11, 620924.	1.3	4
1213	Resource-efficient pooled sequencing expands translational impact in solid tumors. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2021, 19, 18-23.	0.1	1
1214	Guidelines for clinical evaluation of antiâ€cancer drugs. Cancer Science, 2021, 112, 2563-2577.	1.7	17
1215	DNA Damage Repair Gene Set as a Potential Biomarker for Stratifying Patients with High Tumor Mutational Burden. Biology, 2021, 10, 528.	1.3	4
1216	In silico prediction of the functional consequences of nsSNPs in human beta-catenin gene. Gene Reports, 2021, 23, 101066.	0.4	2

#	Article	IF	Citations
1217	Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches. Frontiers in Cell and Developmental Biology, 2021, 9, 666156.	1.8	12
1218	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. Oncologist, 2021, 26, 835-844.	1.9	16
1219	NTRK fusions and Trk proteins: what are they and how to test for them. Human Pathology, 2021, 112, 59-69.	1.1	23
1220	Detection of actionable mutations in archived cytological bile specimens. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 837-847.	1.4	8
1221	Profiling of 520 Candidate Genes in 50 Surgically Treated Chinese Small Cell Lung Cancer Patients. Frontiers in Oncology, 2021, 11, 644434.	1.3	7
1222	A Rare BRAF Fusion in Advanced Rectal Cancer Treated with Anti-Epidermal Growth Factor Receptor Therapy. Case Reports in Oncology, 2021, 14, 938-943.	0.3	1
1223	Immunogenomics in personalized cancer treatments. Journal of Human Genetics, 2021, 66, 901-907.	1.1	10
1224	Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment. Frontiers in Endocrinology, 2021, 12, 674616.	1.5	9
1225	A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report. OncoTargets and Therapy, 2021, Volume 14, 3739-3744.	1.0	6
1226	Efficient representations of tumor diversity with paired DNA-RNA aberrations. PLoS Computational Biology, 2021, 17, e1008944.	1.5	2
1227	Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs. Cancers, 2021, 13, 3200.	1.7	15
1228	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology. Npj Precision Oncology, 2021, 5, 58.	2.3	5
1229	Postgraduate training in Cancer Geneticsâ€"a cross-specialty survey exploring experience of clinicians in Ireland. Irish Journal of Medical Science, 2021, , 1.	0.8	2
1230	CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research, 2021, 27, 4025-4035.	3.2	51
1231	Clinical utility of whole-genome sequencing in precision oncology. Seminars in Cancer Biology, 2022, 84, 32-39.	4.3	35
1232	Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesisâ€"New insight and futuristic vision. International Journal of Biological Macromolecules, 2021, 180, 739-752.	3.6	39
1234	Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment. Aging, 2021, 13, 16541-16566.	1.4	3
1235	Atypical clear cell sarcoma of the pleura presenting as large pleural effusion with 22q12 abnormality: A challenging case with twists and turns. Human Pathology: Case Reports, 2021, 24, 200489.	0.2	1

#	Article	IF	Citations
1236	Update on adrenal cortical neoplasia. Diagnostic Histopathology, 2021, 27, 240-251.	0.2	0
1237	Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. , 2021, 9, e002558.		7
1238	Clinical Experience of Cerebrospinal Fluidâ€"Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. Journal of Molecular Diagnostics, 2021, 23, 742-752.	1.2	17
1239	Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. Cancer Biomarkers, 2021, 31, 119-126.	0.8	1
1240	The association between ERK inhibitor sensitivity and molecular characteristics in colorectal cancer. Biochemical and Biophysical Research Communications, 2021, 560, 59-65.	1.0	4
1241	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	5.8	68
1242	Genomic characteristics of invasive mucinous adenocarcinoma of the lung with multiple pulmonary sites of involvement. Modern Pathology, 2022, 35, 202-209.	2.9	12
1243	Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumorsâ€"A Cohort Study. Frontiers in Endocrinology, 2021, 12, 653401.	1.5	3
1244	A Brief Overview and Update on Major Molecular Genomic Alterations in Solid, Bone and Soft Tissue Tumors, and Hematopoietic As Well As Lymphoid Malignancies. Archives of Pathology and Laboratory Medicine, 2021, 145, 1358-1366.	1.2	2
1245	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 787-800.	0.9	25
1246	Correlations between tumor mutation burden and immune infiltrates and their prognostic value in pancreatic cancer by bioinformatic analysis. Life Sciences, 2021, 277, 119505.	2.0	12
1247	Definition of Biologically Distinct Groups of Conjunctival Melanomas According to Etiological Factors and Implications for Precision Medicine. Cancers, 2021, 13, 3836.	1.7	10
1248	Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome. JCO Global Oncology, 2021, 7, 1141-1150.	0.8	7
1249	Comparison of the oncogenomic landscape of canine and feline hemangiosarcoma shows novel parallels with human angiosarcoma. DMM Disease Models and Mechanisms, 2021, 14, .	1.2	18
1251	Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma. Npj Precision Oncology, 2021, 5, 70.	2.3	8
1252	Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology. Seminars in Cancer Biology, 2022, 84, 23-31.	4.3	10
1253	TMB or not TMB as a biomarker: That is the question. Critical Reviews in Oncology/Hematology, 2021, 163, 103374.	2.0	114
1254	The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 871-878.	2.3	10

#	Article	IF	Citations
1256	Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP). Scientific Reports, 2021, 11, 15112.	1.6	2
1257	Regulations, Open Data and Healthcare Innovation: A Case of MSK-IMPACT and Its Implications for Better Cancer Care. Cancers, 2021, 13, 3448.	1.7	2
1258	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology, 2021, 161, 196-210.	0.6	23
1259	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. Npj Breast Cancer, 2021, 7, 96.	2.3	38
1260	A pan-cancer transcriptomic study showing tumor specific alterations in central metabolism. Scientific Reports, 2021, 11, 13637.	1.6	11
1261	Cell Biology of Canonical Wnt Signaling. Annual Review of Cell and Developmental Biology, 2021, 37, 369-389.	4.0	83
1262	Global Implementation of Precision Oncology. JCO Precision Oncology, 2021, 5, 854-858.	1.5	5
1263	Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome. Cancer Medicine, 2021, 10, 6227-6238.	1.3	14
1264	Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing. Future Oncology, 2021, 17, 4171-4183.	1.1	3
1265	Tumor Promoting Effect of BMP Signaling in Endometrial Cancer. International Journal of Molecular Sciences, 2021, 22, 7882.	1.8	14
1266	Technological readiness and implementation of genomicâ€driven precision medicine for complex diseases. Journal of Internal Medicine, 2021, 290, 602-620.	2.7	18
1267	A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries. Oncology and Therapy, 2021, 9, 311-327.	1.0	1
1268	Intensityâ€modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. Cancer, 2021, 127, 4161-4170.	2.0	8
1269	Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. BMC Medicine, 2021, 19, 154.	2.3	32
1270	Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients. Cancers, 2021, 13, 3376.	1.7	8
1271	Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre. American Journal of Pathology, 2021, 191, 1281-1291.	1.9	3
1272	Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics. International Journal of Molecular Sciences, 2021, 22, 7411.	1.8	3
1273	Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 1859-1871.	0.5	16

#	Article	IF	Citations
1274	Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias. JCO Precision Oncology, 2021, 5, 1147-1150.	1.5	4
1275	Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers. Journal of Thoracic Oncology, 2021, 16, 1149-1165.	0.5	18
1276	IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies. American Journal of Surgical Pathology, 2021, 45, 1190-1204.	2.1	26
1277	A pan-cancer organoid platform for precision medicine. Cell Reports, 2021, 36, 109429.	2.9	45
1278	Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites. Npj Breast Cancer, 2021, 7, 93.	2.3	17
1279	The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduction and Targeted Therapy, 2021, 6, 249.	7.1	131
1280	Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Deathâ€Ligand 1 Blockade Responses. Hepatology, 2021, 74, 1914-1931.	3.6	48
1282	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , .	3.0	6
1283	Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. International Journal of Clinical Oncology, 2021, 26, 2142-2150.	1.0	9
1284	Precision oncology: a clinical and patient perspective. Future Oncology, 2021, 17, 3995-4009.	1.1	22
1285	The BAF chromatin remodeling complexes: structure, function, and synthetic lethalities. Biochemical Society Transactions, 2021, 49, 1489-1503.	1.6	13
1286	TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology, 2021, 5, 1259-1269.	1.5	10
1288	ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 670040.	2.2	33
1289	Molecular interactions of IRF4 in B cell development and malignancies. Biophysical Reviews, 2021, 13, 1219-1227.	1.5	6
1290	Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. European Journal of Medicinal Chemistry, 2021, 220, 113499.	2.6	12
1291	Whole-exome sequencing in osteosarcoma with distinct prognosis reveals disparate genetic heterogeneity. Cancer Genetics, 2021, 256-257, 149-157.	0.2	6
1292	Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers. Orphanet Journal of Rare Diseases, 2021, 16, 363.	1.2	1
1293	Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics. JCO Precision Oncology, 2021, 5, 1297-1311.	1.5	9

#	Article	IF	Citations
1294	Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Frontiers in Immunology, 2021, 12, 721030.	2.2	36
1295	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nature Communications, 2021, 12, 5137.	5.8	63
1296	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	3.0	66
1297	Genomic characterization of head and neck squamous cell carcinoma. Okayama Igakkai Zasshi, 2021, 133, 99-103.	0.0	0
1298	Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. BMC Cancer, 2021, 21, 972.	1.1	6
1299	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes and Cancer, 2022, 61, 303-313.	1.5	15
1300	Mutations of p53 associated with pancreatic cancer and therapeutic implications. Annals of Hepato-biliary-pancreatic Surgery, 2021, 25, 315-327.	0.1	21
1301	Panâ€cancer analysis of prognostic metastatic phenotypes. International Journal of Cancer, 2022, 150, 132-141.	2.3	19
1302	Advances in colorectal cancer genomics and transcriptomics drive early detection and prevention. International Journal of Biochemistry and Cell Biology, 2021, 137, 106032.	1.2	5
1303	Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation. Nature Communications, 2021, 12, 4853.	5.8	27
1305	Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology, 2021, 12, 643282.	2.2	17
1306	Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test. Journal of Molecular Diagnostics, 2021, 23, 1515-1533.	1.2	10
1307	Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. Nature Communications, 2021, 12, 4789.	5.8	21
1308	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	0.8	83
1309	Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers. Cancers, 2021, 13, 4317.	1.7	3
1310	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 5818-5827.	3.2	14
1311	Identification of a TP53 Deletion in an Undifferentiated Embryonal Sarcoma of the Liver Provides Clinically Relevant Longitudinal Detection of Circulating Tumor DNA. JCO Precision Oncology, 2021, 5, 1421-1425.	1.5	1
1312	Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy. Gastric Cancer, 2021, 24, 1342-1354.	2.7	13

#	Article	IF	Citations
1313	Radiation Response Prediction Model Based on Integrated Clinical and Genomic Data Analysis. Cancer Research and Treatment, 2022, 54, 383-395.	1.3	4
1314	Immune-checkpoint inhibitors in pituitary malignancies. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	2
1315	Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. Clinical Cancer Research, 2021, 27, 6197-6208.	3.2	20
1316	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	2.0	24
1317	Editorial: Integration of Multi-Omics Techniques in Cancer. Frontiers in Genetics, 2021, 12, 733965.	1.1	3
1318	Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarkerâ€"Reply. JAMA Oncology, 2021, 7, 1245.	3.4	0
1319	The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors. Journal of Thoracic Oncology, 2021, 16, 1392-1402.	0.5	12
1320	Predicting functional consequences of mutations using molecular interaction network features. Human Genetics, 2022, 141, 1195-1210.	1.8	9
1321	The Re-analysis of LC-SCRUM-Asia Successfully Detected an Overlooked <i>ROS1</i> Fusion Gene in a Lung Adenocarcinoma Patient and Led to Proper Treatment. Japanese Journal of Lung Cancer, 2021, 61, 303-309.	0.0	0
1322	Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. JCO Precision Oncology, 2021, 5, 1312-1324.	1.5	15
1323	INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discovery, 2022, 12, 356-371.	7.7	68
1325	Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice. Cancers, 2021, 13, 4564.	1.7	6
1326	Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 751407.	2.2	34
1327	Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nature Cancer, 2021, 2, 1071-1085.	5.7	57
1328	Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. International Immunopharmacology, 2021, 98, 107807.	1.7	13
1329	High resolution copy number inference in cancer using short-molecule nanopore sequencing. Nucleic Acids Research, 2021, 49, e124-e124.	6.5	14
1330	Inhibition of nonsense-mediated decay rescues p53Î²/Î³ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. Journal of Biological Chemistry, 2021, 297, 101163.	1.6	18
1331	Trends in Diagnosis and Treatment of Metastatic Cancer in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 572-579.	0.6	15

#	Article	IF	Citations
1332	Expanding the spectrum of thyroid carcinoma with somatic DICER1 mutation: a survey of 829 thyroid carcinomas using MSK-IMPACT next-generation sequencing platform. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 293-302.	1.4	16
1333	Targeting steroid hormone receptors for antiâ€cancer therapyâ€"A review on small molecules and nanotherapeutic approaches. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1755.	3.3	9
1334	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 2021, 74, 1429-1444.	3.6	73
1335	Practical considerations in screening for genetic alterations in cholangiocarcinoma. Annals of Oncology, 2021, 32, 1111-1126.	0.6	77
1336	Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. British Journal of Cancer, 2021, 125, 1356-1364.	2.9	3
1337	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer, 2021, 159, 66-73.	0.9	17
1338	Genetic features of Bâ€cell lymphoblastic lymphoma with <scp>TCF3â€PBX1</scp>. Cancer Reports, 2022, 5, e1559.	0.6	4
1339	TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	24
1340	Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers, 2021, 13, 4803.	1.7	6
1341	Advances in the management of cholangiocarcinoma. World Journal of Hepatology, 2021, 13, 1003-1018.	0.8	10
1342	Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. Journal of Clinical Oncology, 2021, 39, 3822-3828.	0.8	4
1343	Clinicopathologic Features and Response to Therapy ofNRG1Fusionâ€"Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of Clinical Oncology, 2021, 39, 2791-2802.	0.8	32
1344	Reply to: â€˜Real-world prevalence across 159Â872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.â€™ by D. Fabrizio etÂal.. Annals of Oncology, 2021, 32, 1194-1197.	0.6	2
1345	The Landscape of PIK3CA Mutations in Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 201-215.	1.0	24
1346	Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell, 2021, 39, 1245-1261.e6.	7.7	58
1347	JCGA: the Japanese version of the Cancer Genome Atlas and its contribution to the interpretation of gene alterations detected in clinical cancer genome sequencing. Human Genome Variation, 2021, 8, 38.	0.4	3
1348	TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas. Endocrine Pathology, 2022, 33, 304-314.	5.2	4
1349	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. Translational Oncology, 2021, 14, 101153.	1.7	5

#	Article	IF	Citations
1350	Cancer diagnosis using artificial intelligence: a review. Artificial Intelligence Review, 0, , 1.	9.7	8
1351	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?. Npj Breast Cancer, 2021, 7, 120.	2.3	9
1352	Rosette-Forming Glioneuronal Tumor in the Pineal Region: A Series of 6 Cases and Literature Review. Journal of Neuropathology and Experimental Neurology, 2021, 80, 933-943.	0.9	7
1353	PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer. Molecular Therapy, 2022, 30, 621-631.	3.7	17
1354	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature Communications, 2021, 12, 5606.	5.8	76
1355	Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. Expert Review of Clinical Pharmacology, 2021, 14, 1233-1252.	1.3	14
1356	Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. Cancers, 2021, 13, 4926.	1.7	52
1357	Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDHwt glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab127.	0.4	5
1358	Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. BMC Medicine, 2021, 19, 223.	2.3	14
1359	Stromal tumor-infiltrating lymphocytes level as a prognostic factor for resected intrahepatic cholangiocarcinoma and its prediction by apparent diffusion coefficient. International Journal of Clinical Oncology, 2021, 26, 2265-2274.	1.0	0
1360	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 731.e1-731.e15.	0.8	7
1361	Late phase 1 studies: concepts and outcomes. Lancet Oncology, The, 2021, 22, e446-e455.	5.1	2
1362	Organoids as a Robust Preclinical Model for Precision Medicine in Colorectal Cancer: A Systematic Review. Annals of Surgical Oncology, 2022, 29, 47-59.	0.7	15
1363	PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open, 2021, 6, 100230.	2.0	15
1364	Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Annals of Oncology, 2021, 32, 1626-1636.	0.6	86
1365	Significance and limitations of the use of next-generation sequencing technologies for detecting mutational signatures. DNA Repair, 2021, 107, 103200.	1.3	18
1366	Machine learning in precision medicine to preserve privacy via encryption. Pattern Recognition Letters, 2021, 151, 148-154.	2.6	11
1367	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genetics, 2021, 258-259, 61-68.	0.2	2

#	Article	IF	Citations
1368	Targeting mutated GTPase KRAS in tumor therapies. European Journal of Medicinal Chemistry, 2021, 226, 113816.	2.6	19
1369	Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma. Journal of Neuro-Oncology, 2021, 152, 153-162.	1.4	5
1371	Personalized immunotherapy in cancer precision medicine. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	20
1372	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199299.	1.4	20
1373	Molecular Changes in Retinoblastoma beyond RB1: Findings from Next-Generation Sequencing. Cancers, 2021, 13, 149.	1.7	27
1374	Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?. Current Cancer Research, 2021, , 27-54.	0.2	0
1375	Somatic data usage for classification of germ line variants. , 2021, , 169-192.		0
1376	Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. JCO Precision Oncology, 2021, 5, 6-16.	1.5	2
1377	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British Journal of Cancer, 2021, 124, 1214-1221.	2.9	14
1378	Morphological, immunohistochemical, and genetic analyses of bronchiolar adenoma and its putative variants. Journal of Pathology: Clinical Research, 2021, 7, 287-300.	1.3	10
1379	Prognostic Value of Diverse TP53 Mutations in Metastatic Cancers: An Analysis of the Cbioportal Database. SSRN Electronic Journal, 0, , .	0.4	0
1380	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical Cancer Research, 2021, 27, 2226-2235.	3.2	25
1381	Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precision Oncology, 2021, 5, 133-144.	1.5	22
1382	PI3KCA Mutations in Uterine Cervix Carcinoma. Journal of Clinical Medicine, 2021, 10, 220.	1.0	11
1383	Proteogenomic approach to drug targets in osteosarcomas with different original sites. Journal of Electrophoresis, 2021, 65, 1-11.	0.2	1
1384	A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background. Methods in Molecular Biology, 2021, 2262, 323-334.	0.4	1
1385	Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy. Molecular Oncology, 2020, 14, 1719-1730.	2.1	62
1386	Measuring Tumor Mutational Burden Using Whole-Exome Sequencing. Methods in Molecular Biology, 2020, 2055, 63-91.	0.4	6

#	Article	IF	Citations
1387	Molecular Pathology and Genomics of Melanoma. , 2020, , 381-422.		1
1388	Pharma-Oncogenomics in theÂEra of Personal Genomics: A Quick Guide to Online Resources and Tools. Advances in Experimental Medicine and Biology, 2019, 1168, 103-115.	0.8	2
1389	â€˜Overcoming the Bottleneckâ€™: Knowledge Architectures for Genomic Data Interpretation in Oncology. , 2020, , 305-327.		8
1390	Molecular Pathology and Genomics of Melanoma. , 2019, , 1-42.		2
1391	Cancer Genomics in Precision Oncology: Applications, Challenges, and Prospects. , 2020, , 453-499.		9
1392	Managing the genomic revolution in cancer diagnostics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 175-194.	1.4	3
1393	Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all?. Annals of Oncology, 2020, 31, 967-969.	0.6	3
1394	Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: AÂFeasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate. JTO Clinical and Research Reports, 2020, 1, 100077.	0.6	18
1395	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Molecular Cell, 2020, 78, 1096-1113.e8.	4.5	114
1396	Discovering functional evolutionary dependencies in human cancers. Nature Genetics, 2020, 52, 1198-1207.	9.4	15
1397	iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17470-17479.	3.3	20
1398	SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. Journal of Experimental Medicine, 2021, 218, .	4.2	138
1399	Prevalence and clinicopathological/molecular characteristics of mismatch repair protein-deficient tumours among surgically treated patients with prostate cancer in a Japanese hospital-based population. Japanese Journal of Clinical Oncology, 2021, 51, 639-645.	0.6	4
1400	Dual inhibition of DNA-PK and DNA polymerase theta overcomes radiation resistance induced by p53 deficiency. NAR Cancer, 2020, 2, zcaa038.	1.6	18
1401	Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma. Clinical Orthopaedics and Related Research, 2021, 479, 838-852.	0.7	10
1402	Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. American Journal of Surgical Pathology, 2021, 45, 77-92.	2.1	30
1429	Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias. British Journal of Haematology, 2021, 193, 570-580.	1.2	9
1430	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research, 2020, 26, 3239-3247.	3.2	135

#	Article	IF	Citations
1431	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating Î²-Catenin Signaling. Molecular Cancer Research, 2021, 19, 573-584.	1.5	10
1432	Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. JCI Insight, 2018, 3, .	2.3	21
1433	Secretome profiling identifies neuron-derived neurotrophic factor as a tumor-suppressive factor in lung cancer. JCI Insight, 2019, 4, .	2.3	15
1434	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. Journal of Clinical Investigation, 2019, 129, 4276-4289.	3.9	134
1435	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation, 2020, 130, 2712-2726.	3.9	112
1436	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. Journal of Clinical Investigation, 2020, 130, 6668-6676.	3.9	28
1437	Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097419.	1.4	15
1438	Mutation profiling of anaplastic ependymoma grade III by Ion Proton next generation DNA sequencing. F1000Research, 2019, 8, 613.	0.8	5
1439	Mutation Hotspots in the Î²-Catenin Gene: Lessons from the Human Cancer Genome Databases. Molecules and Cells, 2019, 42, 8-16.	1.0	83
1440	Cancer of Unknown Primary (<scp>CUP</scp>): genetic evidence for a novel nosological entity? A case report. EMBO Molecular Medicine, 2020, 12, e11756.	3.3	10
1441	Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer. Endocrine-Related Cancer, 2019, 26, R211-R235.	1.6	15
1442	Metastatic-initiating cells and lipid metabolism. Cell Stress, 2017, 1, 110-114.	1.4	6
1443	Male patients with TERT mutation may be more likely to benefit from immunotherapy, especially for melanoma. Aging, 2020, 12, 17288-17294.	1.4	7
1444	Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85Î± and p85Î². Oncotarget, 2017, 8, 55863-55876.	0.8	16
1445	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget, 2018, 9, 9741-9750.	0.8	12
1446	The clinical impact of using complex molecular profiling strategies in routine oncology practice. Oncotarget, 2018, 9, 20282-20293.	0.8	15
1447	Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways. Oncotarget, 2018, 9, 25386-25401.	0.8	3
1448	Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget, 2019, 10, 2384-2396.	0.8	119

#	Article	IF	Citations
1449	Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications. Oncotarget, 2019, 10, 4038-4052.	0.8	12
1450	Oncologist uptake of comprehensive genomic profile guided targeted therapy. Oncotarget, 2019, 10, 4616-4629.	0.8	13
1451	Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay. Oncotarget, 2019, 10, 5181-5193.	0.8	15
1452	Does breast carcinoma belong to the Lynch syndrome tumor spectrum? â€“ Somatic mutational profiles vs. ovarian and colorectal carcinomas. Oncotarget, 2020, 11, 1244-1256.	0.8	11
1453	MEK inhibitors in non-V600 BRAF mutations and fusions. Oncotarget, 2020, 11, 3900-3903.	0.8	9
1454	Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Annals of Translational Medicine, 2019, 7, 640-640.	0.7	103
1456	Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer. Cancer Management and Research, 2020, Volume 12, 13479-13487.	0.9	12
1457	The Function of RAS Mutation in Cancer and Advances in its Drug Research. Current Pharmaceutical Design, 2019, 25, 1105-1114.	0.9	53
1458	Mutational Testing in Gastrointestinal Stromal Tumor. Current Cancer Drug Targets, 2019, 19, 688-697.	0.8	6
1459	A Case Report of a Non-small-cell Lung Cancer Patient Who Was EGFR-negative on a Conventional Test but Was Discovered to Have an EGFR Uncommon Mutation on Comprehensive Genomic Profiling and Responded to Afatinib. Japanese Journal of Lung Cancer, 2020, 60, 429-433.	0.0	2
1460	MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. Life Science Alliance, 2020, 3, e201900545.	1.3	27
1461	Mutational Analysis of Field Cancerization in Bladder Cancer. Bladder Cancer, 2020, 6, 253-264.	0.2	12
1462	Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response. Cancers, 2020, 12, 2835.	1.7	8
1463	Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2021, 22, 240.	1.8	101
1464	When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma. Journal of Immunotherapy and Precision Oncology, 2020, 3, 69-82.	0.6	2
1465	Role of liver biopsy in hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 6041-6052.	1.4	92
1466	Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers. Endocrinology and Metabolism, 2020, 35, 44.	1.3	21
1467	Identification of circulating tumor DNA using a targeted 545â€‘gene next generation sequencing panel in patients with gastric cancer. Oncology Letters, 2020, 19, 2251-2257.	0.8	2

#	Article	IF	Citations
1468	Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors. Oncology Letters, 2020, 20, 27.	0.8	3
1469	And they said it couldn't be done: Predicting known driver mutations from H&E slides. Journal of Pathology Informatics, 2019, 10, 17.	0.8	8
1470	Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Research and Treatment, 2019, 51, 951-962.	1.3	48
1471	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. Cancer Research and Treatment, 2019, 51, 211-222.	1.3	12
1472	Precision medicine for gastrointestinal cancer: Recent progress and future perspective. World Journal of Gastrointestinal Oncology, 2019, 12, 1-20.	0.8	31
1473	Holistic cancer genome profiling for every patient. Swiss Medical Weekly, 2020, 150, w20158.	0.8	5
1474	Tumor Mutation Burden and Depression in Lung Cancer: Association With Inflammation. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 434-442.	2.3	10
1475	Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 517-521.	2.3	25
1476	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. ELife, 2018, 7, .	2.8	217
1477	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. ELife, 2019, 8, .	2.8	31
1478	Proteomic analysis of lung cancer cells reveals a critical role of BCAT1 in cancer cell metastasis. Theranostics, 2021, 11, 9705-9720.	4.6	16
1479	EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nature Reviews Clinical Oncology, 2022, 19, 51-69.	12.5	101
1480	TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. Modern Pathology, 2022, 35, 117-127.	2.9	16
1481	Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy. Leukemia and Lymphoma, 2022, 63, 131-141.	0.6	1
1482	Secretory Carcinoma of the Thyroid in a 49-Year-Old Man Treated with Larotrectinib: Protracted Clinical Course of Disease Despite the High-Grade Histologic Features. Head and Neck Pathology, 2022, 16, 612-620.	1.3	6
1483	Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience. Healthcare (Switzerland), 2021, 9, 1395.	1.0	1
1484	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. Clinical Cancer Research, 2022, 28, 45-56.	3.2	13
1485	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. Npj Breast Cancer, 2021, 7, 135.	2.3	9

#	Article	IF	Citations
1486	Development and Validation of Targeted Gene Sequencing Panel Based Companion Diagnostic for Korean Patients with Solid Tumors. Cancers, 2021, 13, 5112.	1.7	0
1487	Tumor Suppressor FBXW7 and Its Regulation of DNA Damage Response and Repair. Frontiers in Cell and Developmental Biology, 2021, 9, 751574.	1.8	11
1488	Contextualizing Genes by Using Text-Mined Co-Occurrence Features for Cancer Gene Panel Discovery. Frontiers in Genetics, 2021, 12, 771435.	1.1	3
1489	The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine. Pathology International, 2021, 71, 725-740.	0.6	27
1490	Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. Cancers, 2021, 13, 5028.	1.7	27
1492	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging, 2021, 13, 23416-23434.	1.4	17
1493	Emerging biomarkers in metastatic urothelial carcinoma: tumour mutational burden, PD-L1 expression and APOBEC polypeptide-like signature in a patient with complete response to anti-programmed cell death protein-1 inhibitor. Ecancermedicalscience, 2021, 15, 1306.	0.6	2
1494	Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma. Frontiers in Pharmacology, 2021, 12, 721181.	1.6	5
1505	VIII. Clinical Sequencing for Leukemia. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1324-1330.	0.0	0
1508	Clinical application of cfDNA: moving in the right direction, but still a long way to go. Oncotarget, 2018, 9, 35199-35200.	0.8	0
1510	Mutational landscape of pancreatic cancer and genomic analysis using EUS-FNA samples. Suizo, 2018, 33, 923-929.	0.1	1
1511	Novel Approaches to Immunotherapy in Triple Negative Breast Cancer. International Journal of Cancer Management, 2018, In Press, .	0.2	1
1512	Large-scale Genomic Testing Facilitates Precision Medicine in Routine Cancer Care. Oncology & Hematology Review, 2019, 15, 25.	0.2	0
1513	How far advanced the application of NGS technology to head and neck cancer?. Japanese Journal of Head and Neck Cancer, 2019, 45, 343-349.	0.0	0
1515	CAR-T Therapy for Solid Tumors: Development of New Strategies. Trends in Immunotherapy, 2018, 2, .	0.2	1
1517	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. SSRN Electronic Journal, 0, , .	0.4	0
1526	Genomic Profiling for Patients with Solid Tumors: A Single-Institution Experience. Annals of Clinical Oncology, 2019, , 1-7.	0.0	1
1529	Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Korean Society for Head and Neck Oncology, 2019, 35, 1-10.	0.1	0

#	Article	IF	Citations
1530	MICROSATELLITE INSTABILITY AND GASTRIC CARCINOMA. REVIEW OF THELITERATURE. , 2019, 18, 17-24.	0.3	1
1533	Comprehensive Molecular Characterization of Urological Malignancies: Literature Review of Landmark Studies. The Korean Journal of Urological Oncology, 2019, 17, 125-135.	0.1	1
1534	MappingÂthe Radiogenome of Human Cancers. Cancer Drug Discovery and Development, 2020, , 35-61.	0.2	0
1535	Genome Medicine for Brain Tumors: Current Status and Future Perspectives. Neurologia Medico-Chirurgica, 2020, 60, 531-542.	1.0	5
1543	Mutation profiling of anaplastic ependymoma grade III by Ion Proton next generation DNA sequencing. F1000Research, 2019, 8, 613.	0.8	7
1545	Use of Biomarkers in Individualization of Treatment. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 989-991.	2.3	0
1546	Cancer genomic profiling. Suizo, 2020, 35, 313-321.	0.1	0
1547	Hedgehog Pathway Alterations Downstream of Patched-1 Are Common in Infundibulocystic Basal Cell Carcinoma. American Journal of Dermatopathology, 2021, 43, 266-272.	0.3	10
1551	Case of acute promyelocytic leukemia with basophilic differentiation and an ETV6 mutation. Journal of Hematopathology, 2021, 14, 333-336.	0.2	1
1552	Discovery of MK-4688: an Efficient Inhibitor of the HDM2â€“p53 Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2021, 64, 16213-16241.	2.9	14
1554	A mixture model for signature discovery from sparse mutation data. Genome Medicine, 2021, 13, 173.	3.6	8
1555	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	9.4	110
1556	Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma. Frontiers in Pharmacology, 2021, 12, 739501.	1.6	3
1557	S100 and Pan-Trk Staining to Report NTRK Fusion-Positive Uterine Sarcoma: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. International Journal of Gynecological Pathology, 2021, 40, 24-27.	0.9	11
1558	Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing. Archives of Pathology and Laboratory Medicine, 2021, 145, 692-698.	1.2	10
1560	Carcinomas of the Gastrointestinal Tract. , 2021, , 427-472.		0
1566	Tumor Heterogeneity: Challenges and Perspectives for Gastrointestinal Cancer Therapy. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 1-15.	0.2	0
1568	Precision medicine in the genomic era. , 2020, , 445-452.		0

#	Article	IF	Citations
1569	A comprehensive analysis of the angiogenesis-related genes in glioblastoma multiforme vs. brain lower grade glioma. Arquivos De Neuro-Psiquiatria, 2020, 78, 34-38.	0.3	7
1570	Experience with Large Panel Next-generation Sequencing in Patients with Advanced Solid Cancers at Juntendo University Hospital. Juntendo Medical Journal, 2020, 66, 392-402.	0.1	0
1571	Comparative mutational analysis of distal colon cancer with rectal cancer. Oncology Letters, 2020, 19, 1781-1788.	0.8	2
1577	Identification of New Tumor-Related Gene Mutations in Chinese Gastrointestinal Stromal Tumors. Frontiers in Cell and Developmental Biology, 2021, 9, 764275.	1.8	4
1578	The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585.	9.4	44
1579	TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. Cancers, 2021, 13, 5502.	1.7	2
1580	Systematic Pan-Cancer Characterization of Nuclear Receptors Identifies Potential Cancer Biomarkers and Therapeutic Targets. Cancer Research, 2022, 82, 46-59.	0.4	3
1581	Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. Genome Medicine, 2021, 13, 175.	3.6	12
1587	Functional Enrichment Analysis of Deregulated Long Non-Coding RNAs in Cancer Based on their Genomic Neighbors. , 2020, , .		0
1588	Winning the Fight Against Cancer. Annals of the Academy of Medicine, Singapore, 2020, 49, 779-788.	0.2	1
1589	Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes. Current Gene Therapy, 2020, 20, 84-99.	0.9	11
1590	PIK3CA-Related Overgrowth Syndrome (PROS) and Angiosarcoma: A Case Report. Eplasty, 2020, 20, ic6.	0.4	1
1591	Liver diseases fibrosis and cirrhosis. , 2022, , 107-153.		0
1592	Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 658-661.	2.3	0
1593	Predictive Value of Maxâ€™s Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Cell and Developmental Biology, 2021, 9, 728647.	1.8	0
1594	Genomic and molecular features distinguish young adult cancer from later-onset cancer. Cell Reports, 2021, 37, 110005.	2.9	21
1595	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. Clinical Cancer Research, 2022, 28, 728-737.	3.2	20
1596	HER2â€‰+â€‰breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature Communications, 2021, 12, 6667.	5.8	47

#	Article	IF	Citations
1597	Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care. Journal of Community Genetics, 2022, 13, 523-538.	0.5	4
1598	Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature, 2021, 599, 679-683.	13.7	183
1599	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature Communications, 2021, 12, 6821.	5.8	15
1600	Early TP53 Alterations Shape Gastric and Esophageal Cancer Development. Cancers, 2021, 13, 5915.	1.7	7
1601	Constructing germline research cohorts from the discarded reads of clinical tumor sequences. Genome Medicine, 2021, 13, 179.	3.6	25
1602	GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genomics, 2021, 1, 100029.	3.0	94
1603	The GA4GH Variation Representation Specification: A computational framework for variation representation and federated identification. Cell Genomics, 2021, 1, 100027.	3.0	18
1604	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. Cancers, 2021, 13, 5847.	1.7	16
1605	Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma. Frontiers in Medicine, 2021, 8, 755657.	1.2	2
1606	Precise Identification of Recurrent Somatic Mutations in Oral Cancer Through Whole-Exome Sequencing Using Multiple Mutation Calling Pipelines. Frontiers in Oncology, 2021, 11, 741626.	1.3	7
1607	Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics. Frontiers in Oncology, 2021, 11, 712505.	1.3	3
1608	Psychological predictors of advanced cancer patientsâ€™ preferences for return of results from comprehensive tumor genomic profiling. American Journal of Medical Genetics, Part A, 2022, 188, 725-734.	0.7	2
1609	Genomic Stratification of Resectable Colorectal Liver Metastasis Patients and Implications for Adjuvant Therapy and Survival. Annals of Surgery, 2022, 275, 371-381.	2.1	4
1610	Machine learning-based prediction of drug and ligand binding in BCL-2 variants through molecular dynamics. Computers in Biology and Medicine, 2022, 140, 105060.	3.9	8
1611	LTF Regulates the Immune Microenvironment of Prostate Cancer Through JAK/STAT3 Pathway. Frontiers in Oncology, 2021, 11, 692117.	1.3	13
1612	Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. Oncogene, 2022, 41, 444-458.	2.6	13
1613	Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. Nature Communications, 2021, 12, 6804.	5.8	39
1614	Machine learning of genomic features in organotropic metastases stratifies progression risk of primary tumors. Nature Communications, 2021, 12, 6692.	5.8	16

#	Article	IF	Citations
1615	Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 â€œCREATEâ€•Trial. Cancers, 2021, 13, 6057.	1.7	9
1616	Evolution of metastasis: new tools and insights. Trends in Cancer, 2022, 8, 98-109.	3.8	40
1617	Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nature Communications, 2021, 12, 7033.	5.8	27
1618	Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program. Cancer Discovery, 2022, 12, 938-948.	7.7	19
1619	Genomic Medicine in Central Nervous System Tumors. Juntendo Medical Journal, 2021, 67, 547-552.	0.1	0
1620	Mutant K-Ras Mediated Oxidative Stress in Pancreatic Cancer. , 2021, , 1-11.		0
1621	TP53_PROF: a machine learning model to predict impact of missense mutations in TP53. Briefings in Bioinformatics, 2022, 23, .	3.2	9
1622	Clinical Reliability of Genomic Data Obtained from Spinal Metastatic Tumor Samples. Neuro-Oncology, 2022, , .	0.6	0
1623	Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. Cancer Research and Treatment, 2022, 54, 1-9.	1.3	9
1624	Integrated approach to functional analysis of an ERBB2 variant of unknown significance detected by a cancer gene panel test. Cellular Oncology (Dordrecht), 2022, 45, 121.	2.1	1
1625	Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature. Frontiers in Oncology, 2021, 11, 792003.	1.3	8
1626	Fusionâ€positive nonâ€small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications. Genes Chromosomes and Cancer, 2022, 61, 244-260.	1.5	32
1627	SRDFM: Siamese Response Deep Factorization Machine to improve anti-cancer drug recommendation. Briefings in Bioinformatics, 2022, 23, .	3.2	18
1628	Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2022, 169, 103573.	2.0	2
1629	Proteasome regulators in pancreatic cancer. World Journal of Gastrointestinal Oncology, 2022, 14, 38-54.	0.8	4
1630	Targeting RAS in neuroblastoma: Is it possible?. , 2022, 236, 108054.		9
1631	Novel emerging biomarkers to immunotherapy in kidney cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110593.	1.4	12
1632	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Antiâ€“PD-1 Therapy. JCO Precision Oncology, 2021, 5, 1821-1829.	1.5	17

#	Article	IF	Citations
1633	Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. Journal of Personalized Medicine, 2021, 11, 1348.	1.1	5
1634	Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. Clinical Cancer Research, 2022, 28, 1402-1411.	3.2	24
1635	Regulatory patterns analysis of transcription factor binding site clustered regions and identification of key genes in endometrial cancer. Computational and Structural Biotechnology Journal, 2022, 20, 812-823.	1.9	3
1637	Integrative Genomic Analyses of 1,145 Patient Samples Reveal New Biomarkers in Esophageal Squamous Cell Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 792779.	1.6	4
1638	Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. , 2022, 10, e003087.		31
1639	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers, 2022, 14, 621.	1.7	34
1640	Clinicogenomic characterization of prostate cancer liver metastases. Prostate Cancer and Prostatic Diseases, 2022, 25, 366-369.	2.0	7
1641	Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports, 2022, 38, 110190.	2.9	40
1643	Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary. Oncologist, 2022, 27, e9-e17.	1.9	8
1644	Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer. Frontiers in Immunology, 2022, 13, 777724.	2.2	16
1645	Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. Npj Systems Biology and Applications, 2022, 8, 2.	1.4	0
1646	The proprotein convertase furin in cancer: more than an oncogene. Oncogene, 2022, 41, 1252-1262.	2.6	23
1647	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. Cancer Immunology Research, 2022, 10, 303-313.	1.6	1
1649	Incidental germline findings during molecular profiling of tumor tissues for precision oncology: molecular survey and methodological obstacles. Journal of Translational Medicine, 2022, 20, 29.	1.8	2
1650	Computational methods and translational applications for targeted nextâ€generation sequencing platforms. Genes Chromosomes and Cancer, 2022, 61, 322-331.	1.5	3
1651	Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2022, 89, 255-265.	1.1	1
1652	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. Clinical Cancer Research, 2022, 28, 1614-1627.	3.2	4
1653	An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. Cancer Research Communications, 2022, 2, 10-27.	0.7	2

#	Article	IF	Citations
1654	BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences. Cancer Research, 2022, 82, 12-14.	0.4	3
1655	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	1.4	23
1656	p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration. Cells, 2022, 11, 405.	1.8	3
1658	Massively parallel phenotyping of coding variants in cancer with Perturb-seq. Nature Biotechnology, 2022, 40, 896-905.	9.4	44
1659	Implementation of a prostate cancerâ€specific targeted sequencing panel for credentialing of patientâ€derived cell lines and genomic characterization of patient samples. Prostate, 2022, , .	1.2	1
1660	Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. Journal of Personalized Medicine, 2022, 12, 149.	1.1	14
1661	Mutant K-Ras-Mediated Oxidative Stress in Pancreatic Cancer. , 2022, , 1443-1453.		0
1662	Bioinformatics analysis methods for cell-free DNA. Computers in Biology and Medicine, 2022, 143, 105283.	3.9	3
1663	Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment. Cancers, 2022, 14, 757.	1.7	15
1664	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, 2022, 40, 369-381.	0.8	60
1665	Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers. Oncotarget, 2022, 13, 273-280.	0.8	3
1666	Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials. European Journal of Cancer, 2022, 163, 98-107.	1.3	1
1667	OUP accepted manuscript. Briefings in Bioinformatics, 2022, , .	3.2	4
1668	Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer. Frontiers in Medicine, 2022, 9, 836892.	1.2	4
1669	Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. Breast Cancer Research and Treatment, 2022, 192, 465-484.	1.1	6
1670	Genome Nexus: A Comprehensive Resource for the Annotation and Interpretation of Genomic Variants in Cancer. JCO Clinical Cancer Informatics, 2022, 6, e2100144.	1.0	4
1671	SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nature Cancer, 2022, 3, 188-202.	5.7	26
1672	Recurrent driver mutations in benign tumors. Mutation Research - Reviews in Mutation Research, 2022, 789, 108412.	2.4	8

#	Article	IF	Citations
1673	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	13.5	223
1674	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. JCO Precision Oncology, 2022, 6, e2100242.	1.5	5
1675	ALK, NUT, and TRK Do Not Play Relevant Roles in Gastric Cancerâ€"Results of an Immunohistochemical Study in a Large Series. Diagnostics, 2022, 12, 429.	1.3	1
1676	T cell receptors employ diverse strategies to target a p53 cancer neoantigen. Journal of Biological Chemistry, 2022, 298, 101684.	1.6	9
1678	Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. Nature, 2022, 602, 510-517.	13.7	60
1679	Impact of Tumor Mutational Burden and Gene Alterations Associated with Radiation-Response on Outcomes of Post-Operative Radiation Therapy in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	8
1680	Identification of Early-Onset Metastasis in SF3B1 Mutated Uveal Melanoma. Cancers, 2022, 14, 846.	1.7	7
1681	Small cell lung cancer; recent advances of its biology and therapeutic perspective. Respiratory Investigation, 2022, 60, 197-204.	0.9	4
1682	Cancer gene mutation frequencies for the U.S. population. Nature Communications, 2021, 12, 5961.	5.8	78
1683	Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren. Springer Reference Medizin, 2021, , 1-57.	0.0	0
1684	3. Cancer Gene Profiling Test Promotes Precision Cancer Medicine. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 511-519.	0.0	0
1685	Genomic Heterogeneity as a Barrier to Precision Oncology in Urothelial Cancer. SSRN Electronic Journal, 0, , .	0.4	0
1686	The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1019-1028.	1.2	2
1687	Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations. Annals of Translational Medicine, 2022, 10, 220-220.	0.7	1
1688	Sequence determinants of human gene regulatory elements. Nature Genetics, 2022, 54, 283-294.	9.4	87
1689	Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants. Nature Biotechnology, 2022, 40, 862-873.	9.4	44
1690	Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers, 2022, 14, 1119.	1.7	28
1691	RAS pathway regulation in melanoma. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	11

#	Article	IF	Citations
1692	First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^{G12C} Solid Tumors (KRYSTAL-1). Journal of Clinical Oncology, 2022, 40, 2530-2538.	0.8	130
1693	The Role of Medical Mistrust in Concerns about Tumor Genomic Profiling among Black and African American Cancer Patients. International Journal of Environmental Research and Public Health, 2022, 19, 2598.	1.2	6
1694	A look towards the clonal origin of metastatic pulmonary carcinosarcoma: Report of a patient with an unexpected long-term survival. Tumori, 2022, 108, NP5-NP10.	0.6	1
1695	A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. Genome Medicine, 2022, 14, 20.	3.6	26
1696	<scp>FGFR2</scp>::<scp>TACC2</scp> fusion as a novel <scp>KIT</scp>â€independent mechanism of targeted therapy failure in a multidrugâ€resistant gastrointestinal stromal tumor. Genes Chromosomes and Cancer, 2022, 61, 412-419.	1.5	4
1699	Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. Neurosurgery, 2022, Publish Ahead of Print, .	0.6	0
1701	PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?. Frontiers in Oncology, 2022, 12, 819128.	1.3	135
1702	Genome-wide identification and analysis of prognostic features in human cancers. Cell Reports, 2022, 38, 110569.	2.9	48
1703	Production and Stabilization of Specific Upregulated Long Noncoding RNA HOXD-AS2 in Glioblastomas Are Mediated by TFE3 and miR-661, Respectively. International Journal of Molecular Sciences, 2022, 23, 2828.	1.8	1
1704	Cross-Talk between p53 and Wnt Signaling in Cancer. Biomolecules, 2022, 12, 453.	1.8	15
1705	NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance. Frontiers in Oncology, 2022, 12, 864666.	1.3	28
1706	S6K1-mediated phosphorylation of PDK1 impairs AKT kinase activity and oncogenic functions. Nature Communications, 2022, 13, 1548.	5.8	19
1707	BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective. Frontiers in Oncology, 2022, 12, 863043.	1.3	16
1708	Histone methyltransferase KMT2C plays an oncogenic role in prostate cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1627-1640.	1.2	2
1709	Application of tumoroids derived from advanced colorectal cancer patients to predict individual response to chemotherapy. Journal of Chemotherapy, 2023, 35, 104-116.	0.7	6
1710	Developing an immuneâ€related gene prognostic index associated with progression and providing new insights into the tumor immune microenvironment of prostate cancer. Immunology, 2022, 166, 197-209.	2.0	12
1711	Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy. Cancers, 2022, 14, 1555.	1.7	18
1712	Genomic mutation analysis of circulating tumor DNA in metastatic cutaneous squamous cell carcinoma. Journal of Dermatological Science, 2022, , .	1.0	0

#	Article	IF	Citations
1713	Systematic review and metaâ€analysis of genomic alterations in acral melanoma. Pigment Cell and Melanoma Research, 2022, 35, 369-386.	1.5	6
1714	Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience. Current Issues in Molecular Biology, 2022, 44, 1332-1352.	1.0	4
1716	The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2022, 13, 748674.	1.6	27
1717	Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management. Current Treatment Options in Oncology, 2022, 23, 609-629.	1.3	1
1718	The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space. Journal of Molecular Diagnostics, 2022, , .	1.2	0
1719	Prevalence of UV Mutational Signatures Among Cutaneous Primary Tumors. JAMA Network Open, 2022, 5, e223833.	2.8	11
1720	Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease. Journal of Personalized Medicine, 2022, 12, 444.	1.1	21
1721	Translational advances in pancreatic ductal adenocarcinoma therapy. Nature Cancer, 2022, 3, 272-286.	5.7	90
1722	Temporal dynamics from phosphoproteomics using endoscopic biopsy specimens provides new therapeutic targets in stage IV gastric cancer. Scientific Reports, 2022, 12, 4419.	1.6	4
1724	Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100365.	1.5	1
1725	A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. Frontiers in Oncology, 2022, 12, 786438.	1.3	6
1726	Integrated molecular profiling of patientâ€derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities. International Journal of Cancer, 2022, 151, 240-254.	2.3	7
1728	The impact of whole genome and transcriptome analysis (<scp>WGTA</scp>) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies. Journal of Pathology: Clinical Research, 2022, 8, 395-407.	1.3	3
1729	Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data. Journal of Molecular Diagnostics, 2022, 24, 515-528.	1.2	12
1730	Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay. SLAS Discovery, 2022, , .	1.4	1
1731	Comprehensive genomic profiling of EWSR1/FUS::CREB translocation-associated tumors uncovers prognostically significant recurrent genetic alterations and methylation-transcriptional correlates. Modern Pathology, 2022, 35, 1055-1065.	2.9	13
1732	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	13.7	44
1734	Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature, 2022, 603, 335-342.	13.7	23

#	Article	IF	Citations
1735	Urine- and Blood-Based Molecular Profiling of Human Prostate Cancer. Frontiers in Oncology, 2022, 12, 759791.	1.3	4
1736	Toward Targeted Therapies in Oesophageal Cancers: An Overview. Cancers, 2022, 14, 1522.	1.7	3
1737	Targeted Therapy for Melanomas Without BRAF V600 Mutations. Current Treatment Options in Oncology, 2022, 23, 831-842.	1.3	8
1738	The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein. Cell Death and Differentiation, 2022, 29, 938-945.	5.0	18
1739	Genomic landscape of endometrial carcinomas of no specific molecular profile. Modern Pathology, 2022, 35, 1269-1278.	2.9	33
1740	Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. Journal of Molecular Diagnostics, 2022, 24, 351-364.	1.2	5
1741	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	0.8	96
1742	Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model. Frontiers in Oncology, 2022, 12, 857515.	1.3	1
1743	Recurrent Alterations in the MAPK pathway in Sporadic Pyogenic Granuloma of Childhood. Acta Dermato-Venereologica, 2022, 102, adv00715.	0.6	2
1744	Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas. Gynecologic Oncology Reports, 2022, 40, 100980.	0.3	0
1745	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
1746	Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188707.	3.3	4
1747	Somatic tumor testing implications for Lynch syndrome germline genetic testing. Cancer Genetics, 2022, 264-265, 16-22.	0.2	3
1748	DNA repair and immune checkpoint blockade response. Cancer Genetics, 2022, 264-265, 1-4.	0.2	0
1749	Identification of Trim24 as a new NTRK3 fusion partner in lung adenocarcinoma: Diagnostic challenges of a novel fusion. Human Pathology Reports, 2022, 28, 300625.	0.1	0
1750	Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precision Oncology, 2021, 5, 1840-1852.	1.5	8
1751	MicroSEC filters sequence errors for formalin-fixed and paraffin-embedded samples. Communications Biology, 2021, 4, 1396.	2.0	2
1752	Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. Nature Communications, 2021, 12, 7304.	5.8	17

#	Article	IF	Citations
1753	CDKN2A Deletion Leading to Hematogenous Metastasis of Human Gastric Carcinoma. Frontiers in Oncology, 2021, 11, 801219.	1.3	8
1754	Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report. Journal of Gastrointestinal Oncology, 2021, 12, 3123-3132.	0.6	1
1755	Computational analysis of cancer genome sequencing data. Nature Reviews Genetics, 2022, 23, 298-314.	7.7	38
1756	Clinical, Morphologic, and Molecular Features Associated With Ovarian Metastases From Pattern A Endocervical Adenocarcinomas. American Journal of Surgical Pathology, 2022, 46, 509-518.	2.1	2
1757	A targetable LIFRâˆ'NF-Î¹Bâˆ'LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nature Communications, 2021, 12, 7333.	5.8	117
1758	Immune response pathways enriched in breast cancer samples with brain metastasis. Gland Surgery, 2021, 10, 3334-3341.	0.5	1
1759	Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis. PLoS Genetics, 2021, 17, e1009986.	1.5	24
1760	Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment. Cancers, 2022, 14, 132.	1.7	3
1761	Mutation Analysis of Radioresistant Early-Stage Cervical Cancer. International Journal of Molecular Sciences, 2022, 23, 51.	1.8	4
1762	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers, 2021, 13, 6092.	1.7	14
1763	Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report. Frontiers in Oncology, 2021, 11, 720819.	1.3	3
1764	ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing. Modern Pathology, 2022, 35, 895-902.	2.9	7
1765	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. British Journal of Cancer, 2022, 126, 889-898.	2.9	8
1766	Synchronous Basal Cell Carcinoma and Squamous Cell Carcinoma of Nasal Vestibule With Novel Unique Variants Identified by Whole-exome Sequencing. In Vivo, 2022, 36, 251-257.	0.6	2
1767	KRAS Mutations in Squamous Cell Carcinomas of the Lung. Frontiers in Oncology, 2021, 11, 788084.	1.3	14
1768	The Novel Phosphatase Domain Mutations Q171R and Y65S Switch PTEN from Tumor Suppressor to Oncogene. Cells, 2021, 10, 3423.	1.8	1
1769	GLI1 Gene Alterations in Neoplasms of the Genitourinary and Gynecologic Tract. American Journal of Surgical Pathology, 2022, 46, 677-687.	2.1	16
1771	OUP accepted manuscript. Oncologist, 2022, , .	1.9	1

#	Article	IF	Citations
1772	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2022, , .	0.6	1
1773	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. Oncologist, 2022, , .	1.9	18
1774	Clinical Benefit of Comprehensive Genomic Profiling for Advanced Cancers in India. JCO Global Oncology, 2022, 8, e2100421.	0.8	5
1775	Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. Journal of Personalized Medicine, 2022, 12, 655.	1.1	2
1776	Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors. Journal of Clinical Oncology, 2022, 40, 3077-3087.	0.8	13
1777	Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology. Genome Medicine, 2022, 14, 39.	3.6	22
1779	Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2022, 28, 3318-3328.	3.2	45
1780	Genomic alterations of dermatofibrosarcoma protuberans revealed by wholeâ€genome sequencing. British Journal of Dermatology, 2022, 186, 997-1009.	1.4	8
1781	Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro-Oncology, 2022, 24, 1964-1975.	0.6	15
1782	Cancer Progression Gene Expression Profiling Identifies the Urokinase Plasminogen Activator Receptor as a Biomarker of Metastasis in Cutaneous Squamous Cell Carcinoma. Frontiers in Oncology, 2022, 12, 835929.	1.3	11
1783	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. Nature Communications, 2022, 13, 2144.	5.8	18
1784	Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nature Medicine, 2022, 28, 620-626.	15.2	13
1785	Medullary Thyroid Carcinoma Mutational Spectrum Update and Signaling-Type Inference by Transcriptional Profiles: Literature Meta-Analysis and Study of Tumor Samples. Cancers, 2022, 14, 1951.	1.7	8
1786	AKT mutant allele-specific activation dictates pharmacologic sensitivities. Nature Communications, 2022, 13, 2111.	5.8	10
1787	MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2022, 28, 4456-4465.	3.2	25
1788	Adapting an Undergraduate Summer Internship to a Virtual Format: Implementing a Mentored Cancer Research Experience to Meet Rising Demand for Flexible Learning Environments. Journal of Cancer Education, 2022, , 1.	0.6	0
1789	New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?. Critical Reviews in Oncology/Hematology, 2022, 174, 103682.	2.0	5
1800	The NHS England 100,000 Genomes Project: feasibility and utility of centralised genome sequencing for children with cancer. British Journal of Cancer, 2022, 127, 137-144.	2.9	16

#	Article	IF	Citations
1801	A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nature Communications, 2022, 13, 2206.	5.8	146
1802	RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. Clinical Cancer Research, 2022, 28, 3091-3103.	3.2	8
1803	Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. Oncologist, 2022, 27, 839-848.	1.9	18
1804	A computational framework to unify orthogonal information in DNA methylation and copy number aberrations in cell-free DNA for early cancer detection. Briefings in Bioinformatics, 2022, 23, .	3.2	3
1805	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1450-1459.	1.1	10
1806	Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy, 0, , 200-223.	0.5	7
1807	The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery. Cancers, 2022, 14, 2144.	1.7	5
1808	EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma. Neuro-Oncology, 2022, 24, 1712-1725.	0.6	8
1809	Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine. Journal of Personalized Medicine, 2022, 12, 695.	1.1	3
1810	The Genetic Evolution of Metastasis. Cancer Research, 2022, 82, 1849-1857.	0.4	10
1811	Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing. Genes, 2022, 13, 799.	1.0	4
1812	Using Technology to Enhance Cancer Clinical Trial Participation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 39-45.	1.8	1
1813	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. Cancers, 2022, 14, 2275.	1.7	0
1814	Inside the cracked kernel: establishing the molecular basis of AMG510 and MRTX849 in destabilising KRASG12C mutant switch I and II in cancer treatment. Journal of Biomolecular Structure and Dynamics, 2022, , 1-13.	2.0	4
1815	A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer. Frontiers in Medicine, 2022, 9, 808378.	1.2	5
1816	Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?. Cells, 2022, 11, 1614.	1.8	1
1817	Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. Cancers, 2022, 14, 2381.	1.7	4
1818	Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. Prostate, 2022, , .	1.2	3

#	Article	IF	Citations
1819	Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB. International Journal of Molecular Sciences, 2022, 23, 5097.	1.8	3
1820	NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. Molecular Cell, 2022, 82, 2472-2489.e8.	4.5	18
1821	Characteristics of MYC Amplification and Their Association with Clinicopathological and Molecular Factors in Patients with Breast Cancer. DNA and Cell Biology, 2022, 41, 521-538.	0.9	1
1822	Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. Clinical Genitourinary Cancer, 2022, 20, 431-441.	0.9	5
1823	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2160-2166.	3.2	2
1824	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401.	5.7	126
1825	Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. Journal of Hepatology, 2022, 77, 1026-1037.	1.8	21
1828	Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas. Cancers, 2022, 14, 2454.	1.7	3
1830	Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. Nature Communications, 2022, 13, 2485.	5.8	31
1831	The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling. Journal of the National Cancer Institute, 2022, 114, 1279-1286.	3.0	8
1832	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. International Journal of Gynecological Cancer, 2022, , ijgc-2022-003430.	1.2	5
1834	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers, 2022, 14, 2638.	1.7	12
1835	Precision medicine in cancer: A paradigm shift. Seminars in Cancer Biology, 2022, 84, 1-2.	4.3	5
1836	ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular Cell, 2022, 82, 2443-2457.e7.	4.5	9
1837	Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials. , 2022, 10, e004345.		15
1838	Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen. Frontiers in Immunology, 2022, 13, .	2.2	2
1839	Fabrication and Characterization of Mxene/Cucr2o4 Semiconducting Nanocomposites. SSRN Electronic Journal, 0, , .	0.4	0
1840	Epigenetic Genes Alterations in Metastatic Solid Tumors: Results from the Prospective Precision Medicine MOSCATO and MATCH-R Trials. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
1841	A case of primary peritoneal carcinoma diagnosed as cancer of unknown primary revealed by laparoscopic surgery. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2022, 38, 118-124.	0.0	0
1843	Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival. Clinical Lung Cancer, 2022, 23, 510-521.	1.1	2
1845	Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review. Reproductive Sciences, 2022, 29, 3278-3284.	1.1	1
1846	HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. Current Oncology, 2022, 29, 3748-3758.	0.9	7
1847	Mutational signatures are markers of drug sensitivity of cancer cells. Nature Communications, 2022, 13, .	5.8	29
1848	METâˆ†14 promotes a ligand-dependent, AKT-driven invasive growth. Life Science Alliance, 2022, 5, e202201409.	1.3	7
1849	Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Seminars in Cancer Biology, 2022, 86, 57-68.	4.3	17
1850	Prediction of Tumor Mutation Load in Colorectal Cancer Histopathological Images Based on Deep Learning. Frontiers in Oncology, 0, 12, .	1.3	2
1851	BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. Journal of Clinical Oncology, 2022, 40, 2706-2715.	0.8	21
1852	Future directions for precision oncology in prostate cancer. Prostate, 2022, 82, .	1.2	2
1853	The evolving landscape of prostate cancer somatic mutations. Prostate, 2022, 82, .	1.2	8
1858	Distribution and favorable prognostic implication of genomic <scp>EGFR</scp> alterations in <scp>IDH</scp>â€wildtype glioblastoma. Cancer Medicine, 2023, 12, 49-60.	1.3	7
1859	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	5.8	63
1860	Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencingâ€“Assisted Multiomics Analysis. Cancer Immunology Research, 2022, 10, 811-828.	1.6	21
1861	Whole-genome and transcriptome analysis enhances precision cancer treatment options. Annals of Oncology, 2022, 33, 939-949.	0.6	36
1862	Breast Cancer Genomics: Primary and Most Common Metastases. Cancers, 2022, 14, 3046.	1.7	3
1863	POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. Journal of Thoracic Oncology, 2022, 17, 1109-1121.	0.5	29
1864	Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures. Nature Communications, 2022, 13, .	5.8	15

#	Article	IF	Citations
1865	Genome-wide mapping of somatic mutation rates uncovers drivers of cancer. Nature Biotechnology, 2022, 40, 1634-1643.	9.4	23
1866	A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report. BMC Medical Genomics, 2022, 15, .	0.7	1
1867	Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes. Computers in Biology and Medicine, 2022, 148, 105701.	3.9	7
1868	Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia. Blood, 2022, 140, 875-888.	0.6	12
1869	Genomic determinants of early recurrences in low-stage low-grade endometrioid endometrial carcinoma. Journal of the National Cancer Institute, 0, , .	3.0	1
1870	Genomic Landscape of Metastatic Lymph Nodes and Primary Tumors in Non-Small-Cell Lung Cancer. Pathology and Oncology Research, 0, 28, .	0.9	5
1871	Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. Journal of Clinical Medicine, 2022, 11, 3364.	1.0	20
1872	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. Immunotherapy, 0, , .	1.0	3
1873	Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer. Frontiers in Oncology, 0, 12, .	1.3	5
1874	Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (<scp>KGOG</scp>) Tj ETQq1 1 0.784314 rgBT /Ove	2.4	4
1875	Clinical significance of chromosomal integrity in gastric cancers. International Journal of Biological Markers, 0, , 039361552211062.	0.7	1
1876	Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. Cancers, 2022, 14, 2816.	1.7	3
1877	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 2022, 13, .	5.8	51
1878	Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Frontiers in Oncology, 0, 12, .	1.3	7
1879	Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. Journal of the American College of Surgeons, 2022, 235, 342-349.	0.2	7
1880	Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. Nature Cancer, 2022, 3, 723-733.	5.7	82
1881	The Impact of PIK3R1 Mutations and Insulinâ€“PI3Kâ€“Glycolytic Pathway Regulation in Prostate Cancer. Clinical Cancer Research, 2022, 28, 3603-3617.	3.2	7
1882	Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards. Cancers, 2022, 14, 3193.	1.7	9

#	Article	IF	Citations
1883	The Therapeutic Potential of the Restoration of the p53 Protein Family Members in the EGFR-Mutated Lung Cancer. International Journal of Molecular Sciences, 2022, 23, 7213.	1.8	4
1884	Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. Cancer Discovery, 2022, 12, 2058-2073.	7.7	16
1886	â€œDoing Goodâ€•in U.S. Cancer Genomics? Valuation practices across the boundaries of research and care in rural community oncology. New Genetics and Society, 2022, 41, 254-283.	0.7	0
1887	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. JCO Precision Oncology, 2022, , .	1.5	3
1888	DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient. JCO Precision Oncology, 2022, , .	1.5	1
1889	Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. Clinical Cancer Research, 2022, 28, 4702-4713.	3.2	25
1890	Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report. Communications Medicine, 2022, 2, .	1.9	5
1891	Functional Drug Screening in the Era of Precision Medicine. Frontiers in Medicine, 0, 9, .	1.2	5
1892	Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL. Cancer Research, 2022, 82, 3375-3393.	0.4	2
1893	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 7839.	1.8	13
1894	Endometrial polyps are non-neoplastic but harbor epithelial mutations in endometrial cancer drivers at low allelic frequencies. Modern Pathology, 2022, 35, 1702-1712.	2.9	8
1895	Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment. Frontiers in Oncology, 0, 12, .	1.3	2
1896	Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer. Cancers, 2022, 14, 3476.	1.7	9
1897	JAK2-CHK2 signaling safeguards the integrity of the mitotic spindle assembly checkpoint and genome stability. Cell Death and Disease, 2022, 13, .	2.7	2
1898	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nature Genetics, 2022, 54, 996-1012.	9.4	30
1899	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2022, 28, 4267-4277.	3.2	4
1900	Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma. Journal of Neuro-Oncology, 2022, 159, 397-408.	1.4	1
1903	Integrated Workflow for the Label-Free Isolation and Genomic Analysis of Single Circulating Tumor Cells in Pancreatic Cancer. International Journal of Molecular Sciences, 2022, 23, 7852.	1.8	2

#	Article	IF	Citations
1904	Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. Scientific Reports, 2022, 12, .	1.6	2
1905	In silico comprehensive analysis of coding and non-coding SNPs in human mTOR protein. PLoS ONE, 2022, 17, e0270919.	1.1	2
1906	Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice. Future Oncology, 2022, 18, 2701-2711.	1.1	0
1907	Accelerating drug development in breast cancer: New frontiers for ER inhibition. Cancer Treatment Reviews, 2022, 109, 102432.	3.4	28
1908	Chromosomal instability in cancers of unknown primary. European Journal of Cancer, 2022, 172, 323-325.	1.3	7
1909	A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma. International Immunopharmacology, 2022, 110, 108846.	1.7	4
1911	Expert panel consensus recommendations on the use of circulating tumor <scp>DNA</scp> assays for patients with advanced solid tumors. Cancer Science, 2022, 113, 3646-3656.	1.7	5
1912	Activating mTOR Mutations Are Detrimental in Nutrient-Poor Conditions. Cancer Research, 2022, 82, 3263-3274.	0.4	4
1913	Integration of androgen hormones in endometrial cancer biology. Trends in Endocrinology and Metabolism, 2022, 33, 639-651.	3.1	5
1914	Microsatellite Instabilityâ€“High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles. Clinical Cancer Research, 2022, 28, 4302-4311.	3.2	14
1915	Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?. Head and Neck Pathology, 2022, 16, 1063-1072.	1.3	1
1916	Unusual Clinical Experience in BRAF Exon 15 p.K601E-Mutated Lung Cancer: A Case Report and Brief Review of the Literature. Applied Sciences (Switzerland), 2022, 12, 7552.	1.3	0
1917	Epigenetic geneÂalterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials. European Journal of Cancer, 2022, 173, 133-145.	1.3	1
1918	Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. Cancers, 2022, 14, 3674.	1.7	3
1920	Landscape of somatic alterations in large-scale solid tumors from an Asian population. Nature Communications, 2022, 13, .	5.8	30
1921	Clinical M2 Macrophage-Related Genes Can Serve as a Reliable Predictor of Lung Adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	6
1922	NRF2-pathway mutations predict radioresistance in non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 1510-1513.	1.3	2
1923	NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma. Frontiers in Immunology, 0, 13, .	2.2	4

#	Article	IF	Citations
1924	Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer. Cancers, 2022, 14, 3744.	1.7	10
1925	Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance. JCO Precision Oncology, 2022, , .	1.5	2
1926	Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	7
1927	Tumor mutational burden in non-immunotherapy patients with heavily pretreated metastatic breast cancer: long-term outcomes from a single institution. Journal of Chemotherapy, 2023, 35, 348-356.	0.7	0
1929	AZD4625 is a Potent and Selective Inhibitor of KRASG12C. Molecular Cancer Therapeutics, 2022, 21, 1535-1546.	1.9	2
1930	p73 isoforms meet evolution of metastasis. Cancer and Metastasis Reviews, 2022, 41, 853-869.	2.7	6
1931	Comprehensive characterization of clonality of driver genes revealing their clinical relevance in colorectal cancer. Journal of Translational Medicine, 2022, 20, .	1.8	5
1932	Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nature Medicine, 2022, 28, 1646-1655.	15.2	42
1933	Analytical Principles of Cancer Next Generation Sequencing. Clinics in Laboratory Medicine, 2022, 42, 395-408.	0.7	3
1934	A crossâ€sectional study of the <scp>FDA</scp> approved indications and supporting pivotal trials of smallâ€molecular kinase inhibitors in cancer therapies with the biomarker of cancer driver gene. International Journal of Cancer, 0, , .	2.3	1
1935	Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. Nature Communications, 2022, 13, .	5.8	22
1936	Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients. Genome Medicine, 2022, 14, .	3.6	11
1937	Germline Testing for the Evaluation of Hereditary Cancer Predisposition. Clinics in Laboratory Medicine, 2022, 42, 497-506.	0.7	0
1940	Chromosomal instability in adult-type diffuse gliomas. Acta Neuropathologica Communications, 2022, 10, .	2.4	7
1941	Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory myofibroblastic tumor with a rare GCC2-ALK fusion. Frontiers in Oncology, 0, 12, .	1.3	4
1943	Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Molecular Cancer, 2022, 21, .	7.9	55
1945	Landscape of mutations in early stage primary cutaneous melanoma: An <scp>InterMEL</scp> study. Pigment Cell and Melanoma Research, 2022, 35, 605-612.	1.5	8
1946	Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review. Frontiers in Oncology, 0, 12, .	1.3	6

#	Article	IF	Citations
1947	A Tumorâ€Organoidâ€Based Precision Medicine Platform for the Prediction of Drug Sensitivity of Colorectal Cancer. Advanced Therapeutics, 2022, 5, .	1.6	2
1948	Hereditary leiomyomatosis and renal cell cancer: a case report. Onkourologiya, 2022, 18, 211-216.	0.1	0
1949	PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment. ESMO Open, 2022, 7, 100524.	2.0	3
1950	The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology, 2022, 19, 637-655.	12.5	125
1951	Precision oncology for RET-related tumors. Frontiers in Oncology, 0, 12, .	1.3	11
1952	Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma. Modern Pathology, 0, , .	2.9	1
1953	Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	21
1954	Genetic alterations of Keap1 confers chemotherapeutic resistance through functional activation of Nrf2 and Notch pathway in head and neck squamous cell carcinoma. Cell Death and Disease, 2022, 13, .	2.7	9
1955	Integrated driver mutations profile of chinese gastrointestinal-natural killer/T-cell lymphoma. Frontiers in Oncology, 0, 12, .	1.3	0
1956	Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade. Annals of Surgical Oncology, 2022, 29, 8373-8382.	0.7	2
1957	Ovarian clear cell carcinoma. , 2023, , 55-76.		0
1958	Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer. Nature Communications, 2022, 13, .	5.8	7
1959	AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer. International Journal of Molecular Sciences, 2022, 23, 10819.	1.8	0
1960	Thyroid Oncocytic (HÃ¼rthle Cell) Nodules With Longitudinal Nuclear Grooves. Archives of Pathology and Laboratory Medicine, 2022, , .	1.2	0
1961	Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022, 34, 343-352.	0.7	2
1962	Molecular and Genetic Profiling for the Diagnosis and Therapy of Hepatobiliary and Pancreatic Malignancies. , 2022, , 747-759.		0
1963	Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience. Melanoma Research, 2022, 32, 477-484.	0.6	2
1964	Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nature Cancer, 2022, 3, 1151-1164.	5.7	79

#	Article	IF	Citations
1965	A compendium of co-regulated mitoribosomal proteins in pan-cancer uncovers collateral defective events in tumor malignancy. IScience, 2022, 25, 105244.	1.9	1
1967	GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer. Cell Reports, 2022, 40, 111344.	2.9	9
1968	Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice. Clinical Cancer Research, 2022, 28, 4782-4792.	3.2	11
1969	Primary cutaneous SMARCA4-deficient undifferentiated malignant neoplasm: first two cases with clinicopathologic and molecular comparison to eight visceral counterparts. Modern Pathology, 2022, 35, 1821-1828.	2.9	3
1970	Biomarkers for immune checkpoint inhibitors in solid tumors. Clinical and Translational Oncology, 2023, 25, 126-136.	1.2	3
1971	Optimizing Insertion and Deletion Detection Using Next-Generation Sequencing in the Clinical Laboratory. Journal of Molecular Diagnostics, 2022, 24, 1217-1231.	1.2	6
1972	The Role of Biomarkers in the Management of Colorectal Liver Metastases. Cancers, 2022, 14, 4602.	1.7	5
1973	Aurora Kinases as Therapeutic Targets in Head and Neck Cancer. Cancer Journal (Sudbury, Mass), 2022, 28, 387-400.	1.0	2
1974	Nonâ€small cell lung carcinomas with diffuse coexpression of <scp>TTF1</scp> and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours. Histopathology, 2023, 82, 242-253.	1.6	4
1975	Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice. Cancer Science, 2022, 113, 4300-4310.	1.7	12
1976	Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. Journal of Oncology, 2022, 2022, 1-12.	0.6	2
1977	Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer. European Urology, 2023, 83, 112-120.	0.9	6
1978	Big data in basic and translational cancer research. Nature Reviews Cancer, 2022, 22, 625-639.	12.8	67
1979	Rational development of combination therapies for biliary tract cancers. Journal of Hepatology, 2023, 78, 217-228.	1.8	15
1980	ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nature Communications, 2022, 13, .	5.8	9
1981	APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. Annals of Oncology, 2022, 33, 1284-1295.	0.6	22
1982	RB1-deficient squamous cell carcinoma: the proposed source of combined Merkel cell carcinoma. Modern Pathology, 2022, 35, 1829-1836.	2.9	9
1983	Genomic alterations predictive of poor clinical outcomes in pan-cancer. Oncotarget, 2022, 13, 1069-1077.	0.8	0

#	Article	IF	Citations
1984	Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort. Cancer Discovery, 2022, 12, 2552-2565.	7.7	21
1985	MatchMiner: an open-source platform for cancer precision medicine. Npj Precision Oncology, 2022, 6, .	2.3	8
1987	Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer. Oncogene, 2022, 41, 4905-4915.	2.6	9
1991	Introduction of Tochigi Cancer Biobank established with the aim of developing novel diagnostic and therapeutic methods for cancer. Denki Eido, 2022, 66, 27-30.	0.0	0
1992	Primary Intracranial Spindle Cell Sarcoma, DICER1-Mutant, with MDM2 Amplification Diagnosed on the Basis of Extensive Molecular Profiling. Clinical Medicine Insights: Case Reports, 2022, 15, 117954762211311.	0.3	3
1993	Prinzipien der zellulÃren Tumorgenese und -progression. , 2022, , 835-849.		0
1998	Machine Learning Techniques in Predicting BRAF Mutation Status in Cutaneous Melanoma From Clinical and Histopathologic Features. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 674-680.	0.6	3
1999	APOBEC Mutational Signatures in Hormone Receptorâ€“Positive Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. JCO Precision Oncology, 2022, , .	1.5	6
2000	Patient Selection Approaches in FGFR Inhibitor Trialsâ€”Many Paths to the Same End?. Cells, 2022, 11, 3180.	1.8	8
2001	Cervical Pleuropulmonary Blastoma-like Tumor Associated With DICER1 and TP53 Mutations. International Journal of Gynecological Pathology, 0, Publish Ahead of Print, .	0.9	0
2002	Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential. Medicina (Lithuania), 2022, 58, 1498.	0.8	3
2003	Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention. Clinical Cancer Research, 2022, 28, 5359-5367.	3.2	5
2005	Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers. Gynecologic Oncology, 2022, 167, 458-466.	0.6	7
2007	Genomic characteristics of two breast malignant phyllodes tumors during pregnancy and lactation identified through whole-exome sequencing. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	1
2008	Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular Classification. JCO Precision Oncology, 2022, , .	1.5	2
2009	Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor model. Frontiers in Oncology, 0, 12, .	1.3	0
2011	CREAMMIST: an integrative probabilistic database for cancer drug response prediction. Nucleic Acids Research, 2023, 51, D1242-D1248.	6.5	5
2012	Germline SMARCA4 Deletion as a Driver of Uterine Cancer: An Atypical Presentation. JCO Precision Oncology, 2022, , .	1.5	1

#	Article	IF	Citations
2013	Squamous cell lung cancer: Current landscape and future therapeutic options. Cancer Cell, 2022, 40, 1279-1293.	7.7	22
2014	Drugging KRAS: current perspectives and state-of-art review. Journal of Hematology and Oncology, 2022, 15, .	6.9	34
2015	Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	1.3	4
2017	Selective advantage of epigenetically disrupted cancer cells via phenotypic inertia. Cancer Cell, 2023, 41, 70-87.e14.	7.7	18
2018	SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers. Frontiers in Immunology, 0, 13, .	2.2	1
2019	FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. Nature Communications, 2022, 13, .	5.8	11
2020	KITgenetic alterations in breast cancer. Journal of Clinical Pathology, 2024, 77, 40-45.	1.0	1
2021	Novel GO/LiCr2O4 nanocomposite synthesis, characterizations and electrode testing for electrochemical applications. Materials Science and Engineering B: Solid-State Materials for Advanced Technology, 2023, 287, 116118.	1.7	9
2022	Molecular Characterization of Acquired Resistance to KRASG12Câ€“EGFR Inhibition in Colorectal Cancer. Cancer Discovery, 2023, 13, 41-55.	7.7	25
2023	Integrative analysis of multi-omics data for liquid biopsy. British Journal of Cancer, 2023, 128, 505-518.	2.9	8
2024	Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making. Frontiers in Oncology, 0, 12, .	1.3	3
2026	Germline findings in patients with advanced malignancies screened with paired blood-tumor testing for personalized treatment approaches. European Journal of Cancer, 2022, , .	1.3	0
2027	Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response. Cancers, 2022, 14, 5626.	1.7	3
2028	WaldenstrÃ¶m Macroglobulinemia Whole Genome Reveals Prolonged Germinal Center Activity and Late Copy Number Aberrations. Blood Advances, 0, , .	2.5	1
2029	Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors. European Journal of Cancer, 2023, 179, 124-135.	1.3	11
2030	Selection bias due to delayed comprehensive genomic profiling in Japan. Cancer Science, 2023, 114, 1015-1025.	1.7	9
2031	Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy. Cancer Immunology, Immunotherapy, 2023, 72, 1199-1208.	2.0	12
2032	Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nature Medicine, 2022, 28, 2353-2363.	15.2	41

#	Article	IF	Citations
2034	Improving Reporter Gene Assay Methodology for Evaluating the Ability of Compounds to Restore P53 Activity. International Journal of Molecular Sciences, 2022, 23, 13867.	1.8	0
2035	Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2023, 26, 180-187.	2.0	5
2037	Molecular diagnosis of pancreatobiliary tract cancer by detecting mutations and methylation changes in bile samples. EClinicalMedicine, 2023, 55, 101736.	3.2	4
2038	Tumour mutational burden is overestimated by target cancer gene panels. Journal of the National Cancer Center, 2023, 3, 56-64.	3.0	3
2039	A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma. JTO Clinical and Research Reports, 2023, 4, 100440.	0.6	0
2040	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. , 2022, , 895-915.		0
2041	SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity. Cancer Letters, 2023, 555, 216029.	3.2	3
2042	Pharmacogenomics and Cancer Treatment. , 2022, , 1-16.		0
2043	Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies. Cancers, 2022, 14, 5858.	1.7	2
2045	Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. Expert Opinion on Pharmacotherapy, 2023, 24, 177-195.	0.9	1
2046	Advances in the understanding and treatment of Cutaneous T-cell Lymphoma. Frontiers in Oncology, 0, 12, .	1.3	3
2047	Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas. Annals of Gastroenterological Surgery, 2023, 7, 491-502.	1.2	2
2049	Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies. Nature Communications, 2022, 13, .	5.8	11
2050	Feasibility of shape-sensing robotic-assisted bronchoscopy for biomarker identification in patients with thoracic malignancies. Journal of Thoracic and Cardiovascular Surgery, 2023, 166, 231-240.e2.	0.4	5
2051	Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nature Communications, 2022, 13, .	5.8	2
2052	HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study. European Journal of Cancer, 2023, 181, 62-69.	1.3	5
2053	Targeting the FGF/FGFR axis and its co-alteration allies. ESMO Open, 2022, 7, 100647.	2.0	6
2054	Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Reports, 2022, 41, 111859.	2.9	8

#	Article	IF	Citations
2055	Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. Molecular Biomedicine, 2022, 3, .	1.7	29
2056	Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Annals of Oncology, 2023, 34, 215-227.	0.6	24
2057	HER3 Alterations in Cancer and Potential Clinical Implications. Cancers, 2022, 14, 6174.	1.7	4
2058	Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. Npj Precision Oncology, 2022, 6, .	2.3	18
2060	Ovarian cancer mutational processes drive site-specific immune evasion. Nature, 2022, 612, 778-786.	13.7	51
2061	Molecular Classification of Appendiceal Adenocarcinoma. Journal of Clinical Oncology, 2023, 41, 1553-1564.	0.8	15
2062	Identification of <scp>MET</scp> fusions in solid tumors: A multicenter, large scale study in China. International Journal of Cancer, 2023, 152, 1259-1268.	2.3	4
2063	Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. New England Journal of Medicine, 2023, 388, 44-54.	13.9	100
2064	Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. Journal of Thoracic Oncology, 2023, 18, 463-475.	0.5	24
2065	Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer. Biomolecules, 2022, 12, 1818.	1.8	0
2066	Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell, 2023, 41, 164-180.e8.	7.7	15
2067	The ectonucleotidase CD39 identifies tumor-reactive CD8+ TÂcells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity, 2023, 56, 93-106.e6.	6.6	24
2068	Genetic, Surgical and Oncological Approach to Breast Cancer, with <i>BRCA1, BRCA2, CDH1, PALB2, PTEN</i> and <i>TP53</i> Variants. The Journal of Breast Health, 2022, 19, 55-69.	0.4	1
2069	RAMP: response-aware multi-task learning with contrastive regularization for cancer drug response prediction. Briefings in Bioinformatics, 2023, 24, .	3.2	1
2070	Clinical and technical insights of tumour mutational burden in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2023, 182, 103891.	2.0	6
2071	Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade. , 2022, 10, e005670.		5
2073	CaracterizaciÃ³n molecular por secuenciaciÃ³n de nueva generaciÃ³n obtenida en biopsia lÃquida en una cohorte multicÃ©ntrica de pacientes con diagnÃ³stico de cÃ¡ncer de pulmÃ³n avanzado en Argentina. , 2022, 27, .		0
2074	Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations. Npj Precision Oncology, 2023, 7, .	2.3	9

#	Article	IF	Citations
2075	Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis. Modern Pathology, 2023, 36, 100084.	2.9	4
2076	EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology, 2023, 25, 813-826.	0.6	24
2078	Genetic Heterogeneity and Tissue-specific Patterns of Tumors with MultiplePIK3CAMutations. Clinical Cancer Research, 2023, 29, 1125-1136.	3.2	4
2079	ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS Genetics, 2023, 19, e1010563.	1.5	5
2081	A multiplexed inÂvivo approach to identify driver genes in small cell lung cancer. Cell Reports, 2023, 42, 111990.	2.9	8
2082	Case report: Somatic mutations in microtubule dynamics-associated genes in patients with WNT-medulloblastoma tumors. Frontiers in Oncology, 0, 12, .	1.3	0
2083	Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer. Cell Reports, 2023, 42, 111929.	2.9	25
2084	Ovarian RASoma With Mesonephric-like Adenocarcinoma and Mixed Mullerian Components: A Case Report With Molecular Analysis Demonstrating Multidirectional Mullerian Differentiation. International Journal of Gynecological Pathology, 2023, 42, 620-626.	0.9	2
2085	Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis. Annals of Hepatology, 2023, 28, 100898.	0.6	1
2086	Genomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study. Cancers, 2023, 15, 283.	1.7	3
2087	High-Throughput Prediction of the Impact of Genetic Variability on Drug Sensitivity and Resistance Patterns for Clinically Relevant Epidermal Growth Factor Receptor Mutations from Atomistic Simulations. Journal of Chemical Information and Modeling, 2023, 63, 321-334.	2.5	1
2088	Assessment of Two Commercial Comprehensive Gene Panels for Personalized Cancer Treatment. Journal of Personalized Medicine, 2023, 13, 42.	1.1	3
2089	Application of organoid culture from <scp>HPV18</scp>â€positive small cell carcinoma of the uterine cervix for precision medicine. Cancer Medicine, 2023, 12, 8476-8489.	1.3	4
2090	Therapeutic cancer vaccination against telomerase: clinical developments in melanoma. Current Opinion in Oncology, 2023, 35, 100-106.	1.1	0
2091	Concordance between cancer gene alterations in tumor and circulating tumor <scp>DNA</scp> correlates with poor survival in a realâ€world precisionâ€medicine population. Molecular Oncology, 2023, 17, 1844-1856.	2.1	0
2093	ANALYSIS OF COMMON SOMATIC MUTATIONS IN COLORECTAL CARCINOMA AND ASSOCIATED DYSREGULATED PATHWAYS. Journal of Ayub Medical College, Abbottabad: JAMC, 2023, 35, .	0.1	0
2095	Malignancies in Patients with Celiac Disease: Diagnostic Challenges and Molecular Advances. Genes, 2023, 14, 376.	1.0	2
2096	Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience. European Journal of Cancer, 2023, 183, 79-89.	1.3	2

#	Article	IF	Citations
2097	Genomic landscape of 891 RET fusions detected across diverse solid tumor types. Npj Precision Oncology, 2023, 7, .	2.3	9
2098	Therapeutic landscape and future direction of metastatic colorectal cancer. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 306-322.	8.2	33
2099	LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma. Cancer Discovery, 2023, 13, 1002-1025.	7.7	5
2100	Proteogenomics decodes the evolution of human ipsilateral breast cancer. Communications Biology, 2023, 6, .	2.0	2
2101	Expanding the Molecular Diversity of CIC-Rearranged Sarcomas With Novel and Very Rare Partners. Modern Pathology, 2023, 36, 100103.	2.9	8
2103	Mammary mucinous cystadenocarcinoma with long-term follow-up: molecular information and literature review. Diagnostic Pathology, 2023, 18, .	0.9	3
2104	Participation of ATM, SMG1, and DDX5 in a DNA Damage-Induced Alternative Splicing Pathway. Radiation Research, 2023, 199, .	0.7	1
2105	Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics. Social Science and Medicine, 2023, 324, 115789.	1.8	5
2106	Landscape of chromatin remodeling gene alterations in endometrial carcinoma. Gynecologic Oncology, 2023, 172, 54-64.	0.6	3
2107	Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resistance Updates, 2023, 68, 100962.	6.5	30
2108	Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer. Breast, 2023, 69, 330-341.	0.9	3
2109	Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data. European Journal of Cancer, 2023, 186, 122-132.	1.3	2
2110	Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma. Modern Pathology, 2023, 36, 100150.	2.9	2
2111	Mutated axon guidance gene <scp> PLXNB2 </scp> sustains growth and invasiveness of stem cells isolated from cancers of unknown primary. EMBO Molecular Medicine, 2023, 15, .	3.3	4
2112	Comprehensive analysis of germline drivers in endometrial cancer. Journal of the National Cancer Institute, 2023, 115, 560-569.	3.0	4
2113	Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations. Cancer Research, 2023, 83, 1191-1202.	0.4	3
2114	BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature. Journal of Investigative Dermatology, 2023, 143, 1178-1186.	0.3	1
2115	Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nature Communications, 2023, 14, .	5.8	15

#	Article	IF	Citations
2116	Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma. Heliyon, 2023, 9, e13629.	1.4	0
2117	The role of Evi/Wntless in exporting Wnt proteins. Development (Cambridge), 2023, 150, .	1.2	1
2118	Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. British Journal of Cancer, 2023, 128, 1603-1608.	2.9	3
2119	Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy. Clinical Cancer Research, 2023, 29, 1620-1630.	3.2	10
2120	Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2023, 29, 1368-1374.	3.2	4
2121	ARID1A in cancer: Friend or foe?. Frontiers in Oncology, 0, 13, .	1.3	5
2123	Distinct IDH1/2-associated Methylation Profile and Enrichment ofTP53andTERTMutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma. Cancer Research Communications, 2023, 3, 431-443.	0.7	3
2124	Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends in Pharmacological Sciences, 2023, 44, 222-236.	4.0	30
2125	Tumoral Intraductal Neoplasms of the Bile Ducts Comprise Morphologically and Genetically Distinct Entities. Archives of Pathology and Laboratory Medicine, 2023, 147, 1390-1401.	1.2	5
2126	Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing. Cancer Research Communications, 2023, 3, 501-509.	0.7	1
2127	Building a precision medicine infrastructure at a national level: The Swedish experience. , 2023, 1, .		2
2128	Unified views on variant impact across many diseases. Trends in Genetics, 2023, 39, 442-450.	2.9	3
2129	Integrated molecular and clinical analysis of BRAF-mutant glioma in adults. Npj Precision Oncology, 2023, 7, .	2.3	4
2130	Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. Biochemistry, 2023, 62, 1124-1137.	1.2	0
2131	Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nature Communications, 2023, 14, .	5.8	11
2132	Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. Nature Medicine, 2023, 29, 605-614.	15.2	27
2133	Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer. Cancer Discovery, 2023, 13, 1116-1143.	7.7	11
2134	Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary. Journal of Gastrointestinal Cancer, 2023, 54, 1276-1285.	0.6	0

#	Article	IF	Citations
2135	Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach. Clinical Cancer Research, 2023, 29, 2445-2455.	3.2	1
2136	A Biterm Topic Model for Sparse Mutation Data. Cancers, 2023, 15, 1601.	1.7	0
2137	The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer. Current Issues in Molecular Biology, 2023, 45, 2105-2120.	1.0	1
2138	Adaptation to spindle assembly checkpoint inhibition through the selection of specific aneuploidies. Genes and Development, 2023, 37, 171-190.	2.7	4
2139	Construction of endothelial cellâ€related and autophagyâ€related prognostic models for hepatocellular carcinoma based on singleâ€cell data. Journal of Gastroenterology and Hepatology (Australia), 0, , .	1.4	0
2141	Current and future applications of liquid biopsy in non-small-cell lung cancerâ€”a narrative review. Translational Lung Cancer Research, 2023, 12, 594-614.	1.3	6
2142	Ductal Adenocarcinoma and Pancreatic Intraepithelial Neoplasia. , 2023, , 157-220.		0
2143	Telomere Length Changes in Cancer: Insights on Carcinogenesis and Potential for Non-Invasive Diagnostic Strategies. Genes, 2023, 14, 715.	1.0	9
2144	SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma. Free Radical Biology and Medicine, 2023, 201, 41-54.	1.3	4
2146	Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
2147	Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific. BMC Pulmonary Medicine, 2023, 23, .	0.8	3
2148	The oncogenic properties of the EWSR1::CREM fusion gene are associated with polyamine metabolism. Scientific Reports, 2023, 13, .	1.6	1
2149	The emerging role of PI3K inhibitors for solid tumour treatment and beyond. British Journal of Cancer, 2023, 128, 2150-2162.	2.9	18
2150	Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling. Communications Biology, 2023, 6, .	2.0	2
2151	Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression. Translational Lung Cancer Research, 2023, 12, 401-404.	1.3	0
2152	Seeing Beyond the Smoke: Reclassifying Lung Cancer by Smoking-Related Mutational Signatures. Journal of Thoracic Oncology, 2023, 18, 396-398.	0.5	0
2153	Immunotherapy in Gastrointestinal Malignancies. , 2023, , 1-23.		0
2154	Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response. Modern Pathology, 2023, 36, 100165.	2.9	2

#	Article	IF	Citations
2155	Rare deleterious mutations in Brutonâ€™s tyrosine kinase as biomarkers for ibrutinib-based therapy: an in silico insight. Journal of Molecular Modeling, 2023, 29, .	0.8	0
2156	Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study. European Journal of Cancer, 2023, 187, 174-184.	1.3	6
2157	Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precision Oncology, 2023, , .	1.5	2
2158	Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program. JCO Precision Oncology, 2023, , .	1.5	2
2159	Glioblastoma with novel <scp>EGFR</scp> mutations (<scp>T790M</scp> and exon 20 insertion) yet unresponsive to osimertinib: A case report. Genes Chromosomes and Cancer, 2023, 62, 423-429.	1.5	2
2160	Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 253.e21-253.e26.	0.8	1
2161	Molecular genetic positioning of small intestine and papilla of Vater carcinomas including clinicopathological classification. Cancer Medicine, 2023, 12, 11491-11502.	1.3	0
2162	InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. PLoS ONE, 2023, 18, e0269324.	1.1	3
2163	The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 6710.	1.8	7
2164	Novel Computational Methods for Cancer Drug Design. Current Medicinal Chemistry, 2023, 30, .	1.2	1
2165	Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Science Translational Medicine, 2023, 15, .	5.8	13
2166	Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer. Current Oncology, 2023, 30, 4094-4109.	0.9	0
2167	Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review). Oncology Reports, 2023, 49, .	1.2	4
2168	Interactome dynamics of RAF1-BRAF kinase monomers and dimers. Scientific Data, 2023, 10, .	2.4	4
2169	Insights into the metastatic cascade through research autopsies. Trends in Cancer, 2023, 9, 490-502.	3.8	5
2170	Prediction of drug sensitivity based on multi-omics data using deep learning and similarity network fusion approaches. Frontiers in Bioengineering and Biotechnology, 0, 11, .	2.0	1
2171	Not all TMB assays are the same: Clinical validity of robust algorithmic germline filtering. Cancer Cell, 2023, 41, 819-820.	7.7	1
2172	Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis. Cell Death Discovery, 2023, 9, .	2.0	2

#	Article	IF	Citations
2173	Ephrin-A4 Ligand (EFNA4) Predicts Poor Prognosis of Hepatocellular Carcinoma and Promotes Tumor Proliferation. Journal of Clinical and Experimental Hepatology, 2023, 13, 767-773.	0.4	0
2174	Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk inÂPatients With Solid Cancer. JACC: CardioOncology, 2023, 5, 246-255.	1.7	2
2175	Genomic mapping of metastatic organotropism in lung adenocarcinoma. Cancer Cell, 2023, 41, 970-985.e3.	7.7	15
2176	Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. International Journal of Molecular Sciences, 2023, 24, 7577.	1.8	2
2177	Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption. PLoS Genetics, 2023, 19, e1010575.	1.5	6
2178	TP53mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy. Blood Advances, 2023, 7, 5172-5186.	2.5	2
2179	Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusionâ€“Positive Pancreatic Adenocarcinoma: A Case Report. JCO Precision Oncology, 2023, , .	1.5	0
2180	Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors. Molecules, 2023, 28, 3615.	1.7	2
2182	mRNA vaccination in breast cancer: current progress and future direction. Journal of Cancer Research and Clinical Oncology, 2023, 149, 9435-9450.	1.2	3
2203	Carcinogenesis and management of human papillomavirus-associated cervical cancer. International Journal of Clinical Oncology, 2023, 28, 965-974.	1.0	3
2204	Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors. International Journal of Clinical Oncology, 2023, 28, 941-955.	1.0	2
2240	The role of chromatin remodeler SMARCA4/BRG1 in brain cancers: a potential therapeutic target. Oncogene, 2023, 42, 2363-2373.	2.6	6
2251	Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2023, 20, 697-715.	12.5	10
2291	Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade. Nature Medicine, 2023, 29, 2458-2463.	15.2	2
2299	Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma. Targeted Oncology, 2023, 18, 643-655.	1.7	2
2304	Precision Medicine. , 2023, , 199-214.		0
2329	Neoplasms of the Sinonasal Tract. , 2023, , 87-272.e19.		0
2335	CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas. Acta Neuropathologica, 0, , .	3.9	1

#	Article	IF	Citations
2336	Pharmacogenomics and Cancer Treatment. , 2023, , 1115-1130.		0
2341	Epigenetic regulation of breast cancer metastasis. Cancer and Metastasis Reviews, 0, , .	2.7	0
2343	Whole-exome and whole-genome sequencing in the molecular diagnostic laboratory. , 2024, , 27-38.		0
2353	Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma. Npj Precision Oncology, 2023, 7, .	2.3	0
2357	Importance of In silico Tools in Anticancer Drug Discovery from Nature. , 2023, , 139-164.		0
2358	Case Report: Identification of a novel STAT3 mutation in EBV-positive inflammatory follicular dendritic cell sarcoma. Frontiers in Oncology, 0, 13, .	1.3	0
2370	Editorial: Studying novel immune signatures, targets, and drugs in hepatobiliary tumors: based on advanced technologies. Frontiers in Immunology, 0, 14, .	2.2	0
2396	Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies. Drugs, 0, , .	4.9	0
2408	Cancer variant modeling in vivo. Nature Biotechnology, 0, , .	9.4	0
2422	Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype. Discover Oncology, 2024, 15, .	0.8	0
2424	An update of predictive biomarkers related to WEE1 inhibition in cancer therapy. Journal of Cancer Research and Clinical Oncology, 2024, 150, .	1.2	1
2425	Genetics of neuronal and glioneuronal cancers. , 2024, , 339-369.		0
2431	BRAF â€" a tumour-agnostic drug target with lineage-specific dependencies. Nature Reviews Clinical Oncology, 2024, 21, 224-247.	12.5	1
2452	Advances in Thyroid Cancer Management Beyond the Pandemic. , 2023, , 1-8.		0
2472	Case report: A familial B-acute lymphoblastic leukemia associated with a new germline pathogenic variant in PAX5. The first report in Mexico. Frontiers in Oncology, 0, 14, .	1.3	0